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ABSTRACT OF DISSERTATION 
 
 
 
 
AGING AND THE DYNORPHINERGIC SYSTEM:   
EVALUATION OF MEMORY AND MOTOR SYSTEMS  
IN PRODYNORPHIN KNOCKOUT MICE 
 
Dynorphins, endogenous peptide neurotransmitters expressed in the central 
nervous system, have been implicated in diverse pathophysiological processes, including 
excitotoxicity, chronic inflammation, traumatic injury, cognitive impairment, and motor 
dysfunction, with significant changes with aging or age-related disease processes.  This 
has led to the hypothesis that the suppression of dynorphin expression would produce 
beneficial effects on learning and memory and motor function.   
 
To assess the phenotypic manifestations of chronic suppression of endogenous 
dynorphin, knockout (KO) mice lacking the coding exons of the gene encoding the 
prodynorphin (Pdyn) precursor protein, were tested in a series of behavioral, biochemical, 
and molecular biological studies.  Moderately aged Pdyn KO perform comparatively 
better than similarly aged wild-type (WT) mice in the water maze task, although no Pdyn 
effect was seen among young adult mice.   In addition, young adult Pdyn KO mice show 
mildly improved performance on a passive avoidance task.  Minimal baseline differences 
were noted in spontaneous locomotor activity in an open-field assay, but Pdyn deletion 
produced a relative sparing of motor dysfunction induced by the neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP).   
 
To investigate the relationship between aging and brain dynorphin expression in 
mice, we examined dynorphin peptide levels at varying ages in hippocampus, striatum, 
and frontal cortex of WT mice by quantitative radioimmunoassay.  While aging produces 
progressive decline in Dyn B in striatum and frontal cortex, Dyn A shows an upward 
trend in frontal cortex without significant change in striatum.  Systemic MPTP produces 
significant short-term elevations in dynorphin peptides that regress to below baseline by 7 
days.   HPLC analysis of striatal dopamine shows an age-dependent increase in basal 
dopamine levels in Pdyn KO mice, an effect that is abolished after MPTP.  Western 
blotting experiments demonstrate that Pdyn deletion is associated with greater 
phosphorylation at the serine-40 site of tyrosine hydroxylase (TH) despite relatively less 
total TH immunoreactivity, suggesting a suppressive effect of dynorphins on dopamine 
synthesis.  Microarray analysis of hippocampal tissue from young and aged WT and Pdyn 
KO mice reveals a number of functional groups of genes demonstrating altered 
expression.  The results of this dissertation support a role of endogenous dynorphins in 
age-associated cognitive and motor dysfunction.  
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 1 
   
CHAPTER 1:  Introduction 
 
Dynorphins, endogenous opioid peptides found in specific pathways in the brain, have 
recently received increased attention for their roles in a variety of physiological and 
pathological processes.  This dissertation will seek to examine the role of these peptides 
in the brain during aging with regard to two major behavioral functionalities that are 
compromised in normal aging and in age-related disorders.  The first is learning and 
memory, a major aspect of cognition that has been exensively studied across multiple 
species and technical disciplines, but for which little is known about mechanisms 
contributing to age-related impairment.  The second is motor function, a prominent 
feature of both normal aging and pathological states such as Parkinson's disease.   In both 
these areas, dynorphin peptides have been suggested to influence behavioral endpoints.  
This chapter will summarize the existing literature on the known properties and actions of 
dynorphins, with particular attention to their roles in the above functional domains, and 
establish the rationale for studies described in subsequent chapters. 
 
Introduction to dynorphins 
First isolated in 1979 (Goldstein et al., 1979), the dynorphins were described originally in 
terms of their opiate properties, namely as  opioid receptor (KOR) agonists.  Numerous 
other studies since have identified other mechanisms by which these peptides influence 
the many neurobiological processes in which they have been implicated.   Historically, 
when these peptides were first identified, they were given the name “dynorphin” to 
indicate their relatively high potency in an ileal tissue contractility inhibition assay when 
compared to morphine (Goldstein et al., 1979).  The term dynorphin generally refers to 
peptides obtained by proteolytical cleavage of a polypeptide precursor encoded by the 
prodynorphin (Pdyn) gene and most commonly refer to dynorphin A (Dyn A 1-17) or 
dynorphin B (Dyn B 1-16) [reviewed in (Simonato and Romualdi, 1996; Hauser et al., 
2005)].  Other peptides obtained from this prodynorphin precursor include alpha-
neoendorphin (α-NE), "Big Dynorphin" (Dyn-32), leumorphin (Dyn B 1-29), Leucine-
enkephalin-arginine (Leu-Enk-Arg), and Leucine-enkephalin (Leu-Enk) (Hauser et al., 
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2005).  Biochemically, dynorphin peptides are C-terminal extensions of Leu-Enk in that 
they share the same five amino-terminal residues as Leu-Enk, thereby explaining some 
the pharmacologic similarities between these classes of opiate peptides.  Table 1.1 details 
the amino acid composition of selected prodynorphin-derived peptides.  Notably, these 
peptides have a relatively high proportion of the basic amino acid residues lysine and 
arginine, resulting in their high positive charge, which imparts certain biophysical 
properties that can affect their biochemical interactions (Naqvi et al., 1998; Tan-No et al., 
2001; Marinova et al., 2005). 
 
Table 1.1.  Amino acid composition of selected prodynorphin-derived peptides. 
 
Anatomical distribution of dynorphin peptides 
Immununohistochemistry and in situ hybridization studies have demonstrated that 
dynorphin peptides are widely distributed in the central nervous system (CNS) 
(Khachaturian et al., 1982; Watson et al., 1982a; Watson et al., 1982b; Hurd et al., 1999).  
High Pdyn mRNA levels have been noted in hypothalamus, nucleus accumbens, 
neostriatum, dentate gyrus, hippocampus, cerebral cortex, and spinal cord (Khachaturian 
et al., 1993; Yakovleva et al., 2006b).  One particular area of interest is the hippocampal 
formation, where dynorphins are prominent in mossy fiber terminals (McGinty et al., 
1983; Zamir et al., 1985).  Prodynorphin precursors are synthesized in granule cells of the 
dentate gyrus and transported along the axons of the mossy fiber pathway to terminate at 
synapses in the CA3 region of the hippocampus.  In addition to the mossy fiber-CA3 
pyramidal cell synapses, dynorphins have also been identified at perforant path-granule 
cell synapses and mossy fiber recurrent synapses in the dentate gyrus (Wagner et al., 
1993; Terman et al., 1994; Terman et al., 2000). 
Peptide Sequence 
Dynorphin A (1-17) YGGFLRRIRPKLKWDNQ 
Dynorphin A (2-17) GGFLRRIRPKLKWDNQ 
Dynorphin A (1-13) YGGFLRRIRPKLK 
Dynorphin B YGGFLRRQFKVVT 
Dynorphin 32 (Big Dynorphin) (Dyn A)-KR-(Dyn B) 
-neo-endorphin YGGFLRKYP 
-neo-endorphin YGGFLRKYPK 
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Dynorphins are also distributed in the striatonigral system.  Within the striatum, 
dynorphins are found predominantly colocalized with substance P and GABA within 
dopamine D1-receptor (D1R)-expressing striatonigral projection neurons [reviewed in 
(Steiner and Gerfen, 1998)].  Striatal dynorphinergic neurons project to the substantia 
nigra (SN) and contact tyrosine hydroxylase (TH)-positive dopaminergic neurons (Pickel 
et al., 1993).  Since  opioid receptors are found on presynaptic terminals in striatum and 
on glutamatergic neurons projecting from the subthalamic nucleus to the globus pallidus 
(Abou-Khalil et al., 1984), the neuroanatomical distribution of dynorphins favors a 
opioid-mediated mechanism by which dynorphins can regulate dopamine (DA) release 
and/or function in the striatum.  A recent study employing electron microscopy with dual 
labeling of prodynorphin and either D1R or TH in the rat nucleus accumbens showed that 
a majority (63%) of prodynorphin-containing dendrites colocalized with the D1R (Hara 
et al., 2006).  Moreover, axon terminals containing Pdyn frequently made synaptic 
connections with D1R-containing dendrites and TH-containing axon terminals.  The 
ultrastructural evidence thus supports a mechanism whereby dynorphin peptides can 
readily modulate dopamine release or its postsynaptic effects.  Similarly, 
neuroanatomical colocalization of dynorphins with gonadotropins (Knepel et al., 1985) 
and with vasopressin (Sherman et al., 1986) has also been reported in the anterior 
pituitary and hypothalamus, respectively. 
Outside of the CNS, dynorphin peptides are found in a wide range of tissue and 
organ types, including adrenal glands, heart, lung, and reproductive organs (Simonato 
and Romualdi, 1996).  Additionally, dynorphin-responsive opioid receptors have been 
found on dendritic cells of mice (Kirst et al., 2002), and dynorphin is found in 
sympathetic neurons in the liver in close approximation to -receptor-expressing 
lymphocytes (Kaiser et al., 2003), suggesting a role in neuroimmunomodulation. 
 
Regulation of dynorphin expression 
The control of dynorphin expression occurs at a number of levels.  The molecular biology 
of the Pdyn gene shows the presence of various sites that may be modulated by 
transcription factor binding (Simonato and Romualdi, 1996).  Its promoter contains a 
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functional AP-1 element (Naranjo et al., 1991; Bronstein et al., 1994), and antisense c-fos 
mRNA has been found to reduce Pdyn mRNA levels in vitro (Hunter et al., 1995), which 
suggests that basal expression of dynorphins are at least partially mediated via the AP-1 
site.  The rat Pdyn promoter contains four distinct cAMP response elements (CREs), and 
when bound by CREB, these elements suppress Pdyn transcription (Collins-Hicok et al., 
1994) and can potentially enhance memory processes (Josselyn et al., 2001; Nguyen, 
2001).  In the nucleus accumbens, CREB has been shown to increase Pdyn mRNA 
expression (Carlezon et al., 1998).  The Downstream Regulatory Element Antagonistic 
Modulator (DREAM) transcription factor has been shown to block Pdyn expression in 
spinal cord (Cheng et al., 2002), and this inhibition also occurs in pancreatic islet cells 
during low-calcium states (Jacobson et al., 2006).  Nitric oxide and cyclic GMP (cGMP) 
have also been implicated in suppressing Pdyn gene expression.  In the hippocampus, 
injection of the nitric oxide donor Sin-1 or the cGMP analogue 8-bromo-cGMP reduced 
Pdyn mRNA levels (Johnston and Morris, 1994, 1995), as did injection of NMDA 
(Johnston and Morris, 1995).  Moreover, the nitric oxide synthase inhibitor L-NAME can 
block the amphetamine-induced increase in Pdyn mRNA expression in the striatum and 
amygdala (Przewlocka et al., 1996).  Dynorphin gene expression is also enhanced in 
embryonic stem cell nuclei by exposure to Dyn B, suggesting the presence of a 
feedforward control system via nuclear  receptors (Ventura et al., 2003). 
Environmental and biological factors that are associated with Pdyn gene 
expression have also been identified.  Dynorphin peptides are increased by various types 
of cellular stressors.  Traumatic spinal cord injury causes localized increases in spinal 
cord dynorphins beginning within hours of the insult and lasting weeks, without a 
corresponding change in enkephalin (Faden et al., 1985a, b).  Inoculation of mycobacteria 
to induce joint swelling and inflammation in rats as a model for chronic pain resulted in 
increased dynorphin levels in anterior pituitary, hypothalamus, and spinal cord (Millan et 
al., 1985), as does a Freund’s adjuvant model of peripheral inflammation (Iadarola et al., 
1986).  The increase in dynorphin expression in spinal cord following peripheral 
inflammation is enhanced in aged animals (Zhang et al., 2004a).  In addition, dynorphin 
expression in the hippocampus increases following systemic administration of kainic 
acid, particularly during the process of mossy fiber sprouting (Simpson et al., 1997).  
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Surgical lesioning of the perforant path also mimics this effect (Thai et al., 1996).  
Normal aging is also associated with changes in the dynorphinergic system.  Age-related 
changes in Dyn peptide or Pdyn mRNA expression have been noted in the rodent 
hippocampus and cortex (Jiang et al., 1989; Zhang et al., 1991; Gallagher and Nicolle, 
1993).  Alterations in CREB expression (Collins-Hicok et al., 1994) or binding at the AP-
1 site in the Pdyn promoter (Naranjo et al., 1991; Collins-Hicok et al., 1994; Hunter et al., 
1995; Kitamura et al., 1995) could increase transcription and thus represent feasible 
molecular mechanisms for increased Pdyn with age.  Prior studies had shown significant 
increases of approximately 50% in dynorphin immunoreactivity in the hippocampus and 
frontal cortex of aged rats, especially aged rats who were also memory-impaired (Jiang et 
al., 1989; Gallagher and Nicolle, 1993). Elevated levels of dynorphin A(1-8) in the 
hippocampus and frontal cortex were correlated with deficits in Morris water maze 
performance (Jiang et al., 1989) and with decreased glutamate release (Zhang et al., 
1991).  Increased dynorphin immunoreactivity was also observed in the supragranular 
layer and mossy fiber system of amyloid precursor protein (APP)-overexpressing mice 
(Diez et al., 2000).  In humans, dynorphin A is markedly elevated in the frontal cortex of 
patients with Down syndrome or Alzheimer’s disease (AD) (Risser et al., 1996).  In 
models of PD, several studies have observed decreases in Dyn following experimental 
manipulations that lesion the nigrostriatal dopaminergic pathway (Gerfen et al., 1991), 
produce dopamine depletion as in suppression of the vesicular monoamine transporter 
type 2 (VMAT2) gene (Colebrooke et al., 2007), or cause decreased dopamine receptor 
activity as in D1-receptor knockout mice (Wong et al., 2003). 
 
Pharmacology of dynorphins 
Because the known pharmacological activity of dynorphins is not limited to their 
interaction with the KOR, their effects in vivo have been difficult to fully characterize, 
and many effects of the prodynorphin-derived peptides may vary from one organ system 
to the next [reviewed in (Hauser et al., 2005)].  The interaction at the  opioid receptor 
was the first effect of dynorphins to be characterized, with their particularly high affinity 
for the κ opioid receptor (Goldstein et al., 1979; Chavkin et al., 1982) (Goldstein and 
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Naidu, 1989) that requires the N-terminal tyrosine residue.  Although the affinity of 
dynorphin for κ opioid receptors is within the picomolar range, physiological 
concentrations of dynorphins are still capable of binding to μ and δ opioid receptors 
(Garzon et al., 1984).   
Interestingly, dynorphins at supraphysiological levels demonstrate significant 
interactions with the NMDA receptor (Chen et al., 1995a, b; Chen and Huang, 1998; 
Tang et al., 1999), presumed to be mediated by C-terminal residues.  Depending on the 
particular experimental conditions, the dynorphin peptides can bind to the NMDA 
receptor and either block or potentiate NMDA receptor activation (Brauneis et al., 1996; 
Shukla et al., 1997; Zhang et al., 1997; Caudle and Dubner, 1998; Tang et al., 1999).  
Mass spectrometry studies have confirmed that the positively charged residues of 
dynorphin A 1-17 and its non-opioid counterpart dynorphin A 2-17 allow the peptides to 
form stable complexes with a conserved epitope on the NR1 subunit of the NMDA 
receptor that consists of five adjacent glutamate residues and an aspartate residue (Woods 
et al., 2006).  Dynorphins have also been reported to act at sites that are not affected by 
either opioid or NMDA antagonists (Tang et al., 2000), including direct non-covalent 
interactions with the excitatory amino acids glutamate and aspartate (Woods and Zangen, 
2001), likely a result of their highly basic amino acid constituency.  Additionally, 
dynorphin peptides have also been observed to possess cell-penetrating capabilities and 
interact directly with phospholipid membranes (Lind et al., 2006).  The complex 
pharmacologic activity of dynorphin peptides presents a difficulty when using specific 
pharmacological antagonists to evaluate the role of dynorphins in a particular 
experimental system, since the use of even highly selective opioid agonists or antagonists 
may not be sufficient to distinguish clearly the extent to which dynorphins contribute to a 
given physiological effect.   
 
Review of physiological and pathological processes involving dynorphins 
The fairly broad interactions of dynorphins across multiple receptor and organ systems 
have hindered attempts to elucidate fully the functional significance of dynorphinergic 
activity in vivo.  The literature, however, does support a role of dynorphin peptides in 
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certain neurobiological functions, which include learning and memory, motivation, pain 
and nociception, modulation of seizure threshold, motor activity, and a variety of other 
physiological processes.  Regarding the role of dynorphins in learning and memory, 
several behavioral studies point toward a detrimental effect of excess dynorphin.  Aged 
rats, for instance, exhibit increases in hippocampal dynorphin that correlate with spatial 
memory impairment (Jiang et al., 1989; Gallagher and Nicolle, 1993).  Microinjection of 
dynorphin B into the rat hippocampus similarly showed impaired performance in the 
Morris water maze task (Sandin et al., 1998), and this effect was blocked by the selective 
κ opioid antagonist nor-binaltorphimine, while nor-binaltorphimine alone had no effect 
(Sandin et al., 1998).  Dynorphin was also found to dose-dependently impair retention in 
an inhibitory avoidance task in mice (Introini-Collison et al., 1987), and direct infusion of 
dynorphin A(1-8) into the hippocampus dose-dependently impairs spatial memory in rats 
(McDaniel et al., 1990).  Electrophysiological studies support an ability of dynorphin to 
inhibit neural plasticity by blocking long-term potentiation (LTP), by mechanisms that 
may include presynaptic inhibition of glutamate release via κ opioid receptors or 
postsynaptic modulation of LTP as a retrograde inhibitory neurotransmitter (Wagner et 
al., 1992; Wagner et al., 1993; Weisskopf et al., 1993).  From human studies, AD patients 
have been noted to exhibit large increases in κ opioid receptor levels (Hiller et al., 1987) 
and Dyn A (Yakovleva et al., 2006a), and cognitive performance in AD patients can be 
improved by the nonselective opioid antagonist naloxone (Reisberg et al., 1983).  On the 
other hand, dynorphin activity in the cholinergic system has been noted to be more 
favorable to learning in memory, as it reduces passive avoidance task deficits induced by 
mecamylamine (Hiramatsu et al., 1997; Hiramatsu and Watanabe, 2006) or galanin 
(Hiramatsu et al., 1996). 
Pain control is a common clinical indication for opiate use in general, although 
the  opioid receptor is seldom specifically targeted.  In contrast to other classes of 
opioids, dynorphins have minimal analgesic effects in the brain (Friedman et al., 1981). 
While dynorphin peptides can antagonize analgesic effects in opiate-naïve subjects, they 
may also potentiate analgesia in morphine-tolerant animals [reviewed in (Smith and Lee, 
1988)] while exhibiting minimal withdrawal effects (Khazan et al., 1983), suggesting a 
modulatory role of dynorphins in the pain processing in the brain.  In spinal cord, 
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intrathecal dynorphin administration at low concentrations produces analgesia mediated 
by opioid receptors, but at higher concentratrions can cause allodynia (Vanderah et al., 
1996; Laughlin et al., 1997), flaccid hindlimb paralysis (Faden and Jacobs, 1984; Stevens 
and Yaksh, 1986; Long et al., 1988a; Long et al., 1988b), and neuronal and axonal injury 
(Caudle and Isaac, 1987; Long et al., 1988a; Long et al., 1988b; Hauser et al., 2001). In 
fact, a growing body of literature supports a role of dynorphins in exacerbating 
neuropathic pain, particularly in spinal cord injury models (Lai et al., 2001).    Moreover, 
these latter effects are not mitigated by an opioid antagonist nor by substituting peptides 
lacking the N-terminal tyrosine residue needed for opiate receptor interactions.  This 
implicates the involvement of non-opioid-mediated mechanisms (Bakshi and Faden, 
1990; Vanderah et al., 1996; Shukla et al., 1997; Hauser et al., 2001), such as those 
involving the NMDA receptor (Caudle and Isaac, 1988; Bakshi and Faden, 1990).   
Blocking dynorphin by administering synthetic peptides containing the NR1 epitope of 
the NMDA receptor prevents neurotoxicity in cell culture experiments and in in vivo 
models of dynorphin-induced allodynia and paralysis (Woods et al., 2006).   
Additionally, the effects of dynorphins on glutamate and aspartate release are believed to 
contribute to excitotoxic mechanisms that may exacerbate cellular injury under 
appropriate circumstances.  Intrahippocampal dynorphin injections produce elevations in 
excitatory amino acids in a non-opioid-dependent manner (Faden, 1992).  Potential 
mechanisms include dynorphin-induced increases in intracellular calcium, as previously 
observed in cultured cortical neurons and dorsal root ganglion cells (Tang et al., 2000; 
Lai et al., 2001).   
In contrast to the excitotoxicity roles noted above, dynorphins also have known 
anticonvulsant actions (Przewlocka et al., 1983; Siggins et al., 1986) and inhibitory 
effects on neuronal activity and neurotransmission (Chavkin, 2000).  Dynorphins can 
block glutamate release via κ opioid receptors and post-synaptically modulate LTP 
(Wagner et al., 1992; Wagner et al., 1993; Weisskopf et al., 1993).  Pdyn deletion 
decreases seizure threshold in the kainic acid model (Loacker et al., 2007). 
Dynorphins have also been implicated in inflammation, with in vitro 
administration producing a non-opioid-dependent histamine release from rat mast cells 
(Sydbom and Terenius, 1985) and in vivo experiments showing dynorphin-induced 
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plasma extravasation in rat skin (Chahl and Chahl, 1986).  In models of chronic pain and 
peripheral inflammation, dynorphin immunoreactivity increases in conjunction with 
appearance of chronic nociceptive behavioral patterns and immediate-early gene 
expression (Noguchi et al., 1991; Gillardon et al., 1994; Zhang et al., 2005), and these 
changes can be suppressed by anti-sense oligonucleotides against c-fos (Gillardon et al., 
1994; Zhang et al., 2005).  While Pdyn-derived peptides are not required for initiation of 
neuropathic pain in a spinal nerve ligation model, they are elevated by approximately 10 
days post-ligation and are needed for maintenance of chronic neuropathic pain (Wang et 
al., 2001).  In models of spinal cord hyperalgesia, intrathecal dynorphin injection causes 
release of prostaglandin and excitatory amino acids in cyclooxygenase-dependent and 
opiate-independent mechanisms (Koetzner et al., 2004). 
The role of dynorphin peptides in the motor system, including the dopaminergic 
nigrostriatal pathway, has also begun to receive increased attention in the literature.  In 
the striatum and nucleus accumbens, dynorphins and exogenous  agonists have clearly 
been shown to inhibit dopamine release (Mulder et al., 1984; Herrera-Marschitz et al., 
1986; Di Chiara and Imperato, 1988; Reid et al., 1988; Spanagel et al., 1992; Ronken et 
al., 1993; Schlosser et al., 1995), while  antagonists can elevate basal DA release 
(Spanagel et al., 1992).  Dynorphins also reduce glutamate release in output regions of 
basal ganglia (Maneuf et al., 1995).  Striatal neurons are also susceptible to dynorphin-
induced apoptosis in cell culture models (Tan-No et al., 2001).  Moreover, striatal 
neurons transfected with Dyn-32 (a.k.a. “big dynorphin”) exhibit cytotoxic effects (Tan-
No et al., 2001).  In terms of functional behavioral manifestations, administration of high 
doses of dynorphin peptides into brain regions were demonstrated in early studies to 
induce barrel rotation in rats in a naloxone-independent manner (Smith and Lee, 1988), 
while intrathecal dynorphin administration induces flaccid paralysis (Smith and Lee, 
1988).  More recent studies have shown that activation of the  opioid receptor tends to 
suppress locomotion; for instance, in rats, the  agonist CI-977 decreased locomotion in a 
naloxone-reversible manner (Fernandez et al., 1999).   -opiate receptor deficient mice 
show similar spontaneous locomotor activity compared to WT but are resistant to the 
decreased locomotor activity that accompanies administration of  agonists (Simonin et 
al., 1998).  
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The endocrine system is also affected by endogenous dynorphins.  Dynorphin 
elevates serum prolactin presumably by lowering dopaminergic tone in the 
tuberoinfundibular system (Kreek et al., 1999), thereby removing the inhibitory effect of 
dopamine on prolactin release. Estrogens also appear to control Pdyn expression in the 
anterior pituitary (Spampinato et al., 1995).   Also, dynorphin A(1-17), via a  opioid 
receptor mechanism, can stimulate glucagon release from pancreatic alpha cells 
(Jacobson et al., 2006).  Dynorphin in the hypothalamus colocalizes with vasopressin 
(Sherman et al., 1986), and  opioid agonists and dynorphin analogues have been 
demonstrated to induce water diuresis via negative regulation of antidiuretic hormone in a 
 opioid-dependent manner (Currie et al., 1994; Ohnishi et al., 1994).  Furthermore, 
dynorphins increase serum levels of adrenocorticotropic hormone (ACTH) in both ovine 
and murine models (Cheng et al., 2000; Nardo et al., 2002).  A putative role of 
dynorphins in negative feedback of gonoadotropin acticvity has also been proposed, as 
progesterone increases Dyn A in cerebrospinal fluid and Pdyn mRNA in hypothalamus, 
with resultant inhibition of pulsatile gonatotropin-releasing hormone activity (Goodman 
et al., 2004; Foradori et al., 2005).  Other effects of dynorphin peptides that have been 
reported include decreased blood pressure and heart rate, respiratory depression, body 
temperature regulation, and appetite stimulation (Smith and Lee, 1988).  Fasting 
increases Pdyn expression, while Pdyn suppression increases fatty acid oxidation and 
weight loss (Sainsbury et al., 2007). 
 
Aging and the dynorphinergic system 
Since dynorphins have been implicated in aging, the neurobiology of aging will be briefly 
reviewed here. Aging is associated with a number of physical and behavioral alterations, 
often with distinct neurobiological and neurochemical changes in the CNS and 
commonly associated with functional declines in nervous system function that lead to 
sensory, motor, cognitive, and numerous other types of deficits.  Cognitive changes 
represent an important component of brain aging that has clear relevance to an 
individual’s functional status.  Rat behavioral studies in particular have documented 
significant aging declines in cognitive tasks (Barnes, 1987; Greene and Naranjo, 1987).  
Recent evidence suggests that cognitive decline in most cases cannot be explained solely 
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by decreased neuronal numbers in the aged brain.  Age-related deficits in learning and 
memory are typically attributed not only to varying degrees of degenerative neuronal loss 
but also to functional decreases in neurotransmission or neural plasticity.  One of the 
most widely studied regions related to cognition is the hippocampus. Numerous studies 
have attempted to assess whether hippocampal size, volume, or neuronal number is 
altered with age (Miller and O'Callaghan, 2003).  While earlier studies concluded 
widespread decreases in neuronal density in hippocampus, more recent unbiased 
stereological counting techniques revealed only small or nonsignificant declines.  For 
instance, one study found stereological estimates of hippocampal volume to decrease 
only 2.16% compared to normal adult mice (von Bohlen und Halbach and Unsicker, 
2002).  Neuronal density in hippocampus in this study was found to demonstrate a 
nonsignificant decrease of 4-7%.  While studies in humans have noted progressive 
decline in certain tasks beginning in early young adulthood, the mechanisms underlying 
these changes have been difficult to identify.   
Motor impairments with normal aging have been found across multiple species 
and are likely due to impairments in the dopamine neurotransmitter system in basal 
ganglia motor pathways (Ingram, 2000). Dopamine, synthesized by neurons in the SN 
projecting to the striatum, has been strongly implicated in aging (Reeves et al., 2002).  
For instance, some early studies have reported substantial declines in normal aged 
humans from young adult levels (Kish et al., 1992).  One study (Kish et al., 1992) 
observed a statistically significant 60% loss of dopamine in human postmortem striatal 
specimens in normal 84-year-olds compared to normal 22-year-olds.  However, recent 
studies have concluded that the decreases typically attributed to aging are of much 
smaller magnitude (Friedemann and Gerhardt, 1992; Burwell et al., 1995; Hebert and 
Gerhardt, 1998; Stanford et al., 2003).  One study in mice (Greenwood et al., 1991) found 
no age-related change in DA and its metabolite 3,4-dihydroxyphenylacetic acid 
(DOPAC) relative to striatal wet weight.  However, these monoamine levels were 
increased 5- to 7-fold at 21 months of age compared to at 2 months when expressed 
relative to the proportion of remaining TH-positive neurons, suggesting the existence of 
compensatory effects.  In pathological states such as Parkinson’s disease, clinically 
manifested by symptoms of bradykinesia, gait and posture disturbances, rigidity, and 
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resting tremor (Hornykiewicz and Kish, 1987; Forno, 1996), severe dopaminergic 
neuronal loss in SN is observed (Graybiel et al., 1990), with age as the most identifiable 
risk factor for sporadic cases of PD.   In addition, dopamine dysfunction may also affect 
cognition as well (Nieoullon, 2002; Marie and Defer, 2003; Nieoullon and Coquerel, 
2003; Pillon et al., 2003; Remy and Samson, 2003). The mechanisms by which 
dopaminergic neuron loss occurs either in normal aging or in pathological conditions are 
currently unknown. 
The role of dynorphin peptides in Parkinson’s disease is controversial with at least 
one study reporting decreased dynorphins in SN of PD patients (Waters et al., 1988) and 
some reporting no change (Taquet et al., 1985; Baronti et al., 1991).  Although  agonists 
have been evaluated for therapy in a small clinical trial of PD patients based on 
hypothesized effects on glutamatergic neurons, they were not found to have any 
discernable effects of motor performance and in fact exhibited dose-limiting adverse 
effects, including behavioral aberrations (Giuffra et al., 1993). 
 
Overview of experimental aims 
The experimental studies described in this dissertation primarily involve behavioral, 
biochemical, and molecular biological studies in mice.  Specifically, we make use of a 
strain of knockout (KO) mice lacking the coding exons of the Pdyn gene (Sharifi et al., 
2001).  These mice do not exhibit any gross developmental, morphological, or overt 
behavioral deficits (Sharifi et al., 2001).  To minimize effects related to genetic 
background variation, these mice were maintained within the 129SvEv background and 
compared to 129SvEv WT mice as controls.   The use of Pdyn KO mice offers several 
distinct advantages over studies employing exogenously administered agents.  First, acute 
stresses related to experimental manipulations are minimized.  Second, complexities 
associated with the pharmacodynamics and pharmacokinetics of peptide agents, including 
limitations on in vivo half-lives and distribution or delivery issues, are circumvented.  
Third, because potential dynorphin interactions include more than the  opioid receptor, 
the approach of employing knockout mice enables analysis of effects of Pdyn suppression 
at the gene expression level without necessitating assumptions regarding the types of 
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receptors involved.  In addition, long-term effects and compensatory mechanisms, such 
as those associated with aging, can be more readily evaluated.  The experiments 
described in this dissertation therefore represent novel approaches that would 
complement and enhance existing knowledge of dynorphin peptides in cognition and 
motor function. 
To address the effect of Pdyn deletion on learning and memory impairment with 
age, a series of behavioral experiments will be described in which WT and Pdyn KO 
mice are tested in both spatial and nonspatial learning tasks.   Spatial learning and 
memory was assessed using a Morris water maze paradigm (Morris et al., 1982), and 
non-spatial tasks include both a passive avoidance task, which uses an aversive foot-
shock stimulus, and a paired object recognition assay.   The role of dynorphins in motor 
function was evaluated using open-field analysis of spontaneous locomotion and 
quantitation of striatal content of dopamine and related monoamines under basal 
conditions and following systemic administration of the neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP).  Next, we will discuss quantitaion of dynorphin 
peptides in varying regions of the aging or MPTP-treated mouse brain using 
radioimmunological methods.  Finally, gene expression changes with aging and Pdyn 
deletion were systematically analyzed to identify patterns of upregualted or 
downregulated genes that may shed light on potential mechanisms to explain the 
behavioral and neurochemical findings reported in this dissertation. 
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CHAPTER 2:  Prodynorphin knockout mice demonstrate diminished age-
associated impairment in spatial water maze performance 
 
Introduction 
The endogenous opioid peptide dynorphin, expressed widely in the central nervous 
system (Khachaturian et al., 1982; Watson et al., 1982a; Watson et al., 1982b; Hurd et al., 
1999) and particularly prominent in mossy fiber terminals of the hippocampal formation 
(McGinty et al., 1983; Zamir et al., 1985), has been implicated in modulating learning 
and memory.  Dynorphin peptides are pharmacological agonists at  opioid receptors 
(Chavkin et al., 1982), and to a lesser extent  and  receptors (Garzon et al., 1984), but 
have been observed to interact with other non-opioid targets like the NMDA receptor 
(Chen et al., 1995a, b; Chen and Huang, 1998; Tang et al., 1999) and even the excitatory 
amino acids themselves (Woods and Zangen, 2001).  The effects of endogenous 
dynorphins in learning and memory are supported by reports of their ability to inhibit 
neural plasticity by blocking long-term potentiation (LTP) at mossy fiber-CA3 pyramidal 
cell synapses, perforant path-granule cell synapses, and mossy fiber recurrent synapses in 
the dentate gyrus (Wagner et al., 1993; Terman et al., 1994; Terman et al., 2000).  The 
mechanisms involved include presynaptic inhibition of glutamate release via κ opioid 
receptors and postsynaptic modulation of LTP as a retrograde inhibitory neurotransmitter 
(Wagner et al., 1992; Wagner et al., 1993; Weisskopf et al., 1993).  
Behavioral studies have documented an inhibitory effect of this neuropeptide on 
learning and memory.  In vivo approaches in rats have demonstrated impairment of 
spatial memory upon intrahippocampal injection of dynorphin A(1-8) (McDaniel et al., 
1990) or dynorphin B (Sandin et al., 1998).  Dynorphin was also found to dose-
dependently impair retention in an inhibitory avoidance task in mice (Introini-Collison et 
al., 1987). The findings that dynorphin is elevated in hippocampus and frontal cortex of 
aged rats, especially memory-impaired rats (Jiang et al., 1989; Gallagher and Nicolle, 
1993), further suggested a possible involvement of dynorphins in age-related memory 
deficits.  Of particular relevance to human disease, dynorphin A is markedly elevated in 
the frontal cortex of patients with Down syndrome or Alzheimer’s disease (AD) (Risser 
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et al., 1996) and in mice overexpressing human amyloid precursor protein (Diez et al., 
2000).  Large increases in κ opioid receptor levels have also been noted in brains of AD 
patients (Hiller et al., 1987), and cognitive performance in AD patients can be improved 
by the nonselective opioid antagonist naloxone (Reisberg et al., 1983).  
A definitive causative role of increases in dynorphin in producing memory 
deficits associated with normal aging has not been clearly established, and cellular and 
genetic mechanisms related to its effect in the hippocampus and other parts of the brain 
have not been carefully explored.  To investigate the mechanisms underlying age-
dependent changes in spatial learning and memory and the potential role of dynorphins in 
mediating these changes, we examine in this study the effects of aging in knockout mice 
lacking the coding exons for the precursor prodynorphin (Pdyn) (Sharifi et al., 2001).   
 
Materials and Methods 
Animal subjects 
All animals in this study were wild-type (WT) or Pdyn KO mice that were maintained in 
an approved animal facility at the University of Kentucky.  WT mice were derived from 
the 129SvEv-Tac line, and Pdyn KO mice were originally obtained by targeted deletion 
of the coding exons of the prodynorphin gene and bred into a 129SvEv-Tac background 
as previously described (Sharifi et al., 2001).  These KO mice demonstrate no serious 
structural, developmental, or behavioral phenotypic impairment (Sharifi et al., 2001).  To 
minimize effects of genetic background variation, the WT and Pdyn KO mice used in this 
study were obtained from offspring of multiple matings between Pdyn KO and WT mice.  
The aged mice included in this analysis ranged from 13 to 17 months at the time of 
testing, averaging 15.8 ± 2.0 (mean ± S.D.) months for WT and 15.2 ± 1.8 months for 
KO.  Young mice were 3 to 6 months, averaging 4.1 ± 1.8 months for WT and 3.9 ± 1.5 
months for KO.  Animals were housed in groups of up to 4 per cage with food and water 
ad libitum in a well-ventilated room with a 12 h: 12 h light: dark cycle. Prior to weaning, 
tail specimens were collected from each animal, and DNA was extracted for subsequent 
genotyping to confirm the identity of the Pdyn locus by the polymerase chain reaction 
(PCR) using primer pairs specific for each genotype as described previously (Sharifi et 
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al., 2001).  The following primers were used in the PCR assay to detect deletion of the 
coding exons of Pdyn: 5'-ATCCAGGAAACCAGCAGCGGCTAT-3' and 5'-
ATTCAGACACATCCCACATAAGGACA-3'.  The primers used to detect WT alleles at 
the Pdyn locus were 5'-CAGGACCTGGTGCCGCCCTCAGAG-3' and 5'-
CGCTTCTGGTTGTCCCACTTCAGC-3'.  The products were amplified in a Perkin-
Elmer thermal cycler at 94°C for 5 min, followed by 30 cycles of 94°C for 30 sec, 65°C 
for 30 sec, and 72°C for 30 sec.  Samples were then incubated at 72°C for 5 min, 
followed by electrophoresis on 1% agarose gels containing ethidium bromide and 
visualization under ultraviolet (UV) lighting.  Only male mice were used in the 
behavioral experiments.  All procedures involving animals are approved by the 
Institutional Animal Care and Use Committee at the University of Kentucky.   
 
Water maze spatial navigation testing 
The Morris water maze protocol used in this study was an adaptation of that used 
previously in the detection of subtle spatial learning and memory differences (Fugger et 
al., 1998).  Water maze tests were conducted in a 1-m-diameter circular pool within an 
isolated well-lit room containing a number of two- and three-dimensional cues external to 
pool.  The water was opacified by toxic white powdered paint and held at a constant 
temperature of 27±2oC.  The water maze testing procedure involves one day of the cued 
phase of the water maze task, followed by three consecutive days of the spatial (hidden 
platform) phase.  Twelve trials were performed per day, grouped into four blocks of three 
trials each.  An interval of 20 sec was placed between trials of the same block, with a 15- 
to 20-minute interval between blocks.  During the cued phase, a visible rod was affixed to 
the platform, and the platform location and release points were varied across trials to 
ensure that the vector from the release point to the platform changes between each 
successive pair of trials.  Animals that did not escape more than three times during the 
last six trials of cue discrimination training were considered to have deficits in motivation 
or sensorimotor function and were removed from the study.  During spatial water maze 
testing, the platform location was fixed at a constant position 23 cm from the perimeter of 
the pool in the center of a predetermined quadrant, and the release points were selected 
according to a predetermined pseudorandom schedule from the three non-target 
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quadrants.  In both the cued and spatial tasks, the mouse was allowed to search for the 
platform for a maximum of 60 seconds, after which it was guided to the platform and 
allowed to remain on the platform for 10 seconds.  Video monitoring and tracking were 
performed for each trial using Water Maze v3.44 software interfaced with a Videomex 
recording system (Columbus Instruments, Columbus, Ohio) to record swim distances, 
quadrant preferences, platform crossings, and average proximity to platform.  The 
penultimate trial of each day of spatial water maze testing was an acquisition probe trial 
to assess intra-day spatial learning, and the first trial of Days 2 and 3 of the spatial phase 
served as 24-hour retention probe trials to record how accurately the mice retain the 
correct location of the target platform from the previous day of training.   
 
Latency and path length analysis 
Latency to platform was recorded using a stopwatch or digital timer to assess the total 
time from release of the subject into the pool until the subject successfully climbed onto 
the platform.  Mice failing to locate the platform within the allotted minute were assigned 
a latency of 60 sec.  Path length was recorded automatically by the video monitoring 
software based on the visual contrast between the mouse and the surrounding water.  
Occasional light artifacts were automatically removed by the video processing software, 
and additionally, all trajectories were screened manually in a blinded fashion to eliminate 
path length values for trials containing an unacceptably high content of light artifacts that 
were not removed by the automated artifact removal algorithm. 
 
Probe trial analysis  
The total time of each 60-second probe trial spent in each of the four quadrants was 
recorded by the video processing software and was used to calculate the percentage of 
time the subject spent in the target or opposite quadrants.  During each probe trial, the 
number of platform crossings during the 60-second interval was also recorded 
automatically by the video processing software as detailed below.  A circular area 10 cm 
in diameter was defined in the center of the target quadrant at the position of the target 
platform, and an automated counter recorded the number of times the animal subject 
traversed the defined area.  To minimize the effects of differences in motor activity or of 
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random search strategies, equivalent areas were similarly defined in each of the other 
three quadrants, and the number of these non-target crossings were averaged and 
subtracted from the number of target platform crossings to obtain a net platform crossings 
index.  The expected value of this index in the absence of a spatial memory-dependent 
search strategy is therefore taken to be zero. Average proximity to platform for each 
probe trial was also similarly recorded by the water maze analysis software. 
 
Swim speed measurement 
Average swim speed was estimated for each mouse by taking the mean swim distances 
recorded by the tracking software in each of the five probe trials and dividing by 60 sec, 
the probe trial duration.   
 
Dynorphin A extraction and radioimmunoassay (RIA) 
Frontal cortical and hippocampal tissue were isolated from 3-month (n = 8) and 12-month 
(n = 5) male WT mice following rapid asphyxiation by CO2 and were frozen in liquid 
nitrogen prior to being processed for radioimmunoassay as previously described 
(Christensson-Nylander et al., 1985; Christensson-Nylander and Terenius, 1985; 
Nylander et al., 1991).  Briefly, tissues were incubated in 1 M hot acetic acid containing 
0.01% mercaptoethanol, homogenized by sonication, heated again to 95°C, and 
subsequently centrifuged.  The resulting supernatant was applied onto ion exchange 
columns, and the resulting fractions dried using a vacuum centrifuge and redissolved in 
methanol/0.1 M HCl prior to radioimmunoassay.  Dynorphin A (Dyn A) was radiolabeled 
with 
125
I using chloramine T, and the labeled peptide was purified by high pressure liquid 
chromatography (HPLC).  Samples or standards were incubated with antiserum 
overnight, and antibody-bound peptide was separated from free peptide by the non-
immune globulin precipitation method prior to quantitation.  One hippocampal specimen 
in the 3-month group was lost due to technical reasons. 
 
Statistical analysis 
Statistical analyses were performed using Systat 10 software (SPSS Inc., Chicago, 
Illinois). Three-way ANOVA with repeated measures was used in conjunction with 
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selected a priori comparisons to determine statistical significance between groups and 
across trials or days in the behavioral experiments.  To determine whether the distribution 
of a particular measured variable, such as net platform crossings index, differs from that 
expected by chance, a one-sample Student’s t-test was used for comparison with the 
appropriate reference mean.  The effect of age on dynorphin levels as measured by 
radioimmunoassay was analyzed by the Student’s t-test.  Statistical significance was 
determined based on a p-value less than 0.05. 
 
Results 
Water maze 
A total of 18 aged Pdyn KO mice, 17 aged WT mice, 11 young Pdyn KO mice, and 13 
young WT mice were initially tested on the cue discrimination task to assess visual 
acuity, sensorimotor function, and general motivation.  Two animals, both aged Pdyn KO 
mice, failed to consistently locate the visible platform and were removed from the study.  
Based on the remaining mice, all four groups showed significant learning effects across 
the four blocks of the cued task (Figure 2.1), as determined by a repeated-measures 
ANOVA on either block-averaged latencies [F(3, 159) = 53.3, p<0.0005] or path lengths 
to platform [F(3, 132) = 40.2, p<0.0005].  Not unexpectedly, latencies for the younger 
groups approached optimal values earlier than for the aged groups, resulting in a 
significant age effect [F(1, 53) = 9.90, p<0.003] and learning-age interaction [F(3, 159) = 
5.19, p<0.002] (Figure 2.1).  Individual contrasts revealed that aged mice reached the 
platform more slowly among both Pdyn KO (p<0.003 in Block 2; p<0.05 in Block 3) and 
WT (p<0.02 in Blocks 2 and 3) mice.  However, age effects between groups vanish when 
analyzing path length [F(1, 44) = 3.59, NS] (Figure 2.1), suggesting that the higher 
latencies in the aged groups are largely attributable to differences in swim speed.  Indeed, 
average swim speeds recorded during the five probe trials were significantly higher in 
young mice than aged mice [F(1, 53) = 24.7, p<0.0005], and this effect was apparent 
among both the Pdyn KO (p<0.0005) and WT (p<0.004) genotypes.  Significant 
genotype effects were not observed in either swim speed [F(1, 53) = 1.59, NS] or cued 
task performance [latency: F(1, 53) = 0.007, NS; path length: F(1, 44) = 0.596, NS].  
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To test whether the mice show increased efficiency in locating the submerged 
platform across time, the spatial water maze swim task was performed across three 
consecutive days.  Daily averages for latency to platform showed a monotonic decrease 
across the three days of spatial testing for all groups tested (Figure 2.2).  When analyzing 
individual group performance by repeated-measures ANOVA on daily mean latencies, 
significant learning effects were seen across days for young Pdyn KO and young WT 
groups (p<0.0005) and for the aged Pdyn KO group (p<0.05), but not for the aged WT 
group (p=0.11).  However, ANOVA found no genotype effect [F(1, 53) = 0.376, NS] 
even though a significant aging effect [F(1, 53) = 28.2, p<0.0005], learning effect [F(2, 
106) = 34.6, p<0.0005], and age-learning interaction [F(2, 106) = 5.81, p<0.004] were 
observed.  Significantly higher latencies to platform were evident in aged mouse groups 
compared to young mice within both the WT (p<0.03 on Day 1; p<0.0005 on Days 2 and 
3) and Pdyn KO (p<0.001 on Day 2; p<0.004 on Day 3) genotypes.   
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Figure 2.1.  Cued water maze task performance and swim speed. 
Left: Latency measurements during the cue discrimination task show a highly significant 
trend of learning across trials and a significant age effect during blocks 2 and 3, but no 
Pdyn genotype effect.  Right:  The age effect is absent in the analysis of cued task path 
length, and all four groups demonstrate comparably strong learning across trials.  Far 
right: Young mice swim significantly faster than aged mice, but no significant Pdyn 
genotype effect is seen.
 
 
*
p<0.05, 
**
p<0.02, 
***
p<0.005 relative to young controls. 
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Because individual differences in swim speed may account for some of the 
variance in latencies, the mean path lengths for non-probe trials in each day were also 
analyzed by repeated measures ANOVA to obtain a speed-independent measure of 
spatial memory task performance.  A linear trend across days is clearly evident in the 
daily averages for swim distance (Figure 2.2).  The young Pdyn KO, young WT, and 
aged Pdyn KO groups all demonstrated highly significant learning effects across days 
p<0.0005), as did the aged WT group (p<0.004).  As observed in the latency analysis, 
ANOVA showed a significant age effect [F(1, 53) = 15.7, p<0.0005], learning effect 
[F(2, 106) = 56.2, p<0.0005], and age-learning interaction [F(2, 106) = 3.74, p<0.03], but 
no significant main effect of Pdyn genotype [F(1, 53) = 0.380, NS].  Aged Pdyn KO mice 
on average use a consistently shorter path to the platform than for the aged WT mice, and 
the difference reaches significance on Day 3 (p<0.05).  Average latencies for the aged 
Pdyn KO mice were also less than for aged WT mice but failed to reach significance.  
Figure 2.2.  Spatial water maze navigation performance. 
Left:  Daily means of latency to platform show a monotonically decreasing pattern for all 
four groups with significant age effects. 
*
p<0.025, 
**
p<0.005, 
***
p<0.001 relative to 
respective young controls.  Right:  Mean path lengths similarly show significant age 
differences on Days 2 and 3, but in addition, a significant difference between aged Pdyn 
KO and WT mice is observed on Day 3.  
*
p<0.05, 
**
p<0.02, 
***
p<0.001 relative to young 
controls; 
#
p<0.05 between Pdyn KO and WT. 
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Age effects on path length were also significant for WT mice (p<0.001 on Day 2; 
p<0.005 on Day 3) and for Pdyn KO mice (p<0.02 on Day 2).  
To detect differences among groups in the extent of learning accomplished during 
each day or in the amount of spatial information retained from the previous day’s 
training, three acquisition and two retention probe trials were performed over the course 
of the spatial phase of water maze testing.  Quadrant dwell times, platform crossings, and 
average proximity to target platform were measured.  ANOVA of percent time spent in 
the target quadrant during acquisition probes (Figure 2.3) showed a significant age effect 
[F(1, 53) = 23.4, p<0.0005], learning effect across days [F(2, 106) = 18.3, p<0.0005], 
learning-genotype interaction [F(2, 106) = 4.32, p<0.02], and learning-age interaction 
[F(2, 106) = 3.15, p<0.05].  Target quadrant dwell times for retention probe trials also 
showed a significant age effect [F(1, 53) = 13.7, p<0.001) and learning effect [F(1, 53) = 
14.7). p<0.0005] but no Pdyn genotype effect [F(1, 53) = 0.174, NS].  An analogous 
analysis of opposite quadrant dwell times revealed a significant age effect [F(1, 53) = 
13.6, p<0.001], learning effect [F(2, 106) = 7.79, p<0.001], and learning-genotype 
interaction [F(2, 106) = 3.14, p<0.05] during acquisition and only an age effect [F(1, 53) 
= 10.5, p<0.002] and a learning effect [F(1, 53) = 7.77, p<0.007] during retention.  
Measured averages for target quadrant dwell times were higher in the aged Pdyn 
KO mice than aged WT mice on all three acquisition probe trials, but the difference as 
indicated by ANOVA was significant only at the end of Day 1 (p<0.02).  The acquisition 
trial on Day 1 also indicated the time spent in the opposite quadrant was significantly 
lower for the aged Pdyn KO compared to aged WT mice (p<0.03).   Interestingly, young 
Pdyn KO mice performed approximately as well as young WT mice on most days; 
however, a significant difference (p<0.03) was noted for the Day 3 acquisition probe trial 
with young WT exhibiting relatively increased goal quadrant search behavior.   Genotype 
differences within the young age group were not observed when analyzing opposite 
quadrant dwell times.  Aged WT mice spent significantly less time in the target quadrant 
than young WT mice on all three acquisition trials (p<0.001 on Day 1; p<0.001 on Days 
2 and 3) and on both retention trials (p<0.005 on Day 2; p<0.001 on Day 3).  The age 
effect on target quadrant dwell times within the Pdyn KO mice was not significant on 
either of the retention probes and was significant only on the acquisition probe trial on 
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Figure 2.3.  Quadrant analysis of probe trial performance in the water maze task. 
Left:  Acquisition probe trial analysis suggests aged Pdyn KO mice spend significantly 
more time in the correct quadrant and less time in the opposite quadrant at the end of Day 
1 than aged WT mice.  Moreover, the age effect for the WT mice is quite pronounced all 
three days, whereas the Pdyn KO mice show a significant age effect only on Day 2.  
Interestingly, young Pdyn KO mice perform more poorly than young WT mice on Day 3.  
Right:  Retention probe trials demonstrated an age difference only within the WT mice 
when examining either the target or opposite quadrant. 
*
p<0.03; 
**
p<0.005; 
***
p<0.001.  
The dashed line denotes the reference value expected by chance. 
Day 2 (p<0.02).  Analysis of opposite quadrant dwell times also failed to show 
significant age effects within the Pdyn KO genotype except on Day 3 of acquisition   
(p<0.03), whereas aged WT mice consistently spend significantly more time in the 
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opposite quadrant than young WT mice on all acquisition (p<0.02 on Day 1; p<0.03 on 
Day 2; p<0.003 on Day 3) and both retention (p<0.02 on Day 2; p<0.03 on Day 3) 
probes. 
While quadrant dwell times provide crude indications of spatial learning and 
memory, platform crossings and proximity measures were also recorded to offer a more 
refined assessment.  The net platform crossings index during the probe trials (Figure 2.4) 
showed a significant overall age effect [F(1, 53) = 42.7, p<0.0005 for acquisition; F(1, 
53) = 36.2, p<0.0005 for retention] and a significant repeated measures effect across days 
[F(2, 106) = 4.33, p<0.02 for acquisition; F(1, 53) = 4.09, p<0.05 for retention].  WT 
mice showed highly significant declines in platform crossings with age in acquisition 
(p<0.003 on Day 1; p<0.0005 on Days 2 and 3) and retention (p<0.001 on Day 2; 
p<0.0005 on Day 3) probes.  For Pdyn KO mice, the age differences were smaller but 
still significant during both acquisition (p<0.004 on Days 1 and 2; p<0.04 on Day 3) and 
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Figure 2.4.  Platform crossings in water maze probe trials. 
Left:  The number of times aged Pdyn KO mice cross the target platform location during 
the acquisition probe trials is significantly different from chance as early as the end of 
Day 2, whereas aged WT mice achieve a comparable level of significance much later.   
Right:  In the retention probe trials, although aged Pdyn KO mice have on average more 
platform crossings than aged WT mice, the difference fails to reach statistical 
significance.  In both acquisition and retention, age effects are significant, but for clarity, 
age differences are not depicted on these graphs. 
 *
p<0.025, 
**
p<0.01, 
***
p<0.005, 
#
p<0.0005 relative to chance. 
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retention (p<0.04 on Days 2 and 3).  While no explicit genotype effect was seen in the 
ANOVA model for platform crossings in either the acquisition or retention probes, 
acquisition probe performance for aged WT mice attained levels significantly different 
from chance one day later than aged Pdyn KO mice.  The higher swim speeds observed 
for the younger mice could partially account for a higher number of platform crossings 
especially for mice showing strong preferences for the target quadrant.  
When analyzing average proximity to the target platform location during the 
acquisition probe trials (Figure 2.5), a significant learning effect [F(2, 106) = 13.3, 
p<0.0005], learning-genotype interaction [F(2, 106) = 4.34, p<0.02], and learning-age 
interaction [F(2, 106) = 3.85, p<0.03] were observed, with no significant main effect of 
age [F(1, 53) = 1.40, NS] or Pdyn genotype [F(1, 53) = 0.00, NS].  Aged Pdyn KO mice 
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Figure 2.5.  Average proximity measurements during water maze probe trials. 
Left:  Average proximity to the target platform location during the acquisition probe 
trials was slightly but not significantly lower in aged Pdyn KO compared to aged WT.  
However, young WT mice performed better than aged WT mice on Day 3.  
*
p<0.02.  
Right:  No significant differences were detected in average proximity measures during 
retention trials. 
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were on average closer to the target platform location than aged WT mice on each day, 
with the largest difference at the end of Day 1 approaching statistical significance 
(p=0.057).  The only significant age difference was observed on Day 3 between young 
WT and aged WT mice (p<0.02).  During retention probes, however, the proximity 
measurements were not found to demonstrate any significant effects. 
 
Measurement of Dyn A in brain 
To test whether dynorphin levels are altered with aging in normal mice, Dyn A in frontal 
cortex and hippocampus was measured by radioimmunoassay in young and aged male 
WT mice.  A two-tailed t-test detected quantitatively higher Dyn A levels in frontal 
cortex [t(11) = 2.83, p<0.02] but not in hippocampus [t(12) = 0.051, NS] of 12-month 
WT mice compared to 3-month controls (Figure 2.6).  To assess whether additional 
elevations in dynorphin may occur at more advanced ages, Dyn A was also measured in a 
small number (n = 3) of 24-month male WT mice.  Dyn A levels for the 24-month age 
point [9.20 ± 1.22 fmol/mg (mean ± S.E.M.)] were comparable to the 12-month group 
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Figure 2.6.  Dyn A quantitation by RIA in mouse brain. 
Dynorphin A levels show significant age-dependent increases in frontal cortex but not 
hippocampus of WT mice.  
*
p<0.02 relative to 3-mo. mice. 
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and were also significantly different from the 3-month controls [t(9) = 5.34, p<0.0005].  
In hippocampus, Dyn A levels were relatively unchanged across all three age groups.  
Dyn A was also measured in females aged 12 months (n = 4) and was found to be present 
in the same amount as in 12-month males in both frontal cortex and hippocampus (data 
not shown). 
 
Discussion 
The present study confirms a significant impairment with aging in the spatial water maze 
task (Gage et al., 1984; Rapp et al., 1987; Magnusson et al., 2003).  The age-related 
impairment is clearly observable for the 13- to 16-month mice used in this study as 
demonstrated by the significant differences shown in the vast majority of the quantitative 
indicators of learning and memory.  Although aging confers an approximately 15 to 20% 
decrease in swim speed in our study, motor activity by itself is unlikely to account for 
most of the age-associated decline in performance since speed-independent 
measurements, such as path length and target quadrant preference, also exhibit highly 
significant differences with age.  Differences in general sensorimotor function, 
motivation to escape the pool, and visual acuity, all of which could potentially be affected 
by age, can be excluded because all groups performed equally well in the cued version of 
the water maze.  In addition, swim stress-induced immobility, in which dynorphins have 
been implicated (Pliakas et al., 2001), cannot account for the variations in water maze 
performance since the trials do not reveal significant reductions in mean trajectory length 
in poorly performing animals. 
The data also suggest that the age-related impairment is partially alleviated by the 
absence of dynorphin.   In most of the indices recorded, young mice show little or no 
Pdyn genotype differences, whereas among aged mice, the absence of dynorphin was 
associated with superior learning and memory scores.  Compared to WT mice, aged 
knockout mice attained modestly greater proficiency in locating the hidden platform and 
appeared to employ spatial search strategies earlier and with greater accuracy than aged 
WT mice.  The results imply that prodynorphin-derived peptides are contributing in part 
to age-related impairment in performance on a spatial memory task, but it is not clear 
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whether this effect is attributable to an effect of dynorphin on cognition or alternatively to 
differences in stress or reward responses that can influence cognitive outcome.  It is 
possible that the differences in water maze performance may be related to a hypothesized 
role of dynorphin in mediating stress responses and the fact that aged animals are more 
susceptible to the effects of stress in disrupting performance in the water maze (Foster, 
1999). Indeed, disruption of dynorphin transmission is associated with interference of 
stress-induced behavioral responses (McLaughlin et al., 2003).  Moreover, treatments 
such as neonatal handling, which reduce neuroendocrine stress responses, are able to 
decrease dynorphin in the frontal cortex and facilitate performance on the water escape 
task in aged animals (Meaney et al., 1988; Ploj et al., 2001). Thus, a reduction in stress 
influences could explain why differences emerged with age and were more apparent early 
in training when stress effects would be expected to be greatest.  Although markers of 
stress were not explicitly assayed in animals performing the water maze task, it seems 
plausible that stress itself or the effects of stress on cognition could account for some of 
the observed effects. 
A detrimental role of dynorphins in disrupting spatial learning is consistent with a 
number of studies (Jiang et al., 1989; McDaniel et al., 1990; Sandin et al., 1998; Hauser 
et al., 1999; Tan-No et al., 2001); however, other recent publications have concluded 
that a rise in dynorphin following brain injury may be beneficial for recovery following 
various insults (Heron et al., 1996; Redell et al., 2003).  Interestingly, young Pdyn KO 
mice perform somewhat more poorly than young WT mice during later probe trials for 
reasons that are not immediately clear.    On the final day of spatial testing, young Pdyn 
KO mice performed significantly worse than young WT mice in the probe trial quadrant 
preference assessment, despite appearing to have shown strong preference for the target 
quadrant on Days 1 and 2, and despite showing latency and path length measures 
quantitatively indistinguishable from young WT mice on all three days.  The present 
data suggest that dynorphins may potentiate the extent of spatial learning at later time 
points.   
The ability of normal aging to unmask the cognitive functional differences 
between Pdyn KO and WT mice can be explained by the findings that dynorphin peptides 
in WT mice increases over 2-fold with aging in the present study.  However, it is not 
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possible to conclude from the data that dynorphin is exerting a direct detrimental effect 
on cognition, since the poorer performance in aged WT mice could in theory be due to 
other mechanisms that independently lead to increased dynorphin levels. 
The significant increases in Dyn A observed in the frontal cortex of both 12- and 
24-month mice suggest that abnormal expression of endogenous dynorphin peptides may 
at least partially contribute to spatial learning and memory with age but not in younger 
animals, in which endogenous dynorphins are present at substantially lower quantities.  
This hypothesis is consistent with earlier published data showing increased dynorphins in 
both frontal cortex and hippocampus of aged memory-impaired rats (Jiang et al., 1989) 
and a more recent study showing elevated Pdyn mRNA in aged rats (Kotz et al., 2004). In 
contrast to the above studies, our results in hippocampus do not show increased 
dynorphin expression with age.  Interestingly, another immunohistochemical study 
reported a slight decrease in dynorphin immunoreactivity in age-impaired rats (Croll et 
al., 1999).  However, the lack of an age-associated increase in hippocampal dynorphins 
does not preclude a possible harmful effect of these neuropeptides on hippocampal 
function with aging, since other age-related changes may alter susceptibility to 
endogenous dynorphins in the absence of overt changes in dynorphin expression. 
Nonetheless, the results in frontal cortex showing the marked age-related increase in 
dynorphin, in combination with the finding that aged prodynorphin knockout mice appear 
relatively spared in a spatial memory task, are compellingly suggestive of a more 
prominent role of frontal cortical dynorphin in learning and memory impairment.   
Despite the fact that the water maze task has long been regarded as a 
hippocampal-dependent task based on studies documenting spatial impairment upon 
selective lesioning of the hippocampus (Jarrard, 1978; Morris et al., 1982), a growing 
body of literature now supports the claim that spatial learning may also be critically 
dependent on other regions of the brain, such as frontal cortex (Owen et al., 1995; 
Kessels et al., 2000).  In fact, in frontal cortex of Alzheimer’s disease or Down’s 
syndrome patients, dynorphin A is increased more than 2-fold compared to elderly 
controls (Risser et al., 1996).  The increases in dynorphin immunoreactivity in aged mice 
could therefore reasonably underlie some of the cognitive deficits observed in water maze 
performance in aged WT mice.  Further experiments, e.g., those involving κ-selective 
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agonists and antagonists, are needed, however, to determine causality and to elucidate the 
mechanistic basis of the apparent adverse effects of elevated endogenous dynorphins. 
 
 
 
  
Copyright © Xuan V. Nguyen  2007 
31 
 
CHAPTER 3:  Effects of aging and Pdyn deletion on nonspatial learning and 
memory and spontaneous locomotion in mice 
 
Introduction 
As detailed in preceding chapters, aging is associated with neurobiological and 
neurochemical changes in the brain and is commonly associated with functional declines 
in neuronal function that lead to sensory, motor, cognitive, and numerous other types of 
deficits.  The mechanisms by which the aging process contributes to these deficits have 
not been elucidated.  Opiate neuropeptides derived from the prodynorphin (Pdyn) gene 
and expressed in hypothalamus, nucleus accumbens, neostriatum, dentate gyrus, 
hippocampus cerebral cortex, and spinal cord (Khachaturian et al., 1993), have been 
implicated in age-related cognitive dysfunction (Jiang et al., 1989; Zhang et al., 1991; 
Nguyen et al., 2005).   Findings of increased dynorphin peptides in hippocampus of 
normal aged rats (Jiang et al., 1989; Zhang et al., 1991; Gallagher and Nicolle, 1993; 
Kotz et al., 2004), in cortex and hippocampus of amyloid precursor protein-
overexpressing mice (Diez et al., 2000), in frontal cortex of Down’s syndrome patients 
(Risser et al., 1996), and in frontal and parietal cortex of Alzheimer’s disease patients 
(Risser et al., 1996; Yakovleva et al., 2006a) strongly implicate dynorphin dysregulation 
in age-related pathophysiological processes.   
The existing literature contains conflicting reports regarding the role of dynorphin 
peptides in learning and memory.  While impairment in spatial learning and memory is 
seen upon intrahippocampal administration of Dyn A(1-8) (McDaniel et al., 1990) or 
dynorphin B (Sandin et al., 1998), some studies have reported that Dyn A(1-13) can 
ameliorate cognitive impairment induced by anticholinergic agents (Itoh et al., 1993a, b; 
Hiramatsu et al., 1996; Hiramatsu et al., 1997; Ukai et al., 1997) through mechanisms 
involving the  opioid receptor, though recent studies have also reported non-opioid-
dependent beneficial effects on memory (Hiramatsu and Watanabe, 2006).  Dynorphin 
was also found to dose-dependently impair retention in an inhibitory avoidance task in 
mice (Introini-Collison et al., 1987).   We have already shown that aging Pdyn knockout 
(KO) mice demonstrate improved performance in the water maze task (Nguyen, 2001).  
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We therefore hypothesize that Pdyn deletion similarly ameliorates age-related 
impairment in other forms of learning and memory.  In the present study, we examine 
two additional learning and memory assays, the passive avoidance test and the paired 
object recognition test.  To evaluate the possibility of differences in nociception 
potentially confounding interpretation of these studies, a tail-flick assay was performed 
on moderately aged Pdyn KO and WT mice.  In addition, because the interpretation of 
these tests also depends on general exploratory activity in the animal subjects, we also 
examine open-field activity to examine effects of both aging and Pdyn deletion.  
Moreover, because of the clinical importance of the dopaminergic system in pathological 
motor dysfunction and given the reported dopamine-inhibitory effects of dynorphins and 
exogenous  agonists in striatum and nucleus accumbens (Mulder et al., 1984; Herrera-
Marschitz et al., 1986; Di Chiara and Imperato, 1988; Reid et al., 1988; Spanagel et al., 
1992; Ronken et al., 1993; Schlosser et al., 1995), we also evaluated open-field activity 
following systemic administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP).  The resulting selective loss of dopaminergic neurons (Arai 
et al., 1990; Sundstrom et al., 1990) is expected to produce functional impairments in 
locomotor activity in these mice, which are hypothesized to be alleviated by Pdyn 
deletion. 
 
Methods 
Animal subjects 
All animals in this study were wild-type (WT) or Pdyn KO mice that were maintained in 
an approved animal facility at the University of Kentucky.  WT mice were derived from 
the 129SvEv-Tac line, and Pdyn KO mice were originally obtained by targeted deletion 
of the coding exons of the prodynorphin gene and bred into a 129SvEv-Tac background 
as described previously (Sharifi et al., 2001).  Animals were housed in groups of up to 4 
per cage with food and water ad libitum in a well-ventilated room with a 12 h: 12 h light: 
dark cycle. Prior to weaning, tail specimens were collected from each animal, and DNA 
was extracted for subsequent genotyping to confirm the identity of the Pdyn locus by the 
polymerase chain reaction (PCR) using primer pairs specific for each genotype.  All 
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procedures involving animals are approved by the Institutional Animal Care and Use 
Committee at the University of Kentucky.    
 
Inhibitory avoidance 
An inhibitory avoidance paradigm was used to evaluate passive recall of an aversive 
stimulus in male 3-month WT (n = 4), 3-month Pdyn KO (n = 4), 13-month WT (n = 8), 
13-month Pdyn KO (n = 8), 24-month WT (n = 6), and 24-month Pdyn KO (n = 6) mice.  
The task tests the mouse subject's ability to employ situational recall to passively avoid 
entry into a dark chamber that is associated with an aversive electrical stimulus.  A 
WinLinc software program (Coulbourn Instruments, Allentown, PA) was used to 
automate the sequence of events during each trial.   In the acquisition trial, the subject is 
placed in the brightly lit environment of the first chamber for 90 seconds, followed by 
automated opening of a door leading to a dark chamber.  If the mouse traverses the 
threshold into the dark chamber, an automated trigger is activated leading to closure of 
the door mechanism, and after a 10-second delay, a 3-second electrical shock at 0.1 
mAmp, which was confirmed to produce visible but not excessive discomfort to the 
mouse, is applied via the conducting medium of the floor of the dark chamber.  A 
retention trial was performed 72 hours after the acquisition trial in a similar manner, 
except that the door to the dark compartment remained open for the duration of the trial 
and no electrical shock was applied in the retention trials.  In both trials, the step-through 
latency, defined as the time from door-opening until the animal crosses into the dark 
chamber, was recorded manually using a stopwatch to a maximum of 900 seconds. 
 
Tail flick assay 
Tail withdrawal to a heat stimulus was assessed using a tail-flick assay in 16-month WT 
(n = 5) and Pdyn KO (n = 5) mice.  The mouse was placed in a restraining device, and the 
tail was positioned within a groove of the heating mechanism.   Trials were performed in 
triplicate to determine the latency from the time of initiation of heat application until the 
animal voluntarily withdraws its tail from the heating mechanism. 
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Open-field assay 
Spontaneous open-field behavioral activity was recorded using an apparatus of four 
activity chambers (Model RXYZCM-8, Accuscan Instruments, Columbus, OH), each 
consisting of a 41 × 41 × 31-cm Plexiglas box with two grids of infrared beams mounted 
at horizontal intervals of 2.5 cm and at a vertical interval of 4.5 cm.  Monitors were 
connected to a Digiscan Analyzer (Model DCM-8, Accuscan Instruments) that converts 
the number and pattern of beam breaks to generate various data parameters, including 
horizontal activity, distance traveled, vertical activity, movement time, and stereotypy 
counts.  During operation, the data were recorded separately for each of six contiguous 5-
min intervals during each 30-minute trial.  Horizontal activity was determined by the 
number of photobeam breaks in a horizontal grid, and vertical activity was quantified as 
number of photobeam interruptions in a more superiorly positioned grid.  Distance 
traveled and movement time was also calculated by the Accuscan software.  Stereotypy 
counts were detected as a set of repeated breaks in the same photobeam or array of 
photobeams.  Movement speed was calculated as distance traveled divided by movement 
time to provide an estimate of speed during periods of active locomotion.  Animals that 
yielded a movement time of zero were excluded from the movement speed analysis, as 
were two speed outliers that were unrealistically high due to aberrantly low movement 
times recorded. 
Mice used in this study include 3-month WT (n = 20), 3-month Pdyn KO (n = 
30), 3-month Pdyn HET (n = 22), and 10-month WT (n = 6) mice.  The 3-month WT 
group contains 10 males and 10 females, and the 3-month Pdyn KO group has 11 males 
and 19 females.  The HET group consists of 11 males and 11 females.  Among 10-month 
WT mice, there are 2 males and 4 females.  The group sizes listed above include mice 
pooled from saline controls from the MPTP experiments that were tested prior to any 
intervention.  In the experiments evaluating effects of MPTP, a regimen of four saline or 
15 mg/kg MPTP intraperitoneal injections at 2-hour intervals was administered to mixed 
male and female 3-month mice, and behavioral testing performed 7 days later.  The saline 
control group contains 2 WT, 4 HET, and 3 KO mice, while the MPTP group contains 3 
WT, 4 HET, and 5 KO mice.  These sample sizes reflect the removal of 4 saline controls 
due to failure of the automated recording system during a post-injection trial.  For 
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analysis, logarithmic transformation of the post- to pre-injection ratios of the relevant 
behavioral parameters was applied to preserve linearity of the underlying distribution.    
 
Object recognition 
A paired visual object recognition assay was used to test the animal subject's inclination 
to preferentially explore novel objects and to recognize familiar objects in an enclosed 
environment.  The objects used in this experiment were non-noxious inanimate objects 
typically found in a laboratory setting and of a size similar to the mouse subject.  Animals 
were habituated to the empty testing chamber for 15 minutes one day prior to testing.  
During each trial, two objects are positioned at predetermined locations equidistant from 
the site at which the mouse is to be placed, and the subject's spontaneous exploratory 
activity is monitored for 15 minutes either by real-time video transmission to an 
investigator located in a different room or by videotape recording.  An investigator 
blinded to the identity of the mice recorded the total number of seconds during each trial 
the subject expends on active exploration of each object as demonstrated by specific 
behavior patterns such as facing the object in close proximity, moving from side to side 
while facing the object, placing one or more forelimbs on the object, or encircling the 
object in close proximity.   Between trials, the testing chamber is cleaned to remove any 
odor cues that may influence subsequent exploratory activity.  Results are expressed as a 
proportion of total exploration time spent on the novel object.  To account for individual 
differences in baseline exploratory activity, total novel object exploration time is also 
presented as a ratio to total cumulative exploration time.  Two different protocols were 
used in implementing the timing of the testing trials.  In the Protocol 1, 6-month WT (n = 
12), 6-month Pdyn KO (n = 3), 12-month WT (n = 8), 12-month KO (n = 8), 24-month 
WT (n = 5), and 24-month KO (n = 6) male mice were monitored in three acquisition 
trials before new target objects are successively introduced in two retention trials 4 and 
24 hours later.    In Protocol 2, testing consists of an acquisition trial, a retention trial 
immediately afterward, and a second retention trial with a different novel object 4 hours 
after the start of the first trial.  Animal subjects in Protocol 2 include 4-month WT (n = 
3), 14-month WT (n = 7), 14-month Pdyn KO (n = 10), 24-month WT (n = 5), and 24-
month KO (n = 5) male mice.  These protocols differ in that Protocol 1 permits a greater 
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amount of time to be spent in the acquisition phase prior to introduction of the first novel 
object, which is thought to enhance the distinction between novel and familiar objects in 
subsequent trials.  The shorter acquisition phase of Protocol 2, on the other hand, may 
enable more subtle differences in object recognition to become manifest.  
 
Results 
Inhibitory avoidance 
An inhibitory avoidance assay was performed on WT and Pdyn KO mice of varying ages 
(Figure 3.1).  Acquisition step-through latencies were recorded in experimentally naïve 
Figure 3.1.  Inhibitory avoidance assay results in mice. 
Effects of age and Pdyn deletion on step-through latency before and 72 hours after an 
electrical foot-shock stimulus were measured in the passive avoidance task.  Significant 
learning effects are seen independently of age and Pdyn genotype.  Acquisition step-
through latencies, which may reflect exploratory activity in naïve animals, are significantly 
increased in Pdyn KO mice, but only at 3 months.  Retention latencies in the 3-month Pdyn 
KO group are also increased, consistent with improved recall of the aversive stimulus.  
Note the ceiling effect in which all four young Pdyn KO mice achieved the predetermined 
maximum latency of 900 sec.    *p<0.05, ***p<0.001 compared to respective 3-month 
controls;  
#
p<0.05, 
###
p<0.001 compared to corresponding WT mice;  
‡
p<0.01, 
††
p<0.001 
compared to the corresponding acquisition trial. 
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mice, while retention latencies at 72 hours were obtained to indicate the subject's ability 
to demonstrate situational recall of the aversive stimulus.  Three-way ANOVA with 
repeated measures was used to evaluate age, Pdyn, and training effects.  An overall 
training effect was highly significant [F(1, 30) = 64.08, p<0.0005], and an age-Pdyn 
interaction was also significant [F(2, 30) = 3.93, p<0.03].  Acquisition scores showed a 
significant effect of age [F(2, 30) = 6.75, p<0.004], Pdyn [F(1, 30) = 6.12, p<0.019], and 
age-Pdyn interaction [F(2, 30) = 5.94, p<0.007]. 
The 3-month Pdyn KO mice latencies exhibit a ceiling effect due to all four mice 
in the group achieving the predetermined maximum latency of 900 sec.  With the 
exception of 3-month Pdyn KO mice showing only a mild tendency toward a significant 
learning effect [F(1, 30) = 3.29, p<0.08] as a result of the elevated pre-stimulus step-
through latency, step-through latencies 72 hours after the initial stimulus were 
consistently increased in all other groups, including 3-month Pdyn KO [F(1, 30) = 14.21, 
p<0.001], 13-month WT [F(1, 30) = 12.79, p<0.001], 13-month Pdyn KO [F(1, 30) = 
15.53, p<0.0005], 24-month WT [F(1, 30) = 17.99, p<0.0005], and 24-month Pdyn KO 
mice [F(1, 30) = 7.93, p<0.009].  Among 3-month mice, Pdyn KO mice show 
significantly higher acquisition [F(1, 30) = 14.62, p<0.001] and retention [F(1, 30) = 
4.51, p<0.042] scores.   The 3-month Pdyn KO retention latency was also significantly 
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Figure 3.2.  Tail-flick latencies as a function of Pdyn genotype.   
This assay demonstrates no effect of Pdyn deletion on nociception or subsequent reflex 
withdrawal to painful stimuli.   
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elevated when compared to that of 24-month Pdyn KO mice [F(1, 30) = 4.21, p<0.049], 
and the acquisition latency means were similarly higher than those of both 13-month 
Pdyn KO [F(1, 30) = 19.29, p<0.0005] and 24-month Pdyn KO mice [F(1, 30) = 21.70, 
p<0.0005].   Beyond the findings associated with the 3-month Pdyn KO mice, no clear 
age-associated trend in retention latencies were observed in this passive avoidance task at 
72 hours.  Because interpretation of the passive avoidance task as an indication of 
memory function assumes the subjects exhibit comparable perception of and response to 
the inciting stimulus, potential effects of dynorphin on pain modulation or perception 
were evaluated by the tail-flick assay.  Tail-flick response measurements show no 
differences between Pdyn KO and WT mice (Figure 3.2). 
 
Open-field analysis 
Spontaneous exploratory and locomotor behavior patterns were analyzed by open-field 
analysis in young adult (3-month) WT, Pdyn KO, and HET mice, with automated 
Figure 3.3.  Horizontal activity measurements during open-field analysis as a function of 
Pdyn genotype.   
Left:  The vertical axis depicts the number of interruptions in the horizontal photobeam 
grid of the activity chamber.  Intra-trial changes in horizontal activity show a gradual 
habituation effect across recording intervals.  Right:  Summed totals of horizontal 
activity show no effect of Pdyn genotype. 
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recording of a series of measured variables during a trial consisting of 6 contiguous 5-
minute intervals (Figure 3.3 through Figure 3.8).  Two-factor repeated measures ANOVA 
shows a significant intra-trial habituation effect as manifested in a significant decline 
across intervals in horizontal activity [F(5, 345) = 36.44, p<0.0005], distance traveled 
[F(5, 345) = 36.58, p<0.0005], movement time [F(5, 345) = 29.76, p<0.0005], stereotypy 
[F(5, 345) = 14.63, p<0.0005], and movement speed [F(5, 165) = 3.90, p<0.005].  The 
one variable analyzed that did not show such an effect was vertical activity, which also 
showed substantial intra-group variability likely related to limited sample size (Figure 
3.6).  No significant effects of Pdyn or Pdyn-habituation interactions were observed for 
any of these variables.  One-way ANOVA performed on the average trial movement 
speed and the summed intra-trial total for all the other variables found no significant 
effects of Pdyn deletion. 
To determine effects of aging on these parameters, a similar analysis was applied 
in 3-month and 10-month WT mice (Figure 3.9 through Figure 3.14).   Similar to the 
preceding ANOVA results, habituation effects were again seen in horizontal activity 
Figure 3.4.  Distance measurements during open-field analysis as a function of Pdyn 
genotype. 
Left:  Intra-trial changes in distance traveled show a gradual habituation effect across 
recording intervals.  Right:  Summed totals of distance measurements show no effect of 
Pdyn genotype. 
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[F(5, 120) = 14.18, p<0.0005], distance traveled [F(5, 120) = 19.39, p<0.0005], 
movement time [F(5, 120) = 15.83, p<0.0005], and stereotypy [F(5, 120) = 13.74, 
p<0.0005].   Additionally, vertical activity showed a significant habituation effect in this 
analysis [F(5, 120) = 2.29, p<0.05], while movement  speed showed no significant intra-
trial changes.  Increased stereotypy counts were observed in older mice [F(1, 24) = 8.95, 
p<0.006] with an age-interval interaction [F(5, 120) = 3.81, p<0.003].   Total stereotypy 
activity during the 30-minute trial was significantly higher in 10-month WT mice 
compared to 3-month WT mice [F(1, 24) = 8.95, p<0.006].  Only a minor age-associated 
decline in average movement speed was observed with aging [F(1, 24) = 5.28, p<0.031], 
with a significant intra-interval age effect noted only near the end of the trial [F(1, 9) = 
7.66, p<0.022].  No other age effects or age-interval interactions were seen in the other 
variables analyzed. 
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Figure 3.5.  Movement time during open-field analysis as a function of Pdyn genotype.  
Left:  The vertical axis depicts the amount of time spent in active locomotion.  Intra-trial 
changes in movement time show a gradual habituation effect across recording intervals.  
Right:  Summed totals of movement time show no effect of Pdyn genotype. 
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Figure 3.6.  Vertical activity during open-field analysis as a function of Pdyn genotype.  
Left:  The vertical axis depicts the number of occurrences of breaks in the more 
superiorly placed photobeams.  Vertical activity shows minimal effects across recording 
intervals.  Right:  Summed totals of vertical activity show no effect of Pdyn genotype. 
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Figure 3.7.  Stereotypy during open-field analysis as a function of Pdyn genotype.  
Left:  The vertical axis depicts the number of occurrences of stereotyped behavior as 
recorded by repeated breaks in the same photobeam or array of photobeams.  Intra-trial 
changes in stereotypy show a gradual habituation effect across recording intervals.  
Right:  Summed totals of stereotypy events show no effect of Pdyn genotype. 
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 As the above results were performed on groups containing both male and female 
mice, a subsequent analysis was performed to assess effects of gender on spontaneous 
open-field activity (Figure 3.15 through Figure 3.20).   ANOVA on summed data from 
the entire 30-minute trial period reveals significant main effects of gender on movement 
time [F(1, 64) = 6.92, p<0.011] and movement speed [F(1, 64)=16.28], p<0.0005], with 
gender-Pdyn interactions observed in horizontal activity [F(2, 64) = 4.14, p<0.02], 
distance traveled [F(2, 64) = 5.85, p<0.005], and movement time [F(2, 64) = 6.19, 
p<0.003].   Extending a similar approach to the aging comparisons in WT mice finds sex 
effects in horizontal activity [F(1, 22) = 10.08, p<0.004], distance traveled [F(1, 22) – 
24.97, p<0.0005], movement time [F(1, 22) = 27.82, p<0.0005], and vertical activity 
[F(1, 22) = 6.41, p<0.019].   Significant interactions between gender and Pdyn genotype 
were noted in recorded distance [F(1, 22) = 11.45, p<0.003] and movement time [F(1, 
22) = 10.46, p<0.004]. 
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Figure 3.8.  Movement speed during open-field analysis as a function of Pdyn genotype.   
Left:  Movement speed is minimally altered across recording intervals.  Right:  Average 
movement speed shows no effect of Pdyn genotype. 
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Figure 3.9.  Horizontal activity measurements during open-field analysis as a function of 
aging.  
Left:   The vertical axis depicts the number of interruptions in the horizontal photobeam 
grid of the activity chamber.  Habituation effects are seen across recording intervals, 
with minimal aging effect.  Right:  Total horizontal activity is unchanged with age. 
 
Figure 3.10.  Distance traveled during open-field analysis as a function of aging.   
Left:   Habituation effects are seen across recording intervals, with minimal aging effect.  
Right:  Total distance traveled is unchanged with age. 
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Figure 3.11.  Movement time during open-field analysis as a function of aging.   
Left:  The vertical axis depicts the amount of time spent in active locomotion.  
Habituation effects are seen across recording intervals, with minimal aging effect.  Right:  
Total movement time is unchanged with age. 
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Figure 3.12.  Vertical activity during open-field analysis as a function of aging.   
Left:   The vertical axis depicts the number of occurrences of breaks in the more 
superiorly placed photobeams.  Minimal habituation effects are seen across recording 
intervals.  Right:  Total vertical activity is unchanged with age. 
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Figure 3.13.  Stereotypy during open-field analysis as a function of aging.   
Left:  The vertical axis depicts the number of occurrences of stereotyped behavior as 
recorded by repeated breaks in the same photobeam or array of photobeams.   
Habituation effects are seen across recording intervals, with significantly increased 
stereotypy seen in 10-month mice.  Right:  Total stereotypy counts are increased with 
age.  *p<0.05, **p<0.01 compared to 3-month mice. 
Figure 3.14.  Movement speed during open-field analysis as a function of aging.   
Left: Movement speed is decreased in 10-month mice across recording intervals.  Right:  
Mean speeds are mildly decreased with age.  *p<0.05 compared to 3-month mice. 
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Horizontal activity in 3-month mice (Figure 3.15) was mildly decreased in male 
Pdyn HET mice compared to either female Pdyn HET mice [F(1, 64) = 4.68, p<0.034] or 
male Pdyn KO mice [F(1, 64) = 5.17, p<0.026].  Female 10-month WT mice also showed 
less horizontal activity than male 10-month WT mice [F(1, 22) = 8.58, p<0.008], but a 
similar gender difference among 3-month WT mice failed to reach significance [F(1, 22) 
= 4.15, p<0.054].  Similar findings were noted in distance (Figure 3.16) and movement 
time (Figure 3.17), with 10-month male WT mice accumulating more distance [F(1,22) = 
17.02, p<0.0005] and spending more time in motion [F(1, 22) = 18.62, p<0.0005] than 3-
month male WT mice.  Ten-month female WT mice showed comparatively less distance 
traveled [F(1, 22) = 22.25, p<0.0005] and movement time [F(1, 22) = 22.92, p<0.0005] 
than their male WT counterparts.  Movement time was also significantly less in female 3-
month mice than males [F(1, 22) = 4.95, p<0.037].  Distance traveled by male Pdyn KO 
mice were significantly higher than for male Pdyn HET mice [F(1, 64) = 10.73, p<0.002] 
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Figure 3.15.  Gender analysis of horizontal activity in open-field task.   
Left: The vertical axis depicts the number of interruptions in the horizontal photobeam 
grid of the activity chamber.   Aging analysis shows increased horizontal activity in 10-
month male mice compared to 10-month females.  Right:  Pdyn analysis shows male 
Pdyn HET mice exhibit less activity than female HET mice or male Pdyn KO mice.  
†
p<0.05, 
‡
p<0.01 compared to corresponding male mice.  
#
p<0.05 Pdyn genotype effect. 
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or female Pdyn KO mice [F(1, 64) = 10.29, p<0.002].  Similarly time in motion was 
significantly higher in Pdyn KO males than Pdyn HET males [F(1, 64) = 14.15, 
p<0.0005] or Pdyn KO females [F(1, 64) = 16.44, p<0.0005].   
No significant contrasts were found in vertical activity (Figure 3.18).  Stereotypy 
assessments were not significantly different among 3-month mice (Figure 3.19), but 
increased stereotypy behavior was noted at 10 months age in both male [F(1, 22) = 4.57, 
p<0.044] and female [F(1, 22) = 5.37, p<0.03] WT mice.  Movement speed calculations 
(Figure 3.20) were consistently higher in females than males for WT [F(1, 64) = 5.40, 
p<0.023], Pdyn HET [F(1, 64) = 6.02, p<0.017], and Pdyn KO mice [F(1, 64) = 4.90, 
p<0.03].  In the aging analysis, 3-month female WT showed significantly higher 
movement speed than 3-month male WT [F(1, 22) = 8.62, p<0.008] or 10-month female 
WT mice [F(1, 22) = 12.55, p<0.002].  
Figure 3.16.  Gender analysis of distance traveled in open-field task.   
Left:  Aging analysis shows significantly increased distance traveled in 10-month males.  
Right:  Pdyn analysis shows male Pdyn KO mice exhibit greater traversed distance than 
male HET mice or female Pdyn KO mice.  ***p<0.001 compared to corresponding 3-
month mice.  
‡
p<0.01, 
††
p<0.001 compared to corresponding male mice.  
##
p<0.01 Pdyn 
genotype effect. 
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Effects of systemic MPTP or saline on open-field behavior in 3-month mice were 
also examined by calculating intrasubject log-ratios of post-injection to pre-injection 
values of each analyzed variable.  ANOVA found an MPTP effect on average speed [F(1, 
15) = 6.97, p<0.019] and significant Pdyn-MPTP interactions in movement time [F(2, 
15) = 4.15, p<0.037] and movement speed [F(2, 15) = 5.73, p<0.014].  While most mice 
showed mild habituation-related decreases in horizontal activity, distance, and movement 
times upon re-exposure to the open-field environment (Figure 3.21), WT mice show 
substantial post-MPTP reduction in exploratory activity, with statistical significance 
demonstrated in the amount of time spent in active locomotion [F(1, 15) = 7.23, 
p<0.017].  WT mice also exhibit a greater post-MPTP decline in traversed distance 
compared to Pdyn KO [F(1, 15) = 5.15, p<0.038] and Pdyn HET mice [F(1, 15) = 6.32, 
p<0.024].  Time spent actively moving was also reduced to a greater extent in post-MPTP 
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Figure 3.17.  Gender analysis of movement time in open-field task.   
Left:  The vertical axis depicts the amount of time spent in active locomotion.  Aging 
analysis shows decreased activity in female mice compared to males at each age point, 
with 10-month males showing significantly increased time in active motion.  Right:  
Pdyn analysis shows male Pdyn KO mice exhibit greater movement time than male HET 
mice or female Pdyn KO mice.  ***p<0.001 compared to corresponding 3-month mice.  
††
p<0.001 compared to corresponding male mice.  
###
p<0.001 Pdyn genotype effect. 
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WT mice compared to post-MPTP Pdyn KO [F(1, 15) = 9.90, p<0.007] or HET mice 
[F(1, 15) = 12.89, p<0.003].  Stereotypy assessments revealed mild differences (Figure 
3.22), primarily in the saline-treated Pdyn HET group, which demosntrated significantly 
less stereotypic behavior in comparison to either WT saline controls [F(1, 15) = 4.99, 
p<0.041] or MPTP-treated HET mice [F(1, 15) = 4.97, p<0.041].  Estimates of average 
movement speed were mildly increased in the post-injection trial for most groups (Figure 
3.22), but MPTP-injected WT mice demonstrate a significantly larger increase in speed 
compared to saline-injected WT mice [F(1, 15) = 13.94, p<0.002], MPTP-injected Pdyn 
KO mice [F(1, 15) = 9.47, p<0.008] and to MPTP-injected HET mice [F(1, 15) = 14.74, 
p<0.002], although this apparent increase in the calculated average speed of MPTP-
injected WT mice is likely artifactual due to the markedly lower amount of time spent in 
active locomotion. 
 
 
 
 
Figure 3.18.  Gender analysis of vertical activity in open-field task.   
Left:  The vertical axis depicts the number of occurrences of breaks in the more 
superiorly placed photobeams.  Aging analysis shows similar trends as other variables 
but with substantial intra-group variability.  No significant effects are seen.   Right:  Pdyn 
analysis shows no significant effects in vertical activity. 
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Figure 3.20.  Gender analysis of movement speed in open-field task.   
Left:  Aging analysis shows mild increase in movement speed of female mice at 3 
months but a decrease at 10 months.   Right:  Pdyn analysis shows consistently elevated 
movement speed in females of all three Pdyn genotypes.  **p<0.01 compared to 
corresponding 3-month mice.   
†
p<0.05, 
‡
p<0.01 compared to corresponding male mice. 
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Figure 3.19.  Gender analysis of stereotypy in open-field task.   
Left:  The vertical axis depicts the number of occurrences of stereotyped behavior as 
recorded by repeated breaks in the same photobeam or array of photobeams.  Aging 
analysis shows increased stereotypy with age in both male and female mice. Right:  Pdyn 
analysis shows no significant effects.  *p<0.05 relative to corresponding 3-month mice. 
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Figure 3.21.  Effects of MPTP and Pdyn deletion on locomotor activity.    
Open-field data were obtained from 3-month mice before and 7 days after intraperitoneal 
injection of saline or MPTP.  Within-subject log-ratios of post-injection to pre-injection 
horizontal activity, distance, and movement time are shown.  WT mice show substantial 
decreases in post-MPTP locomotor indices, while Pdyn KO and HET mice are minimally 
changed.  
#
p<0.05, 
##
p<0.01 compared to corresponding WT mice.  
†
p<0.05 compared to 
saline controls. 
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Figure 3.22.  Effects of MPTP and Pdyn deletion on stereotyped behavior and motor 
speed.  
Open-field data were obtained from 3-month mice before and 7 days after intraperitoneal 
injection of saline or MPTP.  Within-subject log-ratios of post-injection to pre-injection 
stereotypy counts and movement speed are shown.  
#
p<0.05, 
##
p<0.01 compared to 
corresponding WT mice. 
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Object recognition assay 
Performance in a paired object recognition task was evaluated by measuring the amount 
of time spent by the mouse exploring each of two different objects during a series of 5-
minute trials.  Two sets of experiments were performed using slightly different protocols.  
In the first set of experiments, animals were monitored in three habituation trials before 
new target objects are introduced in retention trials 4 and 24 hours later (Figure 3.23).   
The proportion of time spent exploring the new target object was recorded as ratios to 
total intra-trial exploratory time and to total cumulative exploratory time.  While the 
former ratio represents the relative changes in object exploration time during each trial, 
the latter ratio was selected to provide an indication of absolute time spent on the novel 
object while controlling for baseline differences in general exploratory activity.  The 
proportion of time in each trial spent exploring the novel object is found by ANOVA to 
demonstrate significant effects of Pdyn genotype [F(1, 31) = 4.80, p<0.036], trial number 
Figure 3.23.  Effects of age and Pdyn deletion on object recognition using Protocol 1. 
Left:  Novel object preference is expressed as the fraction of total trial exploration time 
spent interacting with the novel object or, in the case of Trials 1-3, the object in the 
position where the novel object of the subsequent trial is to be placed.  Aged Pdyn KO 
mice spend a decreased proportion of exploration time interacting with the novel object 
in the 24-hour retention trial (Trial 5) compared to similarly aged WT mice.  Right: Total 
time spent on the novel object is expressed relative to total cumulative object exploration 
time to control for individual differences in baseline exploratory tendencies.  Total time 
spent on the novel object relative to cumulative exploratory activity is increased in 24-
month Pdyn KO mice.  
#
p<0.05, 
##
p<0.01 compared to corresponding WT mice.  
*p<0.05 compared to corresponding 6-month mice. **p<0.01 compared to 
corresponding 12-month mice. 
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[F(2, 62) = 9.36, p<0.0005], and a trial-Pdyn interaction [F(2, 62) = 4.30, p<0.029].   The 
almost equal division in the amount of time spent on each of the two objects during these 
acquisition trials indicates that the mice show no baseline preference for either object 
location. While there were no significant aging contrasts in this analysis, significantly 
decreased novel object exploration at 24 hours was noted in Pdyn KO mice aged 12 
months [F(1, 31) = 7.64, p<0.01] or 24 months [F(1, 31) = 5.10, p<0.031].  When novel 
object exploration is expressed relative to cumulative exploratory activity, ANOVA 
reveals significant trial effects [F(1, 36) = 16.09, p<0.0005], a trial-Pdyn interaction  
[F(1, 36) = 5.19, p<0.029], and a trial-age interaction [F(2, 36) = 3.58, p<0.038].  
Significant contrasts are seen only at the 4-hour retention trial, in which 24-month Pdyn 
KO mice show elevated novel-object exploratory activity, which was significantly 
different from 24-month WT [F(1, 36) = 5.12, p<0.03], 6-month Pdyn KO [F(1, 36) = 
6.18, p<0.018], and 12-month Pdyn KO mice [F(1, 36) = 7.60, p<0.009].  Total 
exploratory times were also recorded during each trial and analyzed by ANOVA (Figure 
3.24), with significant Pdyn effects [F(1, 36) = 4.62, p<0.038], trial effects [F(4, 144) = 
13.92, p<0.0005], and trial-Pdyn-age interactions [F(8, 144) = 2.49, p<0.015].  In the first 
trial, exploration time in young adult Pdyn KO mice is markedly elevated, resulting in 
significant differences in comparison to 6-month WT [F(1, 36) = 8.77, p<0.005] and 24-
month Pdyn KO mice [F(1, 36) = 5.46, p<0.025].  In contrast, total exploratory time in 
Trial 1 is increased at 24 months in WT mice [F(1, 36) = 7.05, p<0.012].  In Trials 2 and 
3, exploration times in most groups show progressive decline due to habituation effects, 
but 6-month Pdyn KO mice continued to exhibit increased exploratory behavior that is 
statistically significant compared to 6-month WT [F(1, 36) = 20.86, p<0.0005], 12-month 
Pdyn KO [F(1, 36) = 10.90, p<0.002], and 24-month Pdyn KO mice [F(1, 36) = 19.20, 
p<0.0005].  In Trials 4 and 5, with addition of the novel stimulus, most groups show 
increased or unchanged exploration times; however, the only significant inter-group 
difference was found in 24-month Pdyn KO mice, which showed increased total 
exploratory activity in Trial 4 compared to 12-month Pdyn KO mice [F(1, 36) = 5.60, 
p<0.023]. 
In the second object recognition protocol, only three trials were used, with Trials 
2 and 3 serving as retention trials at 1 and 4 hours, respectively (Figure 3.25).  Young 
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WT mice appear to show decreased baseline preference for one of the objects during the 
acquisition trial, resulting in a significant age effect compared to 14-month [F(1, 12 = 
7.86, p<0.016] and 24-month WT mice [F(1, 12) = 12.17, p<0.004].  In Trial 2, the 
proportion of exploratory time on the target object is increased in all groups without any 
between-group differences.  However, in Trial 3, the 4-month WT group shows a 
diminished response to the novel stimulus, resulting in a statistically significant 
difference compared to 14-month WT mice [F(1, 12) = 7.87, p<0.016].  Additionally, 24-
month Pdyn KO mice in Trial 3 also show diminished novel object exploratory activity, 
with findings of statistical significance in comparison to 14-month Pdyn KO mice [F(1, 
23) = 4.425, p<0.047]. Assessment of ratios of novel object exploration times to 
cumulative exploration time under Protocol 2 revealed no significant effects of either 
Pdyn deletion or age. 
 
Figure 3.24.  Effects of age and Pdyn deletion on total exploration time during object 
recognition assay using Protocol 1.   
Pdyn KO mice demonstrate greater exploratory activity that WT mice, especially among 
young adult mice.  *p<0.05, **p<0.01, ***p<0.001 compared to corresponding 6-month 
mice, or where indicated, to corresponding 12-month mice.  
##
p<0.01, 
###
p<0.001 
compared to corresponding WT mice. 
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Discussion 
The above results show that multiple behavioral endpoints are affected by Pdyn deletion 
with some effects showing significant age dependence.   First, in the inhibitory avoidance 
assay, which applies Pavlovian fear conditioning in an operative learning paradigm, Pdyn 
KO and WT mice of varying ages were assessed to determine whether the animal 
subject's motivation to exit a brightly lit chamber exceeds the adverse reaction to a 
negatively reinforcing stimulus. Our results show that young adult mice lacking Pdyn 
exhibit increased step-through latencies during both acquisition and retention passive 
avoidance trials.  The increased retention step-through latency in Pdyn KO mice may 
signify relatively improved 72-hour recall of the aversive stimulus compared to WT 
counterparts.  Since none of the mice in the 3-month Pdyn KO group traversed into the 
dark chamber in the retention trial, the ceiling effect imposed by the 15-mnute maximum 
likely underestimates the magnitude of this Pdyn genotype effect, and it is plausible that 
longer retention intervals may elicit differences in maximal recall interval.   
Figure 3.25.  Effects of age and Pdyn deletion on object recognition using Protocol 2. 
Left:  Novel object preference is expressed as a fraction of total object exploration time 
spent interacting with the novel object or, in the case of Trial 1, the object in the position 
where the novel object of the subsequent trial is to be placed.  An age-related decline in 
novel object interaction is seen in Pdyn KO mice in Trial 3.  Right: Total time spent on 
the novel object is expressed relative to total cumulative object exploration time to 
control for individual differences in baseline exploratory tendencies.  *p<0.05, **p<0.01 
compared to corresponding 4-month mice, or where indicated, to corresponding 14-
month mice. 
56 
 
Dynorphins have been found to dose-dependently impair retention in an inhibitory 
avoidance task in mice (Introini-Collison et al., 1987).  It is plausible that unknown 
compensatory effects in Pdyn KO mice may render such effects less evident in the 
present study.  However, other studies using the passive avoidance task have found Dyn 
A, Dyn B, and Dyn-32 to facilitate retention (Kuzmin et al., 2006) or to prevent 
impairment induced by other pharmacologic agents (Hiramatsu et al., 1996; Ukai et al., 
1997).  The significance of increased acquisition latency in 3-month Pdyn KO mice is 
unclear, given the lack of similar findings in other age groups in this study.  One 
interpretation is that Pdyn KO mice used in the assay have less basal exploratory 
behavior, which may explain the increased step-through latencies both before and after 
the negatively reinforcing stimulus.  However, the open-field data do not support this 
assertion, since young male Pdyn KO mice showed mildly increased basal exploratory 
behavior.  Alternatively a delayed latency may also suggest increased anxiety in Pdyn 
KO mice, as  agonists have been reported to show anxiolytic properties in rodents 
(Privette and Terrian, 1995). 
While the passive avoidance task is often interpreted in the context of operant 
learning, the role of opiates in pain processing pathways may potentially undermine the 
internal validity of studies assuming uniform nociceptive response to adverse stimuli.  
For instance, intrathecal Dyn B and Dyn-32 can induce nociceptive behavior (Tan-No et 
al., 2002).   However, infusion of exogenous Dyn A and B into cerebrospinal fluid 
increases nociceptive latencies in a hot-plate assay (Kuzmin et al., 2006), indicating 
potential analgesic effects of these peptides.   The absence of a Pdyn deletion effect on 
the tail flick assay in the present study decreases the likelihood of altered perception of 
painful stimuli influencing the animals' performance in the passive avoidance task.  This 
absent pronociceptive effect of dynorphins has been replicated by other investigators 
using Pdyn KO mice (Wang et al., 2001).   
Open-field activity was used in this study to measure spontaneous locomotion as a 
function of age and Pdyn genotype.  While our results show a reproducible intra-trial 
habituation effect, significant Pdyn effects were observed only when analyzing groups 
subclassified by gender.  Male young adult Pdyn KO mice show mild increases in 
markers of baseline exploratory activity, with significant gender differences manifested 
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primarily among KO mice.  An inhibitory action of dynorphins on exploratory behavior 
has been previously documented in rats (Tilson et al., 1986).  While the existing literature 
contains few studies on a gender interaction with Pdyn, anti-estrogen agents have been 
noted to enhance Pdyn expression (Spampinato et al., 1995).  Females may be more 
responsive to dynorphins, since at least one human study found that basal prolactin levels 
and dynorphin-induced prolactin release are significantly higher in females (Kreek et al., 
1999).  Since prolactin release is under tonic inhibition by dopamine, these findings 
suggest a potential mechanism whereby gender effects contribute to differences in motor 
activity.  Interestingly, female mice consistently demonstrated increased movement speed 
across all three Pdyn genotypes in this study. 
Aging in this study yielded a significant but mild decrease in motor speed and an 
increase in stereotyped behavior.  This is consistent with previous studies that have 
shown age-associated decreases in open-field locomotor activity and increases in 
susceptibility to stimulant-induced stereotypic motor behaviors in rats (Dorce and 
Palermo-Neto, 1994).  Interestingly, aging male mice show increases in multiple 
indicators of exploratory behavior that are not evident in aged females.  Some of these 
measures may be attributable to anxiety, based on associated increases in stereotypy 
counts. 
Open-field indicators of locomotor activity are significantly reduced in WT mice 
systemically injected with MPTP, while MPTP-injected Pdyn KO and HET mice show 
no substantial declines in motor activity beyond the habituation effect that is also seen in 
saline controls.  The hypokinetic effect of MPTP, which induces dopaminergic cell loss 
as a model of parkinsonism (Heikkila et al., 1984), is similar to that observed previously 
in C57BL mice (Sedelis et al., 2001; Vijitruth et al., 2006), other mouse strains (Sedelis 
et al., 2001), or rats (Prediger et al., 2006).   Our findings that Pdyn deletion produces a 
relative sparing of MPTP-induced motor dysfunction may be explained by inhibitory 
effects of dynorphin peptides on the striatal dopaminergic system, since dynorphins and 
exogenous  agonists inhibit dopamine release in striatum and nucleus accumbens 
(Mulder et al., 1984; Herrera-Marschitz et al., 1986; Di Chiara and Imperato, 1988; Reid 
et al., 1988; Spanagel et al., 1992; Ronken et al., 1993; Schlosser et al., 1995), while  
antagonists enhance dopamine release (Spanagel et al., 1992).  A mild speed increase is 
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observed in the MPTP-injected WT groups; however it is probable that this finding is 
artifactual due to the significantly decreased movement time and the decreased accuracy 
of distance measures in the setting of substantially depressed motor activity.  It should be 
recognized that the observed changes in open-field behavior may be related to altered 
mechanisms of reward or arousal rather than motor impairment per se. 
Object recognition tasks, which in contrast to the inhibitory avoidance assay or 
water maze tasks permit evaluation of learning in the absence of an aversive stimulus, 
were used to determine effects of aging and Pdyn deletion on recognition and passive 
recall.  In both protocols, average object recognition parameters in Pdyn KO mice are 
slightly lower than their WT counterparts in most comparisons; however the most reliable 
finding is that 24-hour recall in Pdyn KO mice is significantly impaired among 12-month 
and 24-month mice.  However, the proportion of time spent on novel object exploration 
in these cases was substantially less than 50%, suggesting an altered response to novel 
stimuli rather than a recognition memory failure may account for these observations.  In 
fact, despite spending a smaller percentage of time on the novel objects during retention 
trials, the total of time spent exploring either object is substantially elevated in the Pdyn 
KO mice.   The above conjecture is supported by our further findings that young Pdyn 
KO mice show significantly greater total exploration times.  While most groups show 
declining total exploratory activity when presented with only familiar objects during the 
acquisition phase of Protocol 1, the young adult Pdyn KO mice exhibited substantially 
less habituation-related change, resulting in a sustained elevation in total exploratory 
times across all trials.  These findings are internally consistent with the results of our 
open-field experiments showing markedly elevated exploratory indices in young Pdyn 
KO mice. 
The present findings demonstrate subtle changes in learning and memory and 
motor function attributable to Pdyn deletion.  While the improved performance of Pdyn 
KO mice in the passive avoidance trial may appear on initial observation to conflict with 
the minimally affected object recognition parameters, it has previously been proposed 
that the role of dynorphins in memory may depend on the nature of the reinforcing 
stimulus (Yakovleva et al., 2006a).  The variation in the effects of Pdyn deletion on 
performance in the different learning and memory paradigms may be related to the 
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differing neuroanatomical substrates involved in each type of learning task.  For instance, 
a recent study found that subchronic exposure to phencyclidine, which increases striatal 
dynorphin expression, causes impairment of novel object recognition without affecting 
passive avoidance (Shirayama et al., 2007).   Since dopamine mediates the reinforcement 
of addictive behaviors (Bozarth and Wise, 1983) and since the  opioid system is 
believed to modulate dopaminergic tone (Di Chiara and Imperato, 1988; Spanagel et al., 
1992; Kreek, 1996; Kreek et al., 2002), dynorphinergic dysregulation is likely to interfere 
preferentially with tasks involving activation of dopamine-dependent reward pathways.  
In the case of water maze and passive avoidance performance, it is conceivable that the 
reward mechanisms associated with escape from the water maze and avoidance of an 
electrical shock, respectively, are less subject to inhibition in Pdyn KO mice, resulting in 
improved performance. 
Given the fairly diverse pharmacological profile of the various Pdyn-derived 
peptides and their potential roles in not only learning and memory, but also reward 
mechanisms, motor activity, and nociception, further studies are need to clarify the 
mechanisms by which Pdyn deletion produces the effects seen in the present study.  
However, the effects of dynorphins on dopaminergic pathways represent a plausible site 
of action of dynorphins in influencing performance in the behavioral assays discussed 
above.  The following chapter will discuss changes in dopamine with aging and Pdyn 
deletion. 
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CHAPTER 4:  Effects of prodynorphin deletion on striatal dopamine in mice 
during normal aging and in response to MPTP  
Introduction 
Alterations in dopamine neurotransmission in basal ganglia pathways produce motor 
deficits in normal aging (Ingram, 2000) and pathological states like Parkinson’s disease 
(PD) (Hornykiewicz and Kish, 1987; Graybiel et al., 1990; Forno, 1996).  Dopamine, 
synthesized by substantia nigra (SN) neurons projecting to the striatum, has been strongly 
implicated in aging (Carlsson and Winblad, 1976; Kish et al., 1992; Reeves et al., 2002; 
Haycock et al., 2003).  More severe dopaminergic neuronal loss is observed in idiopathic 
Parkinson’s disease (PD), for which advanced age is the most identifiable risk factor.  
However a causal link between aging and these processes is yet unclear.  Accumulating 
evidence of interactions between dynorphin and dopamine pathways in the basal ganglia 
suggests that these endogenous neuropeptides may play important roles in age-related 
dopamine regulation with relevance to mechanisms of age-related motor dysfunction or 
susceptibility to PD. 
Dynorphin peptides are obtained by proteolytic cleavage of a precursor encoded 
by the prodynorphin (Pdyn) gene (Simonato and Romualdi, 1996) and are expressed in 
striatum, hypothalamus, nucleus accumbens, dentate gyrus, hippocampus, cerebral 
cortex, and spinal cord (Khachaturian et al., 1982; Watson et al., 1982a; Watson et al., 
1982b; Khachaturian et al., 1993; Hurd et al., 1999).  Within striatum, dynorphin is 
colocalized with substance P and GABA within dopamine D1-receptor-expressing 
striatonigral projection neurons (Steiner and Gerfen, 1998).  Though originally identified 
as an opiate (Goldstein et al., 1979) with picomolar affinity for opioid receptors 
(Chavkin et al., 1982), dynorphin has a complex pharmacological profile and can 
participate in  or  opioid (Mansour et al., 1995) and non-opioid mechanisms (Brauneis 
et al., 1996; Caudle and Dubner, 1998; Tang et al., 1999; Tang et al., 2000; Woods and 
Zangen, 2001).  Dynorphins and exogenous  agonists inhibit dopamine release in 
striatum and nucleus accumbens (Mulder et al., 1984; Herrera-Marschitz et al., 1986; Di 
Chiara and Imperato, 1988; Reid et al., 1988; Spanagel et al., 1992; Ronken et al., 1993; 
Schlosser et al., 1995), while  antagonists result in enhanced dopamine release 
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(Spanagel et al., 1992).  Conversely, dopamine promotes dynorphin expression via the 
D1-receptor (Li et al., 1986; Li et al., 1988; Li et al., 1990; Bordet et al., 1997; Wong et 
al., 2003). 
Aging has varied effects on dynorphin expression, with age-related elevations in 
dynorphin noted in the hippocampus and frontal cortex (Jiang et al., 1989; Zhang et al., 
1991; Gallagher and Nicolle, 1993) and in spinal cord (Iadarola et al., 1986; Zhang et al., 
2004a).  The molecular and biochemical causes and consequences of altered Pdyn 
expression are unclear, but given the inhibitory roles of dynorphins on dopaminergic 
activity and reports of dynorphin-mediated neurotoxicity (Hauser et al., 1999; Tan-No et 
al., 2001; Goody et al., 2003; Singh et al., 2003), we hypothesized that suppression of 
Pdyn expression would mitigate effects of aging on striatal dopaminergic activity.  In this 
study, we examine the chronic effects of Pdyn deletion on dopamine biosynthesis in mice 
during normal aging by quantitating striatal dopamine content in wild-type (WT) and 
Pdyn knockout (KO) mice. 
 
Methods 
Animal subjects 
Mice used in this study were mixed male and female WT or Pdyn KO mice that were 
maintained in an approved animal facility at the University of Kentucky.  WT mice were 
derived from the 129SvEv-Tac line, and Pdyn KO mice, provided by Dr. Ute 
Hochgeschwender (Oklahoma Medical Research Foundation, Oklahoma City, OK), were 
obtained by targeted deletion of the coding exons of the Pdyn gene and maintained in a 
129SvEv-Tac background (Sharifi et al., 2001).  Animals were housed in groups of up to 
4 per cage with food and water ad libitum in a well-ventilated room with a 12 h: 12 h 
light:dark cycle. Prior to weaning, tail specimens were collected from each animal, and 
DNA was extracted for subsequent genotyping to confirm the identity of the Pdyn locus 
by the polymerase chain reaction (PCR) using primer pairs specific for each allele.  For 
experiments involving 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 3-month 
(n = 3 - 5 per group) and 10-month (n = 5 - 8 per group) mice were injected with 0.9% 
saline or MPTP (Sigma, St. Louis, MO) at a dose of 15 mg/kg intraperitoneally four 
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times at 2-h intervals and euthanized at 7 days post-injection.  A 20-month age point was 
not selected in the MPTP experiments due to logistical reasons pertaining to availability 
of mice of substantially advanced age.  Striatal tissue specimens were dissected on ice 
from CO2-asphyxiated mice, weighed, frozen in liquid nitrogen, and stored at -80°C until 
needed for protein extraction or high-performance liquid chromatography (HPLC) 
analysis. All procedures involving animals were approved by the Institutional Animal 
Care and Use Committee at the University of Kentucky. 
 
HPLC analysis 
HPLC analysis was performed based on methods described previously (Hall et al., 1989).  
Sensitive detection of 3,4-dihydroxyphenylacetic acid (DOPAC), dopamine (DA), 
serotonin (5-HT), norepinephrine (NE), 5-hydroxyindole-3-acetic acid (5-HIAA), and 4-
hydroxy-3-methoxyphenylacetic acid (homovanillic acid; HVA) were performed using an 
isocratic HPLC system (Beckman, Inc., Fullerton, CA) at a flow rate of 2 ml/min coupled 
to a dual-channel electrochemical array detector (model 5100A, ESA, Inc., Chelmsford, 
MA), E1 = +0.35 mV and E2 = -0.25 mV, using an ESA model 5011 dual analytical cell. 
The compounds of interest were separated by reverse-phase chromatography, using a C18 
column (4.6 mm x 75 mm, 3- m particle size, Shiseido CapCell Pak UG120, Shiseido 
Co., LTD., Tokyo, Japan) with a pH 4.1 citrate-acetate mobile phase containing 4.0% 
methanol and 0.341 mM 1-octane-sulfonic acid. By comparison to a set of analytical 
standards, quantities of the species of interest were calculated as pmol per mg wet tissue, 
and the results expressed as means ± standard errors of the mean (SEM).  Samples 
exhibiting aberrantly high quantities of degradation products consistent with post-mortem 
degradation or poor tissue quality were identified and excluded from the analysis based 
on the presence of one or more turnover ratios exceeding 5 standard deviations above the 
sample mean.  Results were pooled from multiple HPLC experiments after applying a 
proportional scaling factor to normalize data to the mean of the 10-mo WT control group 
in each experiment to minimize run-to-run variability in quantitation. 
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Protein extraction and western blotting 
Whole striatal specimens from a separate group of 3- (n = 6 per group) and 21-month (n 
= 8 per group) WT and Pdyn KO mice were dissected and homogenized in lysis buffer 
containing 10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 1 mM Na 
orthovanadate, and protease inhibitor cocktail (1:1000 dilution; Sigma, St. Louis, MO) 
using a Brinkman Kinematic sonicator. Following a 30- to 60-minute incubation on ice, 
samples were centrifuged to remove cell debris, and protein content was determined by  a 
modification of the Lowry assay using the DC Protein Assay kit (catalog #500-0115; 
Bio-Rad Laboratories, Hercules, CA). 
Prior to loading, samples were normalized to a concentration of 1.0 mg/ml and 
subsequently diluted in loading buffer containing 5% 2-mercaptoethanol (BME; Sigma, 
St. Louis, MO), boiled for 5 minutes, and cooled on ice.  Samples containing 7 mg total 
protein were subjected to electrophoresis in 12% polyacrylamide gels, followed by 
transfer onto nitrocellulose membranes. Membranes were then washed in a Tris-buffered 
saline wash buffer containing 0.05% Tween-20, blocked with 5% blotting-grade non-fat 
milk, and incubated at room temperature with primary antibody for a minimum of 2 h.  
The primary antibodies used are as follows:  tyrosine hydroxylase (TH, 1:3000 dilution; 
Pel-Freez Biologicals, Rogers, AK), phospho-Ser40-TH (1:2500 dilution; Chemicon), 
phospho-Ser31-TH (1:2500 dilution; Chemicon, Billerica, MA), dopamine transporter 
(DAT C-20, 1 g/ml; Santa Cruz Biotech, Santa Cruz, CA), synaptophysin (SY38, 1:200 
dilution; Research Diagnostics, Inc., Flanders NJ), and actin (1:3000 dilution, Sigma, St. 
Louis, MO). 
Following repeated washes in wash buffer, membranes were then incubated for 2 
h with horseradish peroxidase-conjugated secondary antibody.  After at least three 
successive rinses in wash buffer, chemiluminescent detection by the ECL-plus system 
(Amersham, Piscataway, NJ) was performed, with subsequent exposure on Amersham 
Hypermax film. For multiple antibody probings on a single blot, membranes were 
stripped by a 40-minute incubation in 0.7% BME at 55°C.   
Film exposures were scanned using an Epson Expression 1640XL scanner under 
transparency mode, and the resulting images were recorded as uncompressed 8-bit 
grayscales at 300 dpi resolution.  Optical densities (ODs) of the band of interest in each 
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lane were measured using Scion Image software (release beta 4.0.2, Scion Corporation, 
Houston, TX) by recording the average pixel grayscale value within rectangular areas of 
a fixed size for a given image.  Background ODs were obtained at multiple points along 
the width of the image, and the average background value was subtracted from each band 
OD prior to normalizing to the respective actin band OD and expressing the results 
relative to the mean value for the image.  Data were obtained by combining results from 
two different gels containing samples from distinct sets of mice and are expressed as 
mean relative ODs ± standard errors of the mean (SEM).   
 
Statistical analysis 
Statistical analyses were performed using Systat 10 software (SPSS, Inc., Chicago, 
Illinois).  Two-way ANOVA was used for evaluating effects of aging and Pdyn, and in 
experiments involving an MPTP component, three-way ANOVA was applied.  Individual 
contrasts were obtained by the least significant difference method. 
 
Results 
Striatal dopamine is elevated in aged Pdyn KO mice  
Quantitative HPLC analysis of dopamine from mouse striatal samples demonstrated that 
dynorphin-deficient mice on average exhibited markedly higher dopamine concentrations 
in striatum than WT mice, especially at increasing age (Figure 4.1). Two-way ANOVA 
of dopamine levels revealed a significant main effect of age [F(2, 24) = 4.77, p<0.018] 
and of Pdyn genotype [F(1, 24) = 5.42, p<0.029].  Striatal dopamine concentrations in 
Pdyn KO mice were significantly higher at 10 months [F(1, 24) = 8.48, p<0.02] and 20 
months [F(1, 24) = 6.44, p<0.008], when compared to 3-month Pdyn KO mice.   
However, the Pdyn genotype effect on total striatal dopamine levels was only statistically 
significant in the 20-month group [F(1, 24) = 4.50, p<0.045].   Notably, there was no 
appreciable age-related decline in total striatal dopamine content in the WT mice of this 
study. 
65 
 
No significant differences with age or Pdyn genotype were noted in the 
metabolites DOPAC or HVA despite an increase in mean DOPAC levels with age.  
However, two-way ANOVA of molar turnover ratios revealed subtle but statistically 
significant differences (Figure 4.2).  With increasing age, the mean DOPAC/DA ratio 
exhibited an increasing trend whereas the mean HVA/DA ratio decreased.  The increase 
in the DOPAC/DA ratio was most prominent among the WT mice with an approximately 
50% elevation at 20 months that was nonetheless short of significance [F(1, 24) = 3.76, 
p<0.064 (NS)].  In contrast, the Pdyn KO mice showed minimal change in the 
DOPAC/DA ratio with age, resulting in a significant Pdyn genotype effect at 20 months 
when examining either DOPAC/DA [F(1, 24) = 4.51, p<0.044] or (DOPAC+HVA)/DA 
[F(1, 24) = 4.91, p<0.036].  A statistically significant age effect was seen only in the 
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Figure 4.1.  Dopamine (DA) and its 
metabolites DOPAC and HVA as a 
function of age and Pdyn 
genotype.   
These results were obtained by HPLC 
analysis of whole striatum homogenates of 
WT and Pdyn KO mice aged 3, 10, and 20 
months.  Note the age-dependent increase 
in dopamine among Pdyn KO mice and 
the significantly increased dopamine in 
aged Pdyn KO mice in comparison to 
aged WT mice.  Data represent means  
SEM.  *p<0.05 relative to corresponding 
3-month mice; 
#
p<0.05 relative to 
corresponding WT mice. 
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HVA/DA ratio, with significant declines noted among WT mice at 10 months [F(1, 24) = 
4.49, p<0.045] and among Pdyn KO mice at 10 months [F(1, 24) = 5.86, p<0.023] and at 
20 months [F(1, 24) = 6.57, p<0.017].  Analysis of norepinephrine, serotonin, and the 
serotonin metabolite HIAA resulted in no significant contrasts (Figure 4.3).  The turnover 
ratio HIAA/5HT also did not show significant age or Pdyn genotype effects (Figure 4.2).   
Although the present study was not initially designed to optimally assess effects 
of gender, inclusion of gender as an additional ANOVA factor reveals a main effect of 
gender on dopamine quantities [F(1, 19) = 5.49, p<0.03] with males averaging 14% 
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
3-mo. 10-mo. 20-mo.
Age
M
o
la
r 
ra
ti
o
s
WT
Pdyn -/-
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
3-mo. 10-mo. 20-mo.
Age
M
o
la
r 
ra
ti
o
s
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
3-mo. 10-mo. 20-mo.
Age
M
o
la
r 
ra
ti
o
s
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
3-mo. 10-mo. 20-mo.
Age
M
o
la
r 
ra
ti
o
s
#
** *
#
D
O
P
A
C
 /
 D
A
(H
V
A
 +
 D
O
P
A
C
) 
/ 
D
A
H
V
A
 /
 D
A
H
IA
A
 /
 5
-H
T
. . .
M
o
la
r 
ra
ti
o
s
 -/-
. . .
M
o
la
r 
ra
ti
o
s
. . .
M
o
la
r 
ra
ti
o
s
. . .
M
o
la
r 
ra
ti
o
s
D
O
P
A
C
 /
 D
A
(H
V
A
 +
 D
O
P
A
C
) 
/ 
D
A
H
V
A
 /
 D
A
H
IA
A
 /
 5
-H
T
Figure 4.2.  Dopamine and serotonin turnover ratios as a function of age and Pdyn 
genotype.   
These results were obtained by HPLC analysis of whole striatum homogenates of WT 
and Pdyn KO mice aged 3, 10, and 20 months.  Only mild decreases in dopamine 
turnover ratios are seen in aged Pdyn KO mice, whereas no trends in serotonin turnover 
were observed.  Data represent means  SEM. *p<0.05 relative to corresponding 3-
month mice; 
#
p<0.05 relative to corresponding WT mice. 
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higher dopamine levels than females irrespective of Pdyn or age (males: 90.5  6.8 
pmol/mg tissue;  females: 79.3  5.9 pmol/mg tissue).  In addition, a Pdyn-gender 
interaction was also significant [F(1, 19) = 5.47, p<0.03], as gender differences were less 
apparent among Pdyn KO mice.  A male gender effect on dopamine levels was observed 
in WT mice [males: 84.5  7.9 pmol/mg tissue; females: 72.8  6.2 pmol/mg tissue; F(1, 
19) = 7.49, p<0.013], but was smaller and not significant in Pdyn KO mice (males: 93.1  
9.4 pmol/mg tissue; females: 88.5  11.0 pmol/mg tissue).    Significant gender effects 
were not observed with other amines or any turnover ratios examined in this set of mice. 
 
Pdyn deletion enhances TH phosphorylation at Ser40  
Western blotting analyses were performed on young (3-month) and aged (21-month) 
mice to detect TH, the rate-limiting enzyme in dopamine synthesis that catalyzes the 
conversion of tyrosine to the dopamine precursor L-dopa (Figure 4.4).  Other 
dopaminergic and neuronal markers were also examined, including DAT, SY38, and 
actin (Figure 4.4).  In addition, because TH activity can be modulated by phosphorylation 
at specific serine sites (Haycock and Haycock, 1991; Sutherland et al., 1993; Harada et 
al., 1996; Lindgren et al., 2000; Lindgren et al., 2001), phospho-Ser40-TH and phospho-
5-HT HIAANE
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Figure 4.3.  HPLC analysis of norepinephrine (NE), serotonin (5-HT), and the serotonin 
metabolite HIAA as a function of age and Pdyn genotype.   
These results were obtained by HPLC analysis of whole striatum homogenates of WT 
and Pdyn KO mice aged 3, 10, and 20 months.  No significant effects were noted for 
these variables.  Data represent means  SEM. 
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Ser31-TH immunoreactivity were also examined.  Two-way ANOVA to evaluate for 
effects of age and Pdyn genotype revealed significant main effects of age [F(1, 24) = 
5.51, p<0.027] and Pdyn genotype [F(1, 24) = 10.40, p<0.004] on TH immunoreactivity 
(Figure 4.5).  A statistically significant age effect was noted only in the WT mice, with 
21-month mice displaying approximately 50% greater TH immunoreactivity than 3-
month mice [F(1, 24) = 4.67, p<0.041].  In both age groups, mean TH immunoreactivity 
in Pdyn KO mice was approximately 60% that of the corresponding WT mean; however 
statistical significance was seen only among the aged mice [F(1, 24) = 9.03, p<0.006].   
Phospho-Ser40-TH also exhibited a significant main effect of aging [F(1, 24) = 
12.69, p<0.002], with aged Pdyn KO mice demonstrating an increase by a factor of 3.6 
compared to young Pdyn KO mice [F(1, 24) = 10.97, p<0.003].  In contrast, phospho-
Ser31-TH showed a significant Pdyn effect [F(1, 24) = 4.76, p<0.039] similar to that 
exhibited by total TH, but there was no statistically significant aging effect.   A 
TH
3-mo WT 3-mo KO 21-mo WT 21-mo KO
DAT
P-Ser40-TH
P-Ser31-TH
SY38
actin
Figure 4.4.  Representative Western blot of mouse striatal homogenates. 
Immunoblot analysis of whole striatum homogenates of WT and Pdyn KO mice aged 3 
and 21 months was performed, and bands representing immunoreactivity to TH, 
phospho-Ser40-TH (P-Ser40-TH), phosphor-Ser31-TH (P-Ser31-TH), dopamine 
transporter (DAT), synaptophysin (SY38), and actin as a function of age and Pdyn 
genotype are shown.   Depicted are blots from a representative gel from one of two 
separate experiments that are pooled for statistical analysis. 
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significant main effect of age was also noted for the dopamine transporter [F(1, 24) = 
5.41, p<0.029], although individual contrasts were not significant in this analysis.  
Correlation analysis confirmed that DAT levels correlated very strongly with TH 
(Pearson's correlation coefficient r = 0.889, Bonferroni-corrected p<0.0005).  No 
significant differences were evident in synaptophysin levels in this study. 
To assess the extent to which the above differences in immunoreactivity to 
phosphorylated TH reflect posttranslational effects as opposed to changes in 
dopaminergic neuron mass, a separate analysis was also performed on phospho-Ser40-
TH: total TH and phospho-Ser31-TH: total TH ratios (Figure 4.5).  This analysis revealed 
no age effect but demonstrated a significant main effect of Pdyn genotype on only the 
phosphor-Ser40-TH: total TH ratio [F(1, 24) = 5.09, p<0.033], which was approximately 
2-fold higher in Pdyn KO mice compared to the respective WT counterparts, with a 
significant difference observed only among the aged groups [F(1, 24 = 4.55, p<0.043]. 
 
Table 4.1.  ANOVA results from analysis of effects of MPTP, age, and Pdyn genotype on 
dopamine and related monoamines.   
Three-way ANOVA was performed on results of monoamine quantitation and their 
respective turnover ratios.  Only variables for which a statistically significant effect or 
interaction is noted are listed below along with corresponding F statistics and p-values. 
 
MPTP effect 
DA F(1, 37) = 54.93 p<0.0005 
DOPAC F(1, 37) = 9.88 p<0.003 
HVA F(1, 37) = 11.76 p<0.002 
5HT F(1, 37) = 22.93 p<0.0005 
HVA / DA F(1, 37) = 11.65 p<0.002 
DOPAC / DA F(1, 37) = 12.15 p<0.001 
(DOPAC + HVA) / DA F(1, 37) = 12.76 p<0.001 
HIAA / 5HT F(1, 37) = 9.13 p<0.005 
Pdyn effect 
5HT F(1, 37) = 4.46 p<0.042 
MPTP x age 
DA F(1, 37) = 9.72 p<0.004 
DOPAC F(1, 37) = 4.61 p<0.038 
HVA F(1, 37) = 4.86 p<0.034 
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MPTP-induced dopamine loss is unaffected by Pdyn deletion 
We also examined dopaminergic changes induced by systemic MPTP, which mimics in 
mice many features of human parkinsonism via toxic degeneration of SN dopaminergic 
neurons (Arai et al., 1990; Sundstrom et al., 1990).  Intraperitoneal MPTP was 
administered to 3- or 10-month Pdyn KO or WT mice, with corresponding saline 
controls.  A 3-way ANOVA to evaluate the effects of MPTP administration, age, or Pdyn 
genotype on dopamine and its metabolites found significant main effects of treatment and 
an MPTP-age interaction but no main effect of age or genotype in this data set (Table 
4.1).   Levels of dopamine in the striatum significantly decreased 7 days following 
intraperitoneal MPTP administration (Figure 4.6).  Among 10-month mice, MPTP 
resulted in a reduction of dopamine levels by 71% in WT mice [F(1, 37) = 34.64, 
p<0.0005] and 73% in Pdyn KO mice [(F(1, 37) = 44.48, p<0.0005] when compared to 
respective saline-injected controls.  The MPTP-associated loss of dopamine among the 3-
month mice was less robust, with MPTP-injected WT mice exhibiting a nonsignificant 
reduction of 40%, and Pdyn KO mice demonstrating a statistically significant 46% 
reduction [(F(1, 37) = 5.66, p<0.023].  Consistent with the preceding analysis, saline-
injected Pdyn KO mice at 10 months showed significantly higher dopamine levels 
compared to 3-month Pdyn KO mice [(F(1, 37) = 8.96, p<0.005].    
The dopamine metabolites DOPAC and HVA also showed significant MPTP-
induced changes, most prominent at 10 months (Figure 4.6).  DOPAC levels decreased 
by over 50% following MPTP administration in 10-month WT [F(1, 37) = 9.98, p<0.003] 
and 10-month Pdyn KO mice [F(1, 37) = 10.08, p<0.003].  Similarly, MPTP caused a 
decrease in HVA by 33% and 44% in 10-month WT [F(1, 37) = 6.95, p<0.012] and 10-
month Pdyn KO mice [F(1, 37) = 16.15, p<0.0005], respectively.   
Serotonin levels also responded significantly to MPTP (Figure 4.7).  MPTP 
administration was associated with an approximately 25% decline in striatal serotonin 
levels in each group with statistical significance noted in 3-month Pdyn KO [F(1, 37) = 
5.70, p<0.022], 10-month WT [F(1, 37) = 12.45, p<0.001], and 10-month Pdyn KO mice 
[F(1, 37) = 6.01, p<0.019].  No significant contrasts were observed in levels of HIAA or 
NE.  However, the serotonin turnover ratio (HIAA / 5HT) was found to increase 
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following MPTP administration in 10-month WT mice to 1.7 times that of saline controls 
[F(1, 37) = 7.40, p<0.01, Figure 4.8]. 
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Figure 4.5.  Densitometric quantitation of Western blot data. 
Immunoreactivity to (a) tyrosine hydroxylase (TH), (b) phospho-Ser40-TH (pSer40-TH), 
(c) phospho-Ser31-TH (pSer31-TH), (d) dopamine transporter (DAT), (e) phospho-
Ser40-TH: total TH ratio, (f) phospho-Ser31-TH: total TH ratio, (g) synaptophysin 
(SY38), and (h) actin are shown as a function of age and Pdyn genotype.  Pdyn KO mice 
demonstrate increased phosphorylation of TH at Ser40 but not Ser31, an effect most 
prominently seen at 21 months. However, total TH immunoreactivity was decreased in 
Pdyn KO mice compared to WT mice.  Data were pooled from two separate gels and 
represent mean relative optical densities (ODs)  SEM.  *p<0.05, **p<0.01 relative to 
corresponding 3-month mice; 
#
p<0.05, 
##
p<0.01 relative to corresponding WT mice. 
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Dopamine turnover ratios also increased upon MPTP administration, more 
prominently among the 10-month mice (Figure 4.8).  MPTP caused DOPAC/DA to 
increase in 10-month WT and Pdyn KO mice to 2.5 [F(1, 37) = 9.57, p<0.004] and 3 
times [F(1, 37) = 10.41, p<0.003] the saline control values, respectively, and HVA/DA 
increased 3.6-fold [F(1, 37) = 9.03, p<0.005] and 3.9-fold [F(1, 37) = 7.89, p<0.008], 
respectively.   Consequently, the (HVA+DOPAC)/DA ratio was increased by a factor of 
2.8 and 3.3 in 10-month WT [F(1, 37) = 9.98, p<0.003] and Pdyn KO mice [F(1, 37) = 
9.99, p<0.003], respectively.  This analysis also revealed modest but statistically 
significant elevations in HVA levels in saline-injected 10-month Pdyn KO mice 
compared to saline-injected 10-month WT mice [F(1, 37) = 4.56, p<0.039] or 3-month 
Pdyn KO mice [F(1, 37) = 5.57, p<0.024].  Inclusion of gender in the ANOVA analysis 
found no significant main effects of gender in any of the monoamine levels examined in 
the above MPTP experiment.  However, a significant MPTP-sex interaction was evident 
in dopamine [F(1, 29) = 10.22, p<0.003]  and HVA levels [F(1, 29) = 4.17, p<0.05).  
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Figure 4.6.  Effect of MPTP on dopamine and its metabolites as a function of age and 
Pdyn genotype.   
These results reflect HLPC measurements of dopamine (DA) and its metabolites in 
whole striatum from 3- and 10-month mice obtained 7 days post-injection of saline or 
MPTP.  Note the decreases in dopamine with milder reductions in DOPAC and HVA in 
response to MPTP.  Data represent means  SEM.   
†
p<0.05, 
‡
p<0.01 relative to 
corresponding saline controls; *p<0.05, **p<0.01 relative to corresponding 3-month 
mice; 
#
p<0.05 relative to corresponding WT mice. 
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MPTP-induced loss of dopamine in males averaged across all groups was 81% compared 
to 41% in females.  MPTP-sex interactions were also noted for the turnover ratios 
HVA/DA [F(1, 29) = 5.69, p<0.024], DOPAC/DA [F(1, 29) = 4.47, p<0.043], 
HIAA/5HT [F(1, 29) = 4.82, p<0.036], and  (HVA+DOPAC)/DA [F(1, 29) = 5.55, 
p<0.026], for which female turnover ratios averaged 40-60% less than the corresponding 
male ratios.  The gender discrepancy in turnover ratios was more pronounced among 10-
month mice, as manifested by significant age-MPTP-sex interactions for DOPAC/DA 
[F(1, 29) = 5.46, p<0.027], HIAA/5HT [F(1, 29) = 8.11, p<0.008], and 
(HVA+DOPAC)/DA [F(1, 29) = 4.56, p<0.041].   
 
Discussion 
In this study, quantitative HPLC was used to identify changes in dopamine, other 
biogenic amines, and related metabolites in mouse striatum with aging, Pdyn deletion, or 
MPTP.  Interestingly, no decline in dopamine levels with aging alone was apparent 
among WT mice.  While several studies have documented declines in striatal dopamine 
with aging in rats (Moretti et al., 1987; Marshall and Rosenstein, 1990), monkeys (Collier 
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Figure 4.7.  Effect of MPTP on NE, 5-HT, and HIAA.   
NE and HIAA show no significant changes in response to MPTP, but 5-HT shows mild 
decreases 7 days after MPTP injection.  Data represent means  SEM.   
†
p<0.05, 
‡
p<0.01 
relative to corresponding saline controls. 
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et al., 2007), and humans (Carlsson and Winblad, 1976; Kish et al., 1992; Haycock et al., 
2003), there have also been studies in rodents describing whole-striatum dopamine 
content to demonstrate minimal or no decline with age (Friedemann and Gerhardt, 1992; 
Burwell et al., 1995; Hebert and Gerhardt, 1998; Stanford et al., 2003).   While the 
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Figure 4.8.  Effect of MPTP on dopamine and serotonin turnover ratios.   
MPTP produces increases in dopamine turnover and serotonin turnover 7 days post-
injection, findings which are statistically significant only among older (10-month) mice.  
Data represent means  SEM.   
†
p<0.05, 
‡
p<0.01 relative to corresponding saline controls. 
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relatively preserved dopamine content among WT mice in this study may be attributable 
to species and strain differences, it also lends support to the view that normal aging alone 
is unlikely to produce the pathological dopamine deficits seen in disorders such as 
Parkinson's disease. 
The use of Pdyn KO mice offers distinct advantages over studies employing 
traditional pharmacologic antagonists as this study does not presume a specific receptor 
interaction and permits evaluation of chronic changes in the presence of compensatory 
effects, which would likely not be feasible when using only exogenously applied agents. 
We show in this study that striatal dopamine is elevated in aging Pdyn KO mice 
compared to aging WT mice.  These findings could be interpreted as a chronic inhibitory 
effect of dynorphin on dopamine biosynthetic activity, or alternatively, a harmful effect 
of dynorphins on dopaminergic cell survival in the SN.  Despite published evidence that 
dynorphin peptides may exhibit toxic or pro-apoptotic effects in both neuronal and non-
neuronal cells under various experimental conditions (Hu et al., 1996; Hauser et al., 
1999; Hu et al., 1999; Hu et al., 2000; Hauser et al., 2001; Tan-No et al., 2001; Goody et 
al., 2003; Singh et al., 2003), the latter interpretation is less likely because in comparison 
to their WT counterparts, 21-month Pdyn KO mice in this study show less 
immunoreactivity to TH, a surrogate marker for dopaminergic neuron mass.  Moreover, a 
putative neurotoxic role of dynorphin is further challenged by reports that dynorphin 
peptides can show neuroprotective properties in some situations (Kong et al., 1997; Liu et 
al., 2001; Gabrilovac et al., 2003).   Differences in total TH levels are therefore unlikely 
to account for the altered dopamine levels seen with aging in Pdyn KO mice.  One study 
examining post-mortem human striata found an aging-associated decline in striatal 
dopamine content without loss of TH (Haycock et al., 2003), suggesting that impaired 
dopaminergic neuron function rather than cell death could account for the relative 
dopamine depletion in aged WT mice relative to aged Pdyn KO mice in this study.  This 
assertion is supported by reports that infusion of dynorphin into the striatum decreases 
dopamine levels by as much as 60% (Zhang et al., 2004b). 
Consequently, we addressed the effect of aging and Pdyn deletion on the 
enzymatic activity of TH, which is subject to physiological regulatory control via 
phosphorylation at Ser31 or Ser40 by different kinase pathways, resulting in increases in 
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the intrinsic rate of catalysis (Haycock and Haycock, 1991; Sutherland et al., 1993; 
Harada et al., 1996; Lindgren et al., 2000; Lindgren et al., 2001). Other investigators, for 
instance, have noted increased Ser31 phosphorylation of TH by neurotrophic factors 
(Salvatore et al., 2004). Although we did not directly measure enzyme activity, our 
results show that a greater proportion of TH molecules in aged Pdyn KO mice are 
phosphorylated at the Ser40 site compared to aged WT mice.  Because activation of 
striatal dopamine D2 receptors selectively inhibits TH phosphorylation at Ser40 via 
inhibition of adenylate cyclase (Lindgren et al., 2001), the increased phospho-Ser40-TH 
in aged Pdyn KO mice may be attributable to decreased D2 receptor activity.  
Alternatively, glutamate acting via NMDA receptors can also decrease TH 
phosphorylation at Ser40 in striatum (Lindgren et al., 2000), and since dynorphin 
peptides have been observed to potentiate NMDA receptor activation (Zhang et al., 1997; 
Woods et al., 2006), the increased Ser40 phosphorylation in dynorphin-deficient mice in 
the present study is consistent with the above observations.  While the precise 
mechanisms underlying the age-associated increases in dopamine in Pdyn KO mice 
remain to be elucidated, the available data suggest a role of dynorphin peptides in 
suppressing dopaminergic neuron function via regulation of dopamine biosynthesis.  
Other potential mechanisms include cellular or metabolic dysfunction caused by toxic 
effects of specific dynorphin peptides as supported by evidence of dynorphin toxicity in 
striatal  neurons (Goody et al., 2003; Singh et al., 2003), spinal neurons (Caudle and 
Isaac, 1987; Qu and Isaac, 1993; Hauser et al., 1999), and non-neuronal cells (Tan-No et 
al., 2001), primarily via non-opioid mechanisms. 
In the present study, the Pdyn-associated differences in dopamine levels are more 
pronounced and are statistically significant at increased age.   The findings that advanced 
age unmasks these effects may reflect age-related alterations in the dynorphinergic 
system.  Increased dynorphin was observed in hippocampus of normal aged rats (Jiang et 
al., 1989; Zhang et al., 1991; Gallagher and Nicolle, 1993; Kotz et al., 2004), the cortex 
and hippocampus of amyloid precursor protein-overexpressing mice (Diez et al., 2000), 
frontal cortex of Down’s syndrome patients (Risser et al., 1996), and frontal and parietal 
cortex of Alzheimer’s disease patients (Risser et al., 1996; Yakovleva et al., 2006a), thus 
implicating dynorphin in age-related pathophysiological processes. Peripheral 
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inflammation also upregulates Pdyn in spinal cord (Iadarola et al., 1986), and aging 
enhances this response (Zhang et al., 2004a).  In striatum, Pdyn expression with aging has 
been less well studied, with some studies showing no changes in aging rats (Zhang et al., 
1991; Kotz et al., 2004) and one study finding decreased Pdyn mRNA in striatum of 
normal aged humans (Backman et al., 2007).  In addition, dynorphin expression is also 
markedly influenced by the dopaminergic system.  In models of PD, decreases in 
dynorphin have been noted following experimental manipulations that lesion the 
nigrostriatal dopaminergic pathway (Gerfen et al., 1991).  Similarly, striatal dynorphin 
expression is increased by dopamine, its biochemical precursors, or exogenous D1 
agonists (Li et al., 1986; Li et al., 1988; Li et al., 1990; Bordet et al., 1997) and is reduced 
in D1-receptor knockout mice (Wong et al., 2003).   The above studies point to a possible 
dysregulation of Pdyn expression with aging that may lead to or be caused by 
perturbations in the dopaminergic system.  In this study, the potential effects of 
dynorphin on the dopaminergic system are abolished in the Pdyn KO mice, permitting 
evaluation of one component of this bidirectional interaction during the aging process. 
However, the molecular and cellular events influencing Pdyn expression during aging 
have not been fully identified and remain an interesting avenue for further research. 
MPTP, in this study, produced declines in striatal dopamine content 7 days after 
injection of a standard sublethal dose, consistent with prior studies using the C57BL6 
strains (Arai et al., 1990; Sundstrom et al., 1990; Ali et al., 1993).   Although the extent 
of dopamine loss is less than the 80% originally reported (Arai et al., 1990; Sundstrom et 
al., 1990), the lower magnitude observed in the present study may be attributed to 
differential susceptibility among different mouse strains, which has previously been 
noted (German et al., 1996).  Dopamine turnover, as reflected in the ratio of levels of 
dopamine metabolites to levels of dopamine, was elevated following MPTP, consistent 
with activation of compensatory mechanisms to replenish dopamine following 
dopaminergic neuronal loss (Zigmond, 1997), while aging alone yielded no changes in 
turnover except for mild decreases with age in Pdyn KO mice that may reflect local 
negative feedback mechanisms.  The MPTP-induced loss of dopamine was more 
prominent among aged mice, suggesting that these compensatory mechanisms are less 
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effective with advanced age, consistent with other studies finding aged-associated 
increases in susceptibility to MPTP (Faden, 1992). 
The gender effects observed in the above MPTP experiment are consistent with 
previous studies in mice.  Attenuation of MPTP-induced dopamine depletion in females 
compared to males has been previously reported in other mouse strains (Freyaldenhoven 
et al., 1996; Miller et al., 1998), suggesting neuroprotective actions of estrogen.  Also, 
increased opioid receptor sensitivity has been noted in females in human studies (Kreek 
et al., 1999), which may explain the mild gender difference in basal striatal dopamine 
present in the WT mice but absent in the Pdyn KO mice of this study.   
Other neurotransmitters, such as norepinephrine and serotonin, were relatively 
unaffected by age or Pdyn genotype in this study, signifying a relatively selective effect 
on the dopaminergic system.  However our data show mild reductions in striatal serotonin 
content by MPTP, in contrast to prior studies documenting unchanged serotonin levels 
following MPTP administration (Chang et al., 1993; Callier et al., 2000).  This finding is 
of uncertain significance but may be explained by strain-specific differences in MPTP 
metabolism, since an MPTP analogue 2'-NH2-MPTP has been shown to produce 
serotonergic deficits (Luellen et al., 2006).  
Interestingly, there was no significant effect of Pdyn genotype on post-MPTP 
dopamine levels, implying that Pdyn deletion confers no protection against MPTP 
toxicity.  This further supports the contention that the effect of Pdyn deletion on striatal 
dopamine content is dependent on survival of MPTP-sensitive dopaminergic neurons, 
consistent with a mechanism involving modulation of dopamine biosynthetic activity 
rather than prevention of neurotoxicity.   
In the context of aging and neurodegenerative disease, the results of this study 
offer insight into one potential means by which striatal dopaminergic activity can be 
modulated by dynorphin peptide neurotransmitters in physiological aging or 
neurodegenerative disease.   Additional studies are needed to elucidate further the 
mechanisms involved and to clarify the relevance of these findings to clinical entities 
such as Parkinson's disease. 
  
Copyright © Xuan V. Nguyen  2007 
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CHAPTER 5:  Radioimmunological quantitation of prodynorphin-derived 
peptides in mice in aging and an MPTP model 
 
Introduction 
Expression of endogenous dynorphin peptides during aging and age-related 
disorders has received increased attention in the neurobiological literature.  Initial 
localization studies have shown that dynorphins are widely distributed in the central 
nervous system (Khachaturian et al., 1982; Watson et al., 1982a; Watson et al., 1982b; 
Hurd et al., 1999), with high Pdyn mRNA levels in hypothalamus, nucleus accumbens, 
neostriatum, dentate gyrus, hippocampus, cerebral cortex, and spinal cord (Khachaturian 
et al., 1993).  Within the striatum, dynorphins colocalize with substance P and GABA 
within dopamine D1-receptor-expressing striatonigral projection neurons [reviewed in 
(Steiner and Gerfen, 1998)], where they appear to regulate dopamine release and function 
in a negative feedback manner.  Since dynorphins or exogenous  agonists inhibit 
dopaminergic activity (Mulder et al., 1984; Herrera-Marschitz et al., 1986; Di Chiara and 
Imperato, 1988; Reid et al., 1988; Spanagel et al., 1992; Ronken et al., 1993; Schlosser et 
al., 1995),  modulation of dynorphin expression by dopamine represents a biologically 
plausible mechanism by which levels of this important neurotransmitter are regulated.  
Lesioning of the nigrostriatal dopaminergic pathway as in some models of PD results in 
decreases in dynorphin levels (Gerfen et al., 1991).  Similarly, striatal dynorphin 
expression is increased by dopaminerigc activity at the D1-receptor (Li et al., 1986; Li et 
al., 1988; Li et al., 1990; Bordet et al., 1997) and is reduced in mice lacking the D1-
receptor (Wong et al., 2003). 
Given the intrinsic variability in the aging process and the diverse environmental 
and species-dependent factors contributing to neuropeptide expression during aging, it is 
not surprising that published reports show significantly varied effects on dynorphin 
expression.  Age-related elevations in dynorphin have been noted in hippocampus and 
frontal cortex (Jiang et al., 1989; Zhang et al., 1991; Gallagher and Nicolle, 1993) and in 
spinal cord (Iadarola et al., 1986; Zhang et al., 2004a).  Pdyn mRNA expression with 
aging in one study was decreased in arcuate nucleus and amygdala, increased in 
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hippocampus, and unchanged in striatum or cortex of male rats (Kotz et al., 2004).  We 
previously noted no change in Dyn A with age in hippocampus but mild elevations in 
frontal cortex (Nguyen et al., 2005).   Although the cellular events influencing Pdyn 
expression during aging have not been fully identified, changes in CREB expression 
(Collins-Hicok et al., 1994) or binding at the AP-1 site in the Pdyn promoter (Naranjo et 
al., 1991; Collins-Hicok et al., 1994; Hunter et al., 1995; Kitamura et al., 1995) could 
potentially increase transcription and thus represent feasible molecular mechanisms for 
increased Pdyn with age.  Upregulation of Pdyn in spinal cord by peripheral 
inflammation (Iadarola et al., 1986) is enhanced with advancing age (Zhang et al., 2004a) 
by mechanisms that have not been fully elucidated.  Recently, increased dynorphin levels 
were observed in the cortex and hippocampus of amyloid precursor protein-
overexpressing mice (Diez et al., 2000) and in frontal cortex of Down’s syndrome or 
Alzheimer’s disease patients (Risser et al., 1996), thus further implicating dynorphins in 
pathophysiological neurological processes.  The above studies point to a possible 
dysregulation of Pdyn expression with aging that may lead to pathological 
manifestations.   
Because of the relative abundance of dynorphin in striatum and the importance of 
this region of the brain during aging, we measure in this study Dyn A and B in striatum 
of mice with particular attention to changes associated with aging.  In addition, we also 
evaluate striatal expression of dynorphin peptides following systemic exposure to the 
neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which produces 
selective dopaminergic neuronal death in the nigrostriatal system (Arai et al., 1990; 
Sundstrom et al., 1990; Ali et al., 1993).  Since dynorphins have been found to be 
upregulated during aging in frontal cortex of rats as discussed above, we also assess 
dynorphin peptide expression in frontal cortical tissue of these mice. 
 
Methods 
Animal subjects 
All animals in this study were wild-type (WT) or Pdyn KO mice that were maintained in 
an approved animal facility at the University of Kentucky.  WT mice were derived from 
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the 129SvEv-Tac line, and Pdyn KO mice were originally obtained by targeted deletion 
of the coding exons of the prodynorphin gene and bred into a 129SvEv-Tac background 
as described previously (Sharifi et al., 2001).  Animals were housed in groups of up to 4 
per cage with food and water ad libitum in a well-ventilated room with a 12 h: 12 h light: 
dark cycle. Prior to weaning, tail specimens were collected from each animal, and DNA 
was extracted for subsequent genotyping to confirm the identity of the Pdyn locus by the 
polymerase chain reaction (PCR) using primer pairs specific for each genotype.  All 
procedures involving animals are approved by the Institutional Animal Care and Use 
Committee at the University of Kentucky.    
The aging studies in frontal cortex used 3-month (n = 6), 10-month (n = 6), and 
20-month (n = 6) male and female WT mice.   Striatal data were pooled from two 
separate experiments such that sample sizes were as follows: 3-month (n = 15), 10-month 
(n = 15), and 20-month (n = 10).  Pdyn KO mice were included as qualitative controls 
consisting of one mouse per group in each experiment.  Pdyn-heterozygous (HET) mice 
(n = 5) were included in the 3-month age group only.  Group sizes listed above reflect 
inclusion of mice pooled from saline control groups from the MPTP studies, as 
preliminary analyses found no significant differences among the saline controls. 
Two separate experimental MPTP protocols were used in this study.  In 
experiments examining short-term post-MPTP effects, 3-month WT (n = 4) and 10-
month WT (n = 5) mice were injected intraperitoneally with a single dose of 30 mg/kg 
MPTP, and striatal specimens were collected 6 hours later.   The second MPTP protocol, 
involving a standard MPTP regimen of four 15 mg/kg intraperitoneal injections at 2-hour 
intervals with striatal tissue collection 7 days post-MPTP, used 3-month WT (n = 3), 3-
month HET (n = 4), 10-month WT (n = 8) mice, and 1-2 Pdyn KO mice per age point as 
qualitative negative controls. 
 
Dynorphin extraction and radioimmunoassay (RIA) 
Frontal cortical and striatal tissue were isolated following rapid asphyxiation by CO2 and 
were frozen in liquid nitrogen prior to being processed for radioimmunoassay as 
previously described (Christensson-Nylander et al., 1985; Christensson-Nylander and 
Terenius, 1985; Nylander et al., 1991). Briefly, tissues were incubated at 95°C in 1 M 
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acetic acid containing 0.01% mercaptoethanol for 5 minutes, homogenized using a 
Brinkman Kinematic sonicator, heated again to 95°C, and subsequently centrifuged at 
20,000 x g.  The supernatant was then stored at -80°C until chromatographic separation. 
Ion exchange chromatography was performed on Sephadex C-25 columns.  
Samples were diluted in Buffer I (0.1 M formic acid, 0.18 M pyridine, pH 3.0) in a 1:1 
(v/v) ratio and applied onto the Sephadex column.   Elution fractions were obtained by 
serial application of 3 ml of Buffer I, Buffer II (0.1 M formic acid, 0.1 M pyridine, pH 
4.3), Buffer III (0.35 M formic acid, 0.35 mM pyridine, pH 4.3), and Buffer IV (1.6 M 
formic acid, 1.6 M pyridine, pH 4.3).  The eluent from Buffer III was used for Leu-Enk-
Arg quantitation, and the eluent from Buffer IV was used for Dyn A and B.   The 
fractions of interest were lyophilized and resuspended in a 1:1 (v/v) mixture of methanol 
and 0.1 M HCl and subsequently stored at 4°C. 
The radiolabeled peptide was generated by the chloramine T method.  
Radioimmunoassays for Dyn A and B were performed by incubating 25 L aliquots of 
each sample in duplicate or triplicate with 100 L of 
125
I-labeled Dyn A or Dyn B peptide 
and 100 L of the primary antiserum for the peptide of interest at 4°C overnight, 
followed by addition of 100 L of a secondary antibody, centrifugation at 1000 rpm, and 
scintillation counting of the resultant pellet.  A similar method was used in the case of 
Leu-Enk-Arg, except that 200 L of charcoal solution was used instead of a secondary 
antibody, and 200 L of the supernatant obtained after centrifugation was used for 
scintillation counting to detect the 
125
I signal in each sample.  Each experiment included a 
set of standards for the peptide of interest in addition to positive and negative controls, 
and sample values were confirmed to be within the linear range of the assay.   Peptide 
concentrations were calculated based on the standard curve and expressed as fmol per mg 
of wet tissue. 
 
Statistical analysis 
Using Systat 10 software (SPSS, Inc., Chicago, Illinois), effects of age, Pdyn genotype, 
and MPTP were assessed by ANOVA, with individual contrasts obtained by the least 
significant differences method.  One Dyn B result in a 20-month cortical specimen was 
excluded due to processing error. 
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Results 
Evaluation of gene dosage on Dyn A and B expression in young adult mice reveals 
proportional declines in peptide levels in Pdyn HET and KO mice (Figure 5.1).  The 
Pdyn KO specimen, included in this data set as a qualitative negative control, 
demonstrated absent or near-absent levels.  HET mouse peptide levels are approximately 
half the levels seen in WT mice, with a statistical significant difference observed in both 
Dyn A [F(1, 9) = 6.20, p<0.034] and Dyn B [F(1, 9) = 6.26, p < 0.034].  The gene dosage 
effects are not apparent in frontal cortex, where expression levels even in WT mice are 
substantially lower than in striatum.  The assay for Leu-Enk-Arg demonstrates some 
nonspecificity as small amounts are detected in Pdyn KO mice.   In addition, HET levels 
of Leu-Enk-Arg are not significantly different from WT, suggesting the presence of 
mechanisms to compensate for the decreased gene dosage. 
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Figure 5.1.  Evaluation of gene dosage on dynorphin peptide levels. 
Radioimmunoassay was performed on young adult mouse striatum and frontal cortex.  
The Pdyn KO group consists of only one specimen and is used only as a qualitative 
control.  Statistical analysis was performed only on WT and HET mice to evaluate 
effects of gene dosage on peptide levels.  HET mice show proportionately decreased 
levels of Dyn A and Dyn B in striatum, but amounts of Leu-Enk-Arg are not 
significantly changed.  In cortex, peptide quantities are minimally altered in Pdyn HET 
mice.  
#
p<0.05 compared to WT mice. 
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RIA analysis of dynorphin B shows a statistically significant main effect of age in 
striatum [F(2, 15) = 7.93, p<0.004] and a tendency toward significance in an aging main 
effect in cortex [F(2, 15) = 3.36, p<0.064], while Dyn A shows no significant change 
(Figure 2.3).   Dyn B declines progressively with advancing age with striatal levels in 10-
month and 20-month mice approaching approximately 50% [F(1, 15) = 6.24, p<0.025] 
and 20% [F(1, 15) = 15.49, p<0.001] of 3-month values, respectively.  In cortex, Dyn B 
does not decrease significantly at 10 months, but by 20 months, levels are approximately 
10% of 3-month controls [F(1, 14) = 6.72, p<0.021].  The Dyn A results contrast our 
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Figure 5.2.  RIA comparison of dynorphin peptides with age in striatum and cortex.    
The Pdyn KO group consists of only one specimen and is used only as a qualitative 
control.  Dyn B showed a significant age-dependent decline with age in both striatum 
and frontal cortex.  Dyn A shows a trend toward an age-dependent increase in cortex that 
was not statistically significant.  
 
*p<0.05, ***p<0.001 compared to 3-month WT 
controls. 
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previous experimental finding of elevated Dyn A in striatum at 24 months that was 
performed on a smaller sample size (n = 4).  Upon pooling the previous experimental 
results with the newer data, this effect was no longer significant.   The Dyn KO control 
specimen again shows near-undetectable levels of Dyn A and Dyn B. 
To assess short-term changes in striatal dynorphin following neurotoxic injury, 
Dyn A and B were quantified by RIA following a single 30 mg/kg dose of intraperitoneal 
MPTP and found to increase in an age-dependent manner (Figure 5.3).  Two-way 
ANOVA for Dyn A shows a significant main effect of MPTP [(F(1, 35) = 11.16, 
p<0.002] but no age main effect or age-MPTP interaction.  Post-MPTP Dyn A is higher 
in both 3-month [F(1, 35) = 4.00, p<0.053] and 10-month mice [F(1, 35) = 7.64, 
p<0.009], with relative increases of 58% and 85%, respectively, although the 3-month 
difference is slightly short of significance.  Dyn B showed absent main effects of age and 
MPTP, but an age-MPTP interaction was noted trending toward significance [F(1, 17) = 
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Figure 5.3.  RIA measurement of dynorphin peptides 6 h after a single sublethal injection 
of MPTP.   
Mean Dyn A levels are increased in both young and aging mice following MPTP, but 
Dyn B is increased only at 10 months.  
†
p<0.05, 
‡
p<0.01 compared to corresponding 
saline control. 
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4.00, p<0.062].  MPTP produced an increase in Dyn B only among 10-month mice [F(1, 
17) = 6.23, p<0.023], yielding an approximately 3.3-fold elevation compared to 10-
month saline controls. 
RIA was also used to evaluate dynorphin peptide expression 7 days after a 
standard intraperitoneal MPTP regimen (Figure 5.4) that has been previously noted to 
produce significant dopamine depletion.   Pdyn KO mice, which were included in this 
study only as qualitative controls and were not incorporated into the ANOVA model, 
showed absent to near-absent levels of Dyn A and B.  Three-month HET mice were also 
used to evaluate the effect of gene dosage on dynorphin peptide levels post-MPTP.  
Three-way ANOVA showed significant omnibus effects for both Dyn A [F(5, 44) = 3.09, 
p<0.018] and Dyn B [F(5, 26) = 5.23, p<0.002].   WT mice showed a decrease in Dyn A 
levels to approximately half that of saline controls, but the difference reached statistical 
significance only among 3-month mice [F(1, 44) = 4.85, p<0.033], with only near-
significant differences noted in 10-month mice [F(1, 44) = 3.94, p<0.053].  As noted in 
the previous analysis, the gene dosage effect was also apparent when comparing 3-month 
WT and HET saline controls, but no genotype or age effect was seen in Dyn A among 
MPTP-injected mice. 
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Figure 5.4.  RIA quantitation of dynorphin peptides 7 days following intraperitoneal 
MPTP.   
Dyn A and B are decreased after MPTP.  Age and Pdyn genotype effects among saline 
controls in this analysis are consistent with findings noted in the preceding figures.   
#
p<0.05, 
##
p<0.01 compared to WT mice;  *p<0.05, **p<0.01 compared to 3-month 
mice; 
†
p<0.05, 
‡
p<0.01 compared to corresponding saline controls. 
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Striatal Dyn B in WT mice also exhibited a substantial decline 7 days following 
MPTP [F(1, 26) = 12.20, p<0.02], to levels approaching 24% of saline controls.   Gene 
dosage effects and age effects were also present among saline-injected mice and 
consistent with the preceding analysis, with 3-month HET mice showing decreased Dyn 
B compared to 3-month WT mice [F(1, 26) = 10.23, p<0.004] and 10-month WT 
showing declines in Dyn B compared to 3-month controls [F(1, 26) = 8.26, p<0.008].  
However, among MPTP-injected mice, no significant effects were observed. 
 
Discussion 
In this study, a radioimmunological assay was used to assess dynorphin peptide 
expression in striatum and frontal cortex of mice.  The internal validity of this study is 
supported by our results confirming the analytical specificity of the assay and the 
essentially linear quantitative relationship between gene dosage and peptide 
concentration for the Dyn A and Dyn B peptides in striatum, although these properties 
are less apparent in the data on Leu-Enk-Arg and the data in frontal cortical specimens. 
In examining dynorphin peptide expression in striatum and frontal cortex with 
aging, we find that aging produces progressive decline in Dyn B while Dyn A shows no 
significant change.  The existing literature on dynorphin alterations with aging contain 
numerous reports of increased dynorphin in aging or aging-associated pathological 
processes, including elevated mRNA or peptide concentrations in the hippocampus of 
normal aged rats (Jiang et al., 1989; Zhang et al., 1991; Gallagher and Nicolle, 1993; 
Kotz et al., 2004), the cortex and hippocampus of amyloid precursor protein-
overexpressing mice (Diez et al., 2000), the frontal cortex of Down’s syndrome patients 
(Risser et al., 1996), and the frontal and parietal cortices of Alzheimer’s disease patients 
(Risser et al., 1996; Yakovleva et al., 2006a).  In striatum, Pdyn expression with aging 
has been less well studied, with some studies showing no changes in aging rats (Zhang et 
al., 1991; Kotz et al., 2004) and one study finding decreased Pdyn mRNA in striatum of 
normal aged humans (Backman et al., 2007).   We previously had noted no significant 
aging effect of Dyn A in hippocampus (Nguyen et al., 2005), but did observe an increase 
in Dyn A in cerebral cortex in a small number of male aged WT mice (Nguyen et al., 
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2005).  Our current results, which incorporated data pooled from the previous study and 
which contain a larger sample size, show only a nonsignificant trend toward increasing 
Dyn A with aging.  Although complete characterization of dynorphin expression during 
aging awaits further studies, our data and that of previous studies clearly implicate a 
dysregulation of dynorphin expression during aging, the consequences of which remain 
to be elucidated. 
Numerous studies have found dynorphin to be elevated following acute and 
chronic stressors such as inflammation (Millan et al., 1985; Sydbom and Terenius, 1985; 
Chahl and Chahl, 1986; Iadarola et al., 1986; Noguchi et al., 1991; Gillardon et al., 1994; 
Zhang et al., 2005) and neuronal injury (Faden et al., 1985a, b; Wang et al., 2001).  It is 
plausible that the age-related dynorphin elevations seen in other studies may be a 
consequence of chronic subclinical episodes of neuronal injury or a manifestation of an 
acute stress response during the period immediately prior to euthanasia.  In the present 
study, HPLC quantitation of dynorphin peptides after a single 30 mg/kg bolus of 
intraperitoneal MPTP injection in WT mice showed increased dynorphin expression 6 
hours following the neurotoxic insult.  While Pdyn mRNA was not explicitly measured in 
this study, one putative mechanism for the increased dynorphins would be upregulation 
of Pdyn gene expression via activation of immediate-early genes and related transcription 
factors (Naranjo et al., 1991; Collins-Hicok et al., 1994; Hunter et al., 1995; Kitamura et 
al., 1995) during the initial phases of neuronal injury following MPTP.  While Dyn A is 
increased by MPTP in both young and middle-aged mice, the MPTP-induced increase in 
Dyn B is seen only among 10-month mice, favoring an age-dependent mechanism in 
which short-term dysregulation of Dyn B preferentially affecting aged individuals may 
lead to impairments in dopaminergic function.  These observations are corroborated by 
existing literature showing that aging enhances Pdyn upregulation in response to 
inflammation in spinal cord models (Zhang et al., 2004a). 
The above findings remarkably contrast with the decreased expression of both 
Dyn A and Dyn B seen at a longer time interval of 7 days post-MPTP.  Since this MPTP 
regimen in these mice produces substantial loss of striatal dopamine and because 
dopamine promotes dynorphin expression via the D1-receptor (Li et al., 1986; Li et al., 
1988; Li et al., 1990; Bordet et al., 1997; Wong et al., 2003), the observed effects are 
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likely a consequence of decreased dopamine D1-receptor activity in a manner analogous 
to that seen in experimental nigrostriatal lesions (Gerfen et al., 1991) or in D1-receptor 
knockout mice (Wong et al., 2003).    
The significance of the observed changes in dynorphin peptide levels in aging is 
still unclear.  While compensatory responses or changes in the enzymatic systems 
responsible for preprodynorphin processing are likely contributing factors, further studies 
are needed to elucidate the causes and consequences of the observed alterations in 
dynorphin peptide levels.  Age-related patterns of gene expression, such as those 
described in the following chapter, may help to explain why these neuropeptide 
transmitters are altered by advanced age. 
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CHAPTER 6:  Microarray analysis of hippocampal gene expression changes 
with aging and prodynorphin deletion 
 
Introduction 
Endogenous dynorphins derived from the product of the prodynorphin (Pdyn) gene have 
been found to have diverse functional roles in a variety of organ systems (Simonato and 
Romualdi, 1996; Hauser et al., 2005).  Dynorphin peptides present in the hypothalamus, 
dentate gyrus, striatum, cortex, and hippocampus exert a multitude of diverse biological 
actions, including effects on pain transmission, seizure activity, learning and memory, 
endocrine function, excitotoxic injury, stress responses, and the immune system 
[reviewed in (Smith and Lee, 1988)].  The mechanisms through which dynorphin and 
related peptides exert many of their effects involve the  opioid receptor (Goldstein et al., 
1979; Chavkin et al., 1982) (Goldstein and Naidu, 1989) and other opioid (Garzon et al., 
1984) and non-opioid receptors (Chen et al., 1995a, b; Chen and Huang, 1998; Tang et 
al., 1999).   
However, the detailed mechanisms for many of the downstream mediators of 
dynorphin activity have not been fully elucidated. The inhibitory actions of dynorphin 
peptides on neurotransmission have been reported to be mediated by depressing calcium 
entry into neurons (Cherubini and North, 1985) via inhibition of voltage-gated calcium 
channels in a manner similar to  and  opioid agonists [reviewed in (Satoh and Minami, 
1995)].  However dynorphins can increase calcium influx via interaction with the 
bradykinin receptor in models of neuropathic pain (Lai et al., 2006).   There have also 
been varying reports in the literature regarding the ability of dynorphins and  agonists in 
general to inhibit adenylate cyclase activity in a manner analogous to that of  agonists 
(Satoh and Minami, 1995).  Other downstream effects of dynorphins include activation of 
NMDA receptors and inflammatory signaling cascades in the case of spinal hyperalgesia 
(Koetzner et al., 2004).  In addition, dynorphnis interact closely with multiple non-
neuronal cells and with the endocrine system (Sherman et al., 1986; Currie et al., 1994; 
Ohnishi et al., 1994; Spampinato et al., 1995; Kreek et al., 1999; Goodman et al., 2004; 
Foradori et al., 2005; Jacobson et al., 2006), suggesting that Pdyn deletion is likely to 
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produce fairly broad gene expression changes, especially in a process as pervasive and 
multifactorial as normal aging. 
Early reports that prodynorphin is elevated in the hippocampus and frontal cortex 
in cognitively impaired subpopulations of aged rats have implicated Pdyn-derived 
peptides in various aspects of aging (Jiang et al., 1989; Zhang et al., 1991).  In vivo 
studies by other laboratories had demonstrated impaired cognitive function in response to 
administration of various dynorphin peptides  (Introini-Collison et al., 1987; Sandin et al., 
1998), but the mechanistic basis for this phenomenon is currently unclear and may range 
from suppressive effects of dynorphin at the glutamatergic synapse to direct toxic effects 
of some of the dynorphin peptides (Hauser et al., 2005).  Based on our experimental 
findings that aged knockout (KO) mice lacking the Pdyn gene perform relatively better 
than comparably aged wild-type (WT) mice (Nguyen et al., 2005) and other observations 
as noted in preceding chapters, we seek in this study to evaluate patterns of alterations in 
hippocampal gene expression with aging and with Pdyn deletion to explore possible 
mechanisms to explain the role of dynorphins in cognitive decline. Because of the broad 
range of interactions of prodynorphin-derived peptides with a variety of cell types and 
biochemical pathways, we initiated the current microarray study to enable systematic 
characterization of patterns of differential gene expression without a priori assumptions 
on any particular gene or set of genes.  Microarray approaches have previously been used 
to assess gene expression profiles with aging and cognitive impairment (Blalock et al., 
2003; Blalock et al., 2004).  By comparing Pdyn KO mice to similarly aged wild-type 
(WT) mice, we expect to identify the molecular mechanisms and intermediary processes 
by which the chronic absence of Pdyn-derived peptides may contribute to the observed 
functional manifestations in mice. 
 
Methods 
Animal subjects 
Pdyn KO mice, generated by deletion of exons 3 and 4 of the Pdyn gene (Sharifi et al., 
2001), and wild-type (WT) 129SvEv-Tac were bred and housed in an approved animal 
facility.  After weaning, genotyping was performed by the polymerase chain reaction 
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(PCR) from DNA isolated from mouse tail tissue using primer pairs specific for each 
genotype.  Microarray analyses were conducted in two separate experiments.  Experiment 
A included young adult (3-month) WT and Pdyn KO male mice in addition to a separate 
set of 22-month WT and Pdyn KO male mice (n = 3 per group).  In Experiment B, only 
aged (22- to 26-month) WT (n = 3) and aged Pdyn KO (n = 3) mice were used, with each 
group consisting of 2 females and 1 male.  In each experiment, fresh hippocampal 
specimens were dissected from CO2-asphyxiated mice and stored at –80°C until 
processing.  All procedures involving animals are approved by the Institutional Animal 
Care and Use Committee at the University of Kentucky. 
 
Microarray processing 
Total RNA was extracted using the Trizol reagent (Gibco BRL) and reconstituted in de-
ionized water treated with diethyl pyrocarbonate (DEPC).  RNA specimens were 
quantitated by optical density and normalized, followed by assessment of molecular 
integrity by electrophoresis.  Samples were then submitted to the University of Kentucky 
Microarray Core Facility for labeling and hybridization onto individual microarray chips.  
Murine MOE430A cDNA microarray chips, with 22,690 probe sets each, were used in 
Experiment A, while murine whole-genome MG U74A version 2 chips, each containing 
12,488 probe sets, were used for Experiment B.  Automated detection of fluorescent 
intensity using an Affymetrix GeneArray scanner was performed according to standard 
manufacturer protocols, yielding a quantitative score for each probe set.   
 
Probe set list selection 
The automated detection system assigns each probe set in each chip a numerical signal 
value and an absent-present designation of absent (A), present (P), or marginal (M).  For 
each probe set, the absent-present score for each group of 3 replicates was calculated by 
first assigning a value of 0 for each A designation, 1 for each P designation, and 0.5 for 
each M designation and summing the total for the group.  Within a given experiment, 
probe sets for which all groups have an absent-present score of less than 1.5 were deemed 
to be absent in a majority of replicates in each group and were excluded from further 
analysis.  Next, lists of probe sets were generated to reflect increases or decreases in 
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mean signal values in each of the planned comparisons.  Experiment A includes the 
following comparisons: young Pdyn KO vs. young WT, aged Pdyn KO vs. aged WT, 
aged WT vs. young WT, and aged Pdyn KO vs. young Pdyn KO.  In Experiment B, aged 
Pdyn KO mice are compared to aged WT mice.    An ANOVA p-value was computed for 
each comparison in Experiment A and a t-statistic p-value was computed for each 
comparison in Experiment B.   Probe set lists for each of the planned comparisons were 
subsequently generated by selecting non-absent probe sets in which the p-value for the 
associated comparison is less then 0.05. 
  
Functional categorization of differentially regulated genes 
A software program known as Expression Analysis Systematic Explorer (EASE) (Hosack 
et al., 2003) was used to systematically identify functional categories of genes, based on 
Biological Process and Molecular Function annotation data in existing Gene Ontology 
(GO) databases (Ashburner et al., 2000), that are over-represented within a given list of 
Affymetrix probe sets.  The software program evaluates for each categorical grouping in 
the GO classification system, the number of probe sets in the input list that under the 
existing annotation database belong to the category being queried, thereby obtaining the 
number of list hits.  A similar process is applied to a reference population, in this case, 
the entire list of probe sets available on the gene chip used, to calculate the number of 
population hits.  By comparing the proportion of list hits to that of population hits, the 
program computes a conservative modification of the Fisher's exact statistic known as the 
EASE score to quantify the probability that over-representation of the identified category 
within the list might occur due to chance.    
For each of the planned experimental comparisons, functional groupings that were 
noted to be significantly over-represented based on an EASE score of less than 0.05 are 
presented.  Functional annotations and other descriptors for each probe set were obtained 
using NetAffx Analysis Center software (Affymetrix) in conjunction with GenBank, 
Swiss-Prot, and related databases, but only GO Biological Process and Molecular 
Function annotations were used in the systematic over-representation analysis.   All p-
values reported in the Results section refer to the EASE score for each specified 
categorical identifier. 
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Results 
Gene expression in WT and Pdyn KO mice were compared to identify genes that show 
altered expression with either aging or Pdyn deletion.  Table 6.1 describes the results of 
the filtering process by which probe set lists were generated.  The results of the over-
representation analysis using biological process annotations are listed in Table 6.2 
through Table 6.15, and the results of an analogous analysis applied to molecular 
function identifiers are presented in Table 6.16 through Table 6.29. 
 
Effects of aging 
We first examined probe sets that show a significant main effect of age in Experiment A 
and analyzed them initially without regard to Pdyn genotype using biological process 
(Table 6.2 and Table 6.3) and molecular function identifiers (Table 6.16 and Table 6.17).  
We find that 44 of the 251 genes downregulated with aging are involved in nervous 
system development, which is significantly higher than the approximately 10% 
prevalence of this identifier in the murine genomic background (p<0.0004).  Similarly 
other downregulated gene categories include those involved in neurogenesis (p<0.017), 
mesenchymal cell differentiation and development (p<0.025), stem cell division 
(p<0.042), cell growth (p<0.047), potassium transport (p<0.012), DNA binding 
(p<0.003), and zinc-mediated transcription factor activity (p<0.034).  The prevalence of 
genes identified as involved in learning and memory is also disproportionately high in the 
age-downregulated probe set list (p<0.004), as are processes such as action potential 
regulation (p<0.026), synaptic transmission (p<0.026), and dopamine receptor signaling 
(p<0.029).  
In contrast, gene categories upregulated by aging include a number of processes 
associated with immune response (p<0.00006), complement activation (p<0.002), acute-
phase response (p<0.024), response to pathogens (p<0.005), and antigen presentation or 
processing (p<0.003).  Cell development genes are also found to be over-represented 
among age-upregulated probe sets (p<0.03). 
Age effects, when evaluated among WT mice only, provide similar results with 
regard to biological process identifiers (Table 6.4 and Table 6.5) and molecular function 
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(Table 6.18 and Table 6.19).  Downregulated gene categories include nervous system 
development (p<0.004) and neurite morphogenesis (p<0.001), as observed in the 
preceding analysis.  In addition, we also find downregulation of genes involved in protein 
phosphorylation (p<0.04), nucleosome assembly (p<0.038), cellular morphogenesis 
(p<0.003), protein transporter activity (p<0.004), and phospho-protein binding (p<0.004).  
Aging in WT mice is also associated with downregulation of numerous cellular processes 
(p<0.026) that broadly include such functions as cell cycle control, protein transport, 
exocytosis, and chromosome organization.  Genes upregulated in aged WT mice 
compared to young WT mice include those involved in neuron development (p<0.023), 
cell death (p<0.046), cell maturation (p<0.043), cell growth (p<0.021), protein transport 
(p<0.007), and calcium binding (p<0.0001).  In addition, upregulated genes also have a 
disproportionately high prevalence of genes identified as being involved in negative 
regulation of cellular processes (p<0.022).  There are relatively fewer genes 
downregulated in aged Pdyn KO mice relative to young KO mice (Table 6.6 and Table 
6.20), such as those involved enzyme-linked receptor signaling pathways (p<0.036) and 
potassium binding (p<0.005), while age-upregulated genes in Pdyn KO mice (Table 6.7 
and Table 6.21) are associated with MHC I-mediated endogenous antigen processing 
(p<0.007), protein binding (p<0.019), RNA binding (p<0.016), and RNA splicing 
(p<0.042). 
 
Effects of Pdyn deletion 
When Experiment A is analyzed without regard to age, main effects of Pdyn deletion are 
present in multiple probe sets.  Genes downregulated with Pdyn deletion (Table 6.8 and 
Table 6.22) are involved in macromolecule metabolism (p<0.0006), including processes 
related to RNA binding (p<0.0001), protein synthesis (p<0.015), protein folding 
(p<0.019).  Electron transport-related processes (p<0.04) and ubiquinol-cytochrome C 
reductase activity (p<0.008) are also over-represented among genes downregulated by 
Pdyn deletion.  Biological process categories for genes upregulated by Pdyn deletion 
(Table 6.9) include neuron differentiation (p<0.026) and regulation of action potential 
(p<0.039), while upregulated molecular function categories (Table 6.23) include ester-
hydrolase activity (p<0.016) and phospho-transferase activity (p<0.036). 
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When probe sets were selected based on significant group contrasts in Experiment 
A, Pdyn deletion among young mice was associated with changes in expression of a 
relatively small number of biological process (Table 6.10 and Table 6.11) and molecular 
function categories (Table 6.24 and Table 6.25).  The only statistically significant 
biological process category over-represented among genes downregulated by Pdyn 
deletion is protein metabolism (p<0.043), but upregulated biological process identifiers 
include cellular biosynthesis (p<0.044) and negative regulation of apoptosis (p<0.021).  
Calmodulin-dependent protein kinase activity is also downregulated by Pdyn deletion in 
young mice (p<0.010), whereas calcium ion binding (p<0.015) and tyrosine kinase 
activity (p<0.043) are among the molecular function identifiers of upregulated genes.  
Among the aged mice of Experiment A, Pdyn deletion is associated with 
downregulation of genes associated with cell growth (p<0.038), vesicle-mediated 
transport (p<0.038), cell differentiation (p<0.044), nervous system development 
(p<0.050), calcium binding (p<0.0001), and potassium binding (p<0.013) (Table 6.12 
and Table 6.26).  In addition, Pdyn deletion was also associated with decreased 
expression of genes identified in the category of negative regulation of cellular processes 
(p<0.046).  Pdyn deletion among aged mice causes upregulation of genes involved in 
neurite morphogenesis (p<0.002) (Table 6.13).  In addition, aged Pdyn KO mice also 
show increased expression of genes involved in positive regulation of transcription 
(p<0.028), phosphoprotein binding (p<0.039), transcription coactivator activity 
(p<0.044), and sequence-specific DNA binding (p<0.006) compared to aged WT mice 
(Table 6.13 and Table 6.27). 
Experiment B, which compares aged WT and Pdyn KO mice in a separate group 
of animals, found upregulation by Pdyn deletion of genes involved in Golgi organization 
and biogenesis (p<0.045) and organelle localization (p<0.025) (Table 6.15).  
Furthermore, 14 of the 117 annotated genes upregulated by Pdyn deletion possess ion 
channel activity (p<0.003), with a majority of these specifically noted to demonstrate 
voltage-gated ion channel activity (p<0.021) (Table 6.29).  The only downregulated 
biological process category was the proteasome activator complex (p<0.033) (Table 
6.14), and molecular function identifiers among genes downregulated in Pdyn KO mice 
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similarly include proteasome activator activity (p<0.031) and NADH dehydrogenase 
activity (p<0.047) (Table 6.28). 
 
Discussion 
In this study, we implement a modification of the Fisher exact analysis to identify 
functional categories of genes upregulated or downregulated by either aging or Pdyn 
deletion using the EASE program.  Analysis of microarray data often is problematic 
because statistical concerns can hinder interpretation of individual results when obtained 
among a very large number of potential comparisons (Blalock et al., 2003).  However, 
when co-regulated groups of genes are assessed, microarray data may yield abundant 
information on patterns of altered gene expression, which tend to be more robust and less 
dependent on individual gene alterations (Ashburner et al., 2000).   
Our findings of increased immune response genes and decreased neurogenesis or 
axonogenesis genes with age are corroborated by previously published microarray studies 
in rats (Rowe et al., 2007).  These observations may reflect impairments in regulation of 
various pathways that may increase susceptibility to various pathological outcomes with 
advancing age.  Genes involved in dopamine receptor signaling are also downregulated 
with aging, consistent with known functional declines in the dopaminergic system with 
age (Kish et al., 1992; Ingram, 2000; Reeves et al., 2002).   
In this study, we use two separate microarray experiments to evaluate effects of 
Pdyn deletion on gene expression.  While the biological process identifiers associated 
with up- and downregulated genes vary between the two experiments, Pdyn-deletion-
associated findings consistently seen in both experiments include a decrease in protein 
metabolism genes, an increase in cellular organization and biogenesis genes, and an 
increase in genes related to ion transport.  The effects of Pdyn deletion in aged mice, 
which include increased expression of genes associated with neurite development and 
general cell metabolic processes such as transcription, suggest a more active and 
functional neuronal environment in the aging hippocampus that may explain previously 
noted amelioration of memory deficits by Pdyn deletion (Nguyen et al., 2005).  Similar 
changes were observed in young mice, in which Pdyn deletion produces upregulation of 
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genes involved in a broad range of developmental processes, cellular physiological 
processes, signal transduction, and suppression of apoptosis.  These observations support 
a generally suppressive effect of dynorphin peptides on cellular functioning in the 
hippocampus. 
One downstream consequence of dynorphin activity is opiate-receptor-mediated 
inhibition of voltage-gated calcium channels (Satoh and Minami, 1995), resulting in 
decreased intracellular calcium (Cherubini and North, 1985).  Our findings in Experiment 
B that Pdyn deletion increases expression of genes involved in ion channel activity, with 
over half of these specifically listed as voltage-gated ion channel genes, suggest that 
control of intracellular calcium may represent an important mechanism responsible for 
tonic  opioid receptor-mediated suppression of calcium-dependent neurotransmitter 
release by dynorphin peptides, consistent with electrophysiological studies (Spadoni et 
al., 2004).  Experiment A also reveals that, among genes downregulated by Pdyn deletion 
in aged mice, close to 20% are involved in calcium ion binding.  In young mice, Pdyn 
deletion produces downregulation of genes with calcium-dependent protein kinase 
activity.  Altered calcium regulation therefore appears to be an important reproducible 
consequence of Pdyn deletion. 
 This microarray analysis was performed on whole hippocampal homogenates.  
Therefore, results are based on expression profiles of tissue specimens comprised of a 
hetereogeneous cellular composition.  Differences in the relative proportion of neurons or 
glial cells within the hippocamps or variations in expression patterns among the different 
subpopulations or cell types may potentially skew the resulting data.  The sensitivity with 
which gene expression differences may be detected may similarly be reduced for genes 
whose expression is altered only in a small subpopulation of cells within the 
hippocampus.  Even with these limitations, we were able to detect a substantial number 
of genes that, within a specified degree of statistical certainty, show altered expression 
with either aging or Pdyn deletion.   
Importantly, this analysis evaluates groups of genes with similar patterns of 
changes in expression and circumvents the need to generate conclusions regarding 
specific probe sets.  Although identification of individual genes may prove helpful in 
focused experiments with well-planned a priori hypotheses, attempts at independent 
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validation of microarray results would be unlikely to yield a high concordance rate unless 
very large numbers of replicates are tested and exceedingly stringent statistical criteria 
are used in probe set selection.   Therefore, in light of the statistical obstacles associated 
with individual probe set data, we focused exclusively in this study on gene categories.  
Furthermore, the results in the tables below contain all statistically significant annotation 
groupings identified in an automated unbiased manner solely using existing annotation 
categories within an established ontological database, thereby avoiding subjective biases 
associated with manual data-mining approaches. 
It should be emphasized that the accuracy of this type of analysis is limited by the 
completeness of the available annotation systems and may be expected to improve as 
bioinformatic databases evolve with further additions to existing knowledge on the 
biochemical, molecular, and cellular processes associated with specific genes. 
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Experiment A – Aging effects 
Total number of probe sets in chip 22690 
Non-absent probe sets 14412 
Non-absent probe sets with aged mice > young mice 7374 
Non-absent probe sets with aged mice < young mice 7034 
Non-absent probe sets with aged WT > young WT 7428 
Non-absent probe sets with aged WT < young WT 6983 
Non-absent probe sets with aged Pdyn KO > young Pdyn KO 7372 
Non-absent probe sets with aged Pdyn KO < young Pdyn KO 7034 
Non-absent probe sets with aged mice > young mice and p<0.05 by ANOVA 313 
Non-absent probe sets with aged mice < young mice and p<0.05 by ANOVA 313 
Non-absent probe sets with aged WT > young WT and p<0.05 by ANOVA 226 
Non-absent probe sets with aged WT < young WT and p<0.05 by ANOVA 266 
Non-absent probe sets with aged Pdyn KO > young Pdyn KO and p<0.05 by ANOVA 54 
Non-absent probe sets with aged Pdyn KO < young Pdyn KO and p<0.05 by ANOVA 92 
 
Experiment A – Pdyn effects 
Total number of probe sets in chip 22690 
Non-absent probe sets 14412 
Non-absent probe sets with Pdyn KO > WT 7510 
Non-absent probe sets with Pdyn KO < WT 6898 
Non-absent probe sets with young Pdyn KO > young WT 7291 
Non-absent probe sets with young Pdyn KO < young WT 7115 
Non-absent probe sets with aged Pdyn KO > aged WT 7472 
Non-absent probe sets with aged Pdyn KO < aged WT 6938 
Non-absent probe sets with Pdyn KO > WT and p<0.05 by ANOVA 187 
Non-absent probe sets with Pdyn KO < WT and p<0.05 by ANOVA 152 
Non-absent probe sets with young Pdyn KO > young WT and p<0.05 by ANOVA 113 
Non-absent probe sets with young Pdyn KO < young WT and p<0.05 by ANOVA 107 
Non-absent probe sets with aged Pdyn KO > aged WT and p<0.05 by ANOVA 189 
Non-absent probe sets with aged Pdyn KO < aged WT and p<0.05 by ANOVA 186 
 
Experiment B – Pdyn effects in aged mice 
Total number of probe sets in chip 12488 
Non-absent probe sets 7487 
Nonabsent probe sets upregulated in Pdyn KO 4064 
Nonabsent probe sets downregulated in Pdyn KO 3423 
Nonabsent probe sets upregulated in Pdyn KO and p<0.05 by t-test 149 
Nonabsent probe sets downregulated in Pdyn KO and p<0.05 by t-test 116 
 
Table 6.1.  Summary of probe set filtering and selection results. 
Probe sets were excluded based on insufficient presence-absence calls or inadequate 
statistical significance of inter-group differences.  Only non-absent probe sets with 
significant inter-group differences by ANOVA (Experiment A) or t-test (Experiment B) 
were included. 
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Table 6.2.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly downregulated with aging in Experiment A. 
Terms used in the following tables reflect those used in the Gene Ontology Biological 
Process database.  Arrows precede categories that are subsets of one or more categories 
listed above them, with increasing numbers of arrows denoting more specific 
categorizations.  List hits and population hits are presented along with the corresponding 
totals.  Note that not all entries within a given probe set list are reflected in the total, since 
some probe sets do not have a corresponding annotation in the ontological system. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
SYSTEM DEVELOPMENT 44 / 251 1114 / 10541 0.0009 
→ NERVOUS SYSTEM DEVELOPMENT 44 / 251 1078 / 10541 0.0004 
→→ CENTRAL NERVOUS SYSTEM DEVELOPMENT 19 / 251 468 / 10541 0.0297 
ANATOMICAL STRUCTURE FORMATION 10 / 251 169 / 10541 0.0193 
→ FORMATION OF PRIMARY GERM LAYER 10 / 251 167 / 10541 0.0180 
MESODERM DEVELOPMENT 10 / 251 198 / 10541 0.0463 
→ MESODERM MORPHOGENESIS 10 / 251 167 / 10541 0.0180 
→→ MESODERM FORMATION 10 / 251 166 / 10541 0.0174 
CELL DEVELOPMENT 25 / 251 628 / 10541 0.0141 
→ NEUROGENESIS 24 / 251 605 / 10541 0.0170 
→→ NEURON DIFFERENTIATION 22 / 251 562 / 10541 0.0261 
→→→ NEURON MATURATION 11 / 251 204 / 10541 0.0235 
→→ NEURON MIGRATION 5 / 251 51 / 10541 0.0323 
→ GERM CELL DEVELOPMENT 11 / 251 182 / 10541 0.0114 
MESENCHYMAL CELL DIFFERENTIATION 9 / 251 149 / 10541 0.0255 
→ MESENCHYMAL CELL DEVELOPMENT 9 / 251 149 / 10541 0.0255 
HINDLIMB MORPHOGENESIS 8 / 251 139 / 10541 0.0474 
→ EMBRYONIC HINDLIMB MORPHOGENESIS 8 / 251 138 / 10541 0.0459 
GROWTH 19 / 251 494 / 10541 0.0464 
CELLULAR MORPHOGENESIS 28 / 251 815 / 10541 0.0478 
REGULATION OF CELL SIZE 16 / 251 396 / 10541 0.0500 
→ CELL GROWTH 16 / 251 393 / 10541 0.0473 
CORTICAL CYTOSKELETON ORGANIZATION AND 
BIOGENESIS 3 / 251 11 / 10541 0.0268 
STEM CELL DIVISION 8 / 251 135 / 10541 0.0416 
LOCALIZATION 99 / 251 3265 / 10541 0.0032 
→ ESTABLISHMENT OF LOCALIZATION 98 / 251 3243 / 10541 0.0038 
→→ TRANSPORT 84 / 251 2865 / 10541 0.0196 
→→→ ION TRANSPORT 32 / 251 864 / 10541 0.0131 
→→→→ CATION TRANSPORT 25 / 251 624 / 10541 0.0131 
→→→→→ METAL ION TRANSPORT 24 / 251 504 / 10541 0.0020 
→→→→→ MONOVALENT INORGANIC CATION 
TRANSPORT 17 / 251 399 / 10541 0.0282 
→→→→→→ POTASSIUM ION TRANSPORT 14 / 251 269 / 10541 0.0118 
COFACTOR BIOSYNTHESIS 13 / 251 295 / 10541 0.0485 
→ COENZYME BIOSYNTHESIS 13 / 251 278 / 10541 0.0332 
RIBONUCLEOTIDE BIOSYNTHESIS 12 / 251 249 / 10541 0.0351 
→ PURINE NUCLEOTIDE BIOSYNTHESIS 12 / 251 245 / 10541 0.0318 
PURINE NUCLEOTIDE METABOLISM 12 / 251 252 / 10541 0.0378 
RIBONUCLEOTIDE METABOLISM 12 / 251 260 / 10541 0.0456 
REGULATION OF GENE EXPRESSION, EPIGENETIC 10 / 251 200 / 10541 0.0488 
NEUROPHYSIOLOGICAL PROCESS 42 / 251 1182 / 10541 0.0078 
→ TRANSMISSION OF NERVE IMPULSE 25 / 251 653 / 10541 0.0215 
→→ REGULATION OF ACTION POTENTIAL 10 / 251 178 / 10541 0.0259 
CELL COMMUNICATION 101 / 251 3338 / 10541 0.0030 
→ SIGNAL TRANSDUCTION 90 / 251 3032 / 10541 0.0105 
→ SYNAPTIC TRANSMISSION 23 / 251 597 / 10541 0.0265 
→→ NEUROMUSCULAR SYNAPTIC TRANSMISSION 8 / 251 133 / 10541 0.0389 
→ ENZYME LINKED RECEPTOR PROTEIN 
SIGNALING PATHWAY 21 / 251 558 / 10541 0.0427 
102 
 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
(continued from previous page) 
→ DOPAMINE RECEPTOR SIGNALING PATHWAY 9 / 251 153 / 10541 0.0292 
BEHAVIOR 25 / 251 567 / 10541 0.0042 
→ LEARNING AND/OR MEMORY 8 / 251 84 / 10541 0.0037 
RHYTHMIC PROCESS 10 / 251 200 / 10541 0.0488 
→ CIRCADIAN RHYTHM 9 / 251 162 / 10541 0.0391 
 
 
Table 6.3. Complete list of Biological Process identifiers over-represented among probe 
sets significantly upregulated with aging in Experiment A. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
DEVELOPMENT 77 / 229 2974 / 10541 0.0499 
→ CELL DIFFERENTIATION 44 / 229 1382 / 10541 0.0082 
→→ CELL DEVELOPMENT 22 / 229 628 / 10541 0.0310 
CELLULAR MACROMOLECULE METABOLISM 77 / 229 2930 / 10541 0.0367 
RESPONSE TO STIMULUS 75 / 229 2723 / 10541 0.0142 
→ RESPONSE TO STRESS 49 / 229 1635 / 10541 0.0148 
→ RESPONSE TO BIOTIC STIMULUS 49 / 229 1400 / 10541 0.0007 
→→ RESPONSE TO OTHER ORGANISM 34 / 229 984 / 10541 0.0072 
→→→ RESPONSE TO PEST, PATHOGEN OR 
PARASITE 34 / 229 965 / 10541 0.0054 
→ IMMUNE RESPONSE 48 / 229 1231 / 10541 0.0001 
→→ HUMORAL IMMUNE RESPONSE 16 / 229 409 / 10541 0.0321 
→→→ COMPLEMENT ACTIVATION 6 / 229 43 / 10541 0.0022 
→→→→ COMPLEMENT ACTIVATION, CLASSICAL 
PATHWAY 4 / 229 31 / 10541 0.0288 
→ DEFENSE RESPONSE 48 / 229 1346 / 10541 0.0005 
→ RESPONSE TO EXTERNAL STIMULUS 32 / 229 978 / 10541 0.0194 
→→ RESPONSE TO WOUNDING 25 / 229 774 / 10541 0.0467 
→→→ ACUTE-PHASE RESPONSE 5 / 229 51 / 10541 0.0241 
ANTIGEN PRESENTATION 7 / 229 65 / 10541 0.0027 
→ ANTIGEN PRESENTATION, ENDOGENOUS 
ANTIGEN 4 / 229 31 / 10541 0.0288 
ANTIGEN PROCESSING 7 / 229 52 / 10541 0.0008 
→ EXOGENOUS ANTIGEN PROCESSING VIA MHC 
CLASS II 3 / 229 12 / 10541 0.0267 
ORGANISMAL PHYSIOLOGICAL PROCESS 70 / 229 2537 / 10541 0.0181 
→ SMOOTH MUSCLE CONTRACTION 7 / 229 106 / 10541 0.0273 
CELL-CELL SIGNALING 31 / 229 964 / 10541 0.0266 
REPRODUCTION 24 / 229 733 / 10541 0.0457 
→ SEXUAL REPRODUCTION 21 / 229 608 / 10541 0.0402 
 
 
Table 6.4.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly downregulated in aged WT mice compared to young WT mice in 
Experiment A. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
SYSTEM DEVELOPMENT 35 / 210 1114 / 10541 0.0069 
→ NERVOUS SYSTEM DEVELOPMENT 35 / 210 1078 / 10541 0.0042 
NEUROGENESIS 22 / 210 605 / 10541 0.0088 
→NEURON DIFFERENTIATION 20 / 210 562 / 10541 0.0160 
→ →NEURON DEVELOPMENT 19 / 210 443 / 10541 0.0031 
→→→ NEURON MORPHOGENESIS DURING 
DIFFERENTIATION 18 / 210 377 / 10541 0.0013 
→→→→ NEURITE MORPHOGENESIS 18 / 210 377 / 10541 0.0013 
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Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
(continued from previous page) 
→→→→→ AXONOGENESIS 15 / 210 348 / 10541 0.0094 
→→→→→ DENDRITE MORPHOGENESIS 8 / 210 157 / 10541 0.0367 
CELLULAR PROCESS 199 / 210 9577 / 10541 0.0261 
→ REGULATION OF CELLULAR PROCESS 83 / 210 3535 / 10541 0.0469 
→→ POSITIVE REGULATION OF CELLULAR 
PROCESS 32 / 210 1111 / 10541 0.0313 
→→ REGULATION OF TRANSPORT 10 / 210 217 / 10541 0.0289 
→ REGULATION OF PROTEIN STABILITY  6 / 210 52 / 10541 0.0036 
→→ PROTEIN STABILIZATION 3 / 210 16 / 10541 0.0391 
→ MITOTIC CELL CYCLE 18 / 210 549 / 10541 0.0454 
→ INTERPHASE 12 / 210 304 / 10541 0.0397 
→→ INTERPHASE OF MITOTIC CELL CYCLE 12 / 210 303 / 10541 0.0389 
→→→ G1/S TRANSITION OF MITOTIC CELL CYCLE 11 / 210 214 / 10541 0.0102 
→ CELLULAR LOCALIZATION 34 / 210 1109 / 10541 0.0112 
→→ ESTABLISHMENT OF CELLULAR 
LOCALIZATION 34 / 210 1102 / 10541 0.0103 
→→→ EXOCYTOSIS 7 / 210 129 / 10541 0.0432 
→→→ INTRACELLULAR TRANSPORT 33 / 210 1079 / 10541 0.0131 
→→→ PROTEIN TRANSPORT 30 / 210 1000 / 10541 0.0236 
→→→→ INTRACELLULAR PROTEIN TRANSPORT 24 / 210 788 / 10541 0.0394 
→→→ NUCLEOCYTOPLASMIC TRANSPORT 14 / 210 386 / 10541 0.0436 
→→→→ REGULATION OF NUCLEOCYTOPLASMIC 
TRANSPORT 5 / 210 62 / 10541 0.0343 
→ PROTEIN LOCALIZATION 30 / 210 1063 / 10541 0.0471 
→→ ESTABLISHMENT OF PROTEIN LOCALIZATION 30 / 210 1034 / 10541 0.0347 
→ NUCLEOTIDE METABOLISM 15 / 210 386 / 10541 0.0215 
→→ NUCLEOTIDE BIOSYNTHESIS 13 / 210 309 / 10541 0.0202 
→ CHROMOSOME ORGANIZATION & BIOGENESIS 
(SENSU EUKARYOTA) 16 / 210 467 / 10541 0.0448 
→→ ESTABLISHMENT AND/OR MAINTENANCE OF 
CHROMATIN ARCHITECTURE 15 / 210 381 / 10541 0.0195 
→ CELL-CELL ADHESION 10 / 210 239 / 10541 0.0485 
→ INTRACELLULAR SIGNALING CASCADE 43 / 210 1545 / 10541 0.0188 
→ PROTEIN COMPLEX ASSEMBLY 15 / 210 410 / 10541 0.0336 
→ CELL ORGANIZATION AND BIOGENESIS 69 / 210 2289 / 10541 0.0002 
→→ CELLULAR MORPHOGENESIS 28 / 210 815 / 10541 0.0057 
→ CELL DIFFERENTIATION 38 / 210 1382 / 10541 0.0336 
→→ CELL DEVELOPMENT 24 / 210 628 / 10541 0.0032 
→→→CELLULAR MORPHOGENESIS DURING 
DIFFERENTIATION 18 / 210 407 / 10541 0.0030 
GAMETOGENESIS 18 / 210 555 / 10541 0.0494 
PRIMARY METABOLISM 133 / 210 6037 / 10541 0.0471 
BIOPOLYMER METABOLISM 67 / 210 2737 / 10541 0.0387 
→ BIOPOLYMER MODIFICATION 54 / 210 1800 / 10541 0.0014 
→→ PROTEIN MODIFICATION 50 / 210 1728 / 10541 0.0049 
→→→ PROTEIN AMINO ACID PHOSPHORYLATION 22 / 210 708 / 10541 0.0415 
→→ BIOPOLYMER METHYLATION 9 / 210 197 / 10541 0.0424 
→ DNA PACKAGING 15 / 210 390 / 10541 0.0233 
→→ CHROMATIN ASSEMBLY OR DISASSEMBLY 7 / 210 112 / 10541 0.0239 
→→→ NUCLEOSOME ASSEMBLY 5 / 210 64 / 10541 0.0379 
POSITIVE REGULATION OF PHYSIOLOGICAL 
PROCESS 32 / 210 1150 / 10541 0.0466 
NEGATIVE REGULATION OF ENZYME ACTIVITY 11 / 210 236 / 10541 0.0192 
→ NEGATIVE REGULATION OF TRANSFERASE 
ACTIVITY 10 / 210 220 / 10541 0.0312 
NEGATIVE REGULATION OF PROTEIN KINASE 
ACTIVITY 10 / 210 216 / 10541 0.0282 
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Table 6.5.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly upregulated in aged WT mice compared to young WT mice in 
Experiment A. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
SYSTEM DEVELOPMENT 28 / 167 1114 / 10541 0.0150 
→ NERVOUS SYSTEM DEVELOPMENT 28 / 167 1078 / 10541 0.0100 
→→ BRAIN DEVELOPMENT 11 / 167 319 / 10541 0.0293 
→→ NEURON DIFFERENTIATION 16 / 167 562 / 10541 0.0316 
→→→ NEURON DEVELOPMENT 14 / 167 443 / 10541 0.0227 
HEART DEVELOPMENT 7 / 167 154 / 10541 0.0348 
DEATH 27 / 167 1131 / 10541 0.0307 
→ CELL DEATH 26 / 167 1121 / 10541 0.0461 
CELL MATURATION 9 / 167 249 / 10541 0.0432 
LOCALIZATION 72 / 167 3265 / 10541 0.0008 
→ LOCALIZATION OF CELL 19 / 167 717 / 10541 0.0331 
→→ CELL MOTILITY 19 / 167 717 / 10541 0.0331 
CELL ORGANIZATION AND BIOGENESIS 55 / 167 2289 / 10541 0.0008 
→ CELLULAR LOCALIZATION 31 / 167 1109 / 10541 0.0021 
→ ESTABLISHMENT OF LOCALIZATION 72 / 167 3243 / 10541 0.0007 
→→ ESTABLISHMENT OF CELLULAR 
LOCALIZATION 31 / 167 1102 / 10541 0.0019 
→ PROTEIN LOCALIZATION 28 / 167 1063 / 10541 0.0084 
→→ ESTABLISHMENT OF PROTEIN LOCALIZATION 27 / 167 1034 / 10541 0.0109 
→→ TRANSPORT 62 / 167 2865 / 10541 0.0042 
→→→ VESICLE-MEDIATED TRANSPORT 22 / 167 621 / 10541 0.0007 
→→→→ EXOCYTOSIS 8 / 167 129 / 10541 0.0042 
→→→ PROTEIN TRANSPORT 27 / 167 1000 / 10541 0.0072 
→→→ INTRACELLULAR TRANSPORT 29 / 167 1079 / 10541 0.0054 
→→→→ INTRACELLULAR PROTEIN TRANSPORT 21 / 167 788 / 10541 0.0228 
→→→→→ PROTEIN TARGETING 18 / 167 544 / 10541 0.0053 
→→ SECRETION 14 / 167 457 / 10541 0.0283 
→→→ SECRETORY PATHWAY 12 / 167 343 / 10541 0.0197 
GROWTH 15 / 167 494 / 10541 0.0240 
MORPHOGENESIS 36 / 167 1494 / 10541 0.0093 
→ CELLULAR MORPHOGENESIS 23 / 167 815 / 10541 0.0089 
→→ REGULATION OF CELL SIZE 13 / 167 396 / 10541 0.0226 
→→→ CELL GROWTH 13 / 167 393 / 10541 0.0214 
→ MORPHOGENESIS OF AN EPITHELIUM 11 / 167 292 / 10541 0.0171 
→ EMBRYONIC MORPHOGENESIS 11 / 167 311 / 10541 0.0252 
TUBE DEVELOPMENT 11 / 167 285 / 10541 0.0147 
→ TUBE MORPHOGENESIS 9 / 167 235 / 10541 0.0324 
DETECTION OF BIOTIC STIMULUS 4 / 167 42 / 10541 0.0281 
CELL-CELL SIGNALING 23 / 167 964 / 10541 0.0486 
FIBROBLAST GROWTH FACTOR RECEPTOR 
SIGNALING PATHWAY 4 / 167 33 / 10541 0.0148 
PROTEIN KINASE CASCADE 18 / 167 677 / 10541 0.0378 
AROMATIC COMPOUND METABOLISM 8 / 167 181 / 10541 0.0243 
SULFUR COMPOUND BIOSYNTHESIS 4 / 167 51 / 10541 0.0461 
NEGATIVE REGULATION OF BIOLOGICAL 
PROCESS 33 / 167 1454 / 10541 0.0294 
→ NEGATIVE REGULATION OF PHYSIOLOGICAL 
PROCESS 30 / 167 1297 / 10541 0.0316 
→ NEGATIVE REGULATION OF CELLULAR 
PROCESS 31 / 167 1366 / 10541 0.0357 
→→ NEGATIVE REGULATION OF CELLULAR 
PHYSIOLOGICAL PROCESS 30 / 167 1259 / 10541 0.0222 
REGULATION OF DEVELOPMENT 14 / 167 463 / 10541 0.0310 
CELL ION HOMEOSTASIS 10 / 167 284 / 10541 0.0356 
SENSORY PERCEPTION OF MECHANICAL 
STIMULUS 8 / 167 208 / 10541 0.0462 
LOCOMOTION 19 / 167 726 / 10541 0.0368 
MUSCLE CONTRACTION 11 / 167 317 / 10541 0.0283 
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Table 6.6.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly downregulated in aged Pdyn KO mice compared to young Pdyn 
KO mice in Experiment A. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
AROMATIC COMPOUND METABOLISM 5 / 73 181 / 10541 0.0351 
ENZYME LINKED RECEPTOR PROTEIN SIGNALING 
PATHWAY 9 / 73 558 / 10541 0.0358 
COENZYME A METABOLISM 3 / 73 47 / 10541 0.0408 
→ COENZYME A BIOSYNTHESIS 3 / 73 46 / 10541 0.0393 
 
Table 6.7.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly upregulated in aged Pdyn KO mice compared to young Pdyn 
KO mice in Experiment A. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
ANTIGEN PROCESSING 3 / 46 52 / 10541 0.0206 
ANTIGEN PRESENTATION 3 / 46 65 / 10541 0.0313 
→ ANTIGEN PRESENTATION, ENDOGENOUS 
ANTIGEN 3 / 46 31 / 10541 0.0077 
→→ ANTIGEN PROCESSING, ENDOGENOUS 
ANTIGEN VIA MHC CLASS I 3 / 46 30 / 10541 0.0072 
METABOLISM 35 / 46 6509 / 10541 0.0367 
→ PRIMARY METABOLISM 33 / 46 6037 / 10541 0.0399 
→→ RNA METABOLISM 8 / 46 653 / 10541 0.0197 
→→→ RNA SPLICING 4 / 46 181 / 10541 0.0417 
RESPONSE TO STIMULUS 19 / 46 2723 / 10541 0.0260 
 
Table 6.8.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly downregulated with Pdyn deletion in Experiment A. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
METABOLISM 88 / 118 6509 / 10541 0.0026 
→ CELLULAR METABOLISM 84 / 118 6194 / 10541 0.0041 
→→ CELLULAR BIOSYNTHESIS 24 / 118 1439 / 10541 0.0435 
→ PRIMARY METABOLISM 80 / 118 6037 / 10541 0.0145 
→ MACROMOLECULE METABOLISM 64 / 118 4082 / 10541 0.0006 
→→MACROMOLECULE BIOSYNTHESIS 20 / 118 966 / 10541 0.0098 
→→→ PROTEIN BIOSYNTHESIS 18 / 118 865 / 10541 0.0145 
→→ PROTEIN METABOLISM 48 / 118 3122 / 10541 0.0092 
→→ CELLULAR MACROMOLECULE METABOLISM 46 / 118 2930 / 10541 0.0077 
→→→ CELLULAR PROTEIN METABOLISM 46 / 118 2888 / 10541 0.0058 
→→→→ PROTEIN FOLDING 8 / 118 244 / 10541 0.0188 
CELLULAR PHYSIOLOGICAL PROCESS 106 / 118 8620 / 10541 0.0126 
→ ATP SYNTHESIS COUPLED ELECTRON 
TRANSPORT 3 / 118 30 / 10541 0.0434 
→ ATP SYNTHESIS COUPLED ELECTRON 
TRANSPORT (SENSU EUKARYOTA) 3 / 118 29 / 10541 0.0408 
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Table 6.9.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly upregulated with Pdyn deletion in Experiment A. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
SYSTEM DEVELOPMENT 24 / 149 1114 / 10541 0.0376 
→ NERVOUS SYSTEM DEVELOPMENT 23 / 149 1078 / 10541 0.0464 
→ CELL DEVELOPMENT 16 / 149 628 / 10541 0.0303 
→→ NEUROGENESIS 16 / 149 605 / 10541 0.0227 
→→→ NEURON DIFFERENTIATION 15 / 149 562 / 10541 0.0264 
REGULATION OF ACTION POTENTIAL 7 / 149 178 / 10541 0.0394 
RESPONSE TO WOUNDING 18 / 149 774 / 10541 0.0434 
CIRCULATION 8 / 149 178 / 10541 0.0127 
GAMETOGENESIS 14 / 149 555 / 10541 0.0482 
 
Table 6.10.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly downregulated in young Pdyn KO mice compared to young WT 
mice in Experiment A. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
PROTEIN METABOLISM 36 / 92 3122 / 10541 0.0432 
 
 
Table 6.11.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly upregulated in young Pdyn KO mice compared to young WT 
mice in Experiment A. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
SYSTEM DEVELOPMENT 15 / 82 1114 / 10541 0.0434 
→ ORGAN DEVELOPMENT 21 / 82 1489 / 10541 0.0078 
→ NERVOUS SYSTEM DEVELOPMENT 15 / 82 1078 / 10541 0.0342 
→→ CENTRAL NERVOUS SYSTEM DEVELOPMENT 11 / 82 468 / 10541 0.0030 
→→→ BRAIN DEVELOPMENT 10 / 82 319 / 10541 0.0007 
TUBE DEVELOPMENT 7 / 82 285 / 10541 0.0222 
→ TUBE MORPHOGENESIS 6 / 82 235 / 10541 0.0344 
MORPHOGENESIS 22 / 82 1494 / 10541 0.0037 
→ EMBRYONIC MORPHOGENESIS 8 / 82 311 / 10541 0.0098 
→ CELLULAR MORPHOGENESIS 12 / 82 815 / 10541 0.0466 
→ MORPHOGENESIS OF AN EPITHELIUM 7 / 82 292 / 10541 0.0246 
→→ MORPHOGENESIS OF EMBRYONIC 
EPITHELIUM 6 / 82 220 / 10541 0.0270 
LOCALIZATION 36 / 82 3265 / 10541 0.0132 
CELL ORGANIZATION AND BIOGENESIS 31 / 82 2289 / 10541 0.0012 
→ MEMBRANE ORGANIZATION AND BIOGENESIS 5 / 82 174 / 10541 0.0448 
→→ MEMBRANE FUSION 5 / 82 96 / 10541 0.0063 
→ VESICLE ORGANIZATION AND BIOGENESIS 3 / 82 39 / 10541 0.0360 
→ CELLULAR LOCALIZATION 20 / 82 1109 / 10541 0.0006 
→ ESTABLISHMENT OF LOCALIZATION 36 / 82 3243 / 10541 0.0118 
→→ SECRETION 9 / 82 457 / 10541 0.0238 
→ PROTEIN LOCALIZATION 17 / 82 1063 / 10541 0.0063 
→→ ESTABLISHMENT OF PROTEIN LOCALIZATION 16 / 82 1034 / 10541 0.0114 
→→ ESTABLISHMENT OF CELLULAR 
LOCALIZATION 20 / 82 1102 / 10541 0.0005 
→→→ SECRETORY PATHWAY 8 / 82 343 / 10541 0.0161 
→→ TRANSPORT 33 / 82 2865 / 10541 0.0105 
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Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
(continued from previous page) 
→→→ NUCLEOBASE, NUCLEOSIDE, NUCLEOTIDE 
AND NUCLEIC ACID TRANSPORT 4 / 82 85 / 10541 0.0275 
→→→→ NUCLEIC ACID TRANSPORT 4 / 82 73 / 10541 0.0185 
→→→ INTRACELLULAR TRANSPORT 19 / 82 1079 / 10541 0.0012 
→→→→ NUCLEOCYTOPLASMIC TRANSPORT 8 / 82 386 / 10541 0.0286 
→→→ REGULATION OF TRANSPORT 6 / 82 217 / 10541 0.0256 
→→→ VESICLE-MEDIATED TRANSPORT 16 / 82 621 / 10541 0.0001 
→→→→ VESICLE FUSION 4 / 82 64 / 10541 0.0130 
→→→→ ENDOSOME TRANSPORT 5 / 82 105 / 10541 0.0086 
→→→→ ENDOCYTOSIS 10 / 82 334 / 10541 0.0010 
→→→→ RECEPTOR MEDIATED ENDOCYTOSIS 4 / 82 85 / 10541 0.0275 
→→→→→ REGULATION OF ENDOCYTOSIS 5 / 82 107 / 10541 0.0092 
→→→→ EXOCYTOSIS 5 / 82 129 / 10541 0.0173 
→→→ PROTEIN TRANSPORT 16 / 82 1000 / 10541 0.0085 
→→→→ INTRACELLULAR PROTEIN TRANSPORT 14 / 82 788 / 10541 0.0067 
→→→→→ PROTEIN TARGETING 10 / 82 544 / 10541 0.0233 
→ RNA LOCALIZATION 4 / 82 76 / 10541 0.0206 
→→ ESTABLISHMENT OF RNA LOCALIZATION 4 / 82 73 / 10541 0.0185 
→→→ RNA TRANSPORT 4 / 82 73 / 10541 0.0185 
→→→→ RNA EXPORT FROM NUCLEUS 4 / 82 72 / 10541 0.0178 
→ ACTIN FILAMENT-BASED PROCESS 7 / 82 318 / 10541 0.0353 
→→ ACTIN CYTOSKELETON ORGANIZATION AND 
BIOGENESIS 7 / 82 291 / 10541 0.0243 
→→→ ACTIN CYTOSKELETON REORGANIZATION 3 / 82 35 / 10541 0.0295 
SIGNAL TRANSDUCTION 32 / 82 3032 / 10541 0.0406 
→  RHO PROTEIN SIGNAL TRANSDUCTION 4 / 82 69 / 10541 0.0159 
→ ENZYME LINKED RECEPTOR PROTEIN 
SIGNALING PATHWAY 11 / 82 558 / 10541 0.0101 
→→ TRANSMEMBRANE RECEPTOR PROTEIN 
TYROSINE KINASE SIGNALING PATHWAY 7 / 82 316 / 10541 0.0344 
→→→ EPIDERMAL GROWTH FACTOR RECEPTOR 
SIGNALING PATHWAY 4 / 82 98 / 10541 0.0395 
→→→ FIBROBLAST GROWTH FACTOR RECEPTOR 
SIGNALING PATHWAY 3 / 82 33 / 10541 0.0264 
→→ TRANSMEMBRANE RECEPTOR PROTEIN 
SERINE/THREONINE KINASE SIGNALING 
PATHWAY 6 / 82 250 / 10541 0.0431 
→→→ TRANSFORMING GROWTH FACTOR BETA 
RECEPTOR SIGNALING PATHWAY 4 / 82 98 / 10541 0.0395 
→ PROTEIN KINASE CASCADE 11 / 82 677 / 10541 0.0340 
→→ POSITIVE REGULATION OF I- B KINASE/NF-
B CASCADE 5 / 82 178 / 10541 0.0480 
CELLULAR BIOSYNTHESIS 18 / 82 1439 / 10541 0.0443 
PROTEIN MODIFICATION 21 / 82 1728 / 10541 0.0353 
→ PROTEIN UBIQUITINATION 7 / 82 319 / 10541 0.0358 
VITAMIN METABOLISM 4 / 82 96 / 10541 0.0375 
REGULATION OF NEUROTRANSMITTER LEVELS 5 / 82 173 / 10541 0.0440 
MUSCLE CONTRACTION 7 / 82 317 / 10541 0.0348 
→ SMOOTH MUSCLE CONTRACTION 4 / 82 106 / 10541 0.0480 
TELOMERASE-DEPENDENT TELOMERE 
MAINTENANCE 3 / 82 44 / 10541 0.0448 
DEATH 15 / 82 1131 / 10541 0.0483 
→ NEGATIVE REGULATION OF PROGRAMMED 
CELL DEATH 8 / 82 364 / 10541 0.0216 
→→ NEGATIVE REGULATION OF APOPTOSIS 8 / 82 363 / 10541 0.0213 
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Table 6.12.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly downregulated in aged Pdyn KO mice compared to aged WT 
mice in Experiment A. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
DEVELOPMENT 55 / 142 2974 / 10541 0.0058 
→ MORPHOGENESIS 32 / 142 1494 / 10541 0.0075 
→→ CELLULAR MORPHOGENESIS 19 / 142 815 / 10541 0.0238 
→→→ REGULATION OF CELL SIZE 11 / 142 396 / 10541 0.0397 
→→→→ CELL GROWTH 11 / 142 393 / 10541 0.0380 
NERVOUS SYSTEM DEVELOPMENT 22 / 142 1078 / 10541 0.0499 
LOCALIZATION 55 / 142 3265 / 10541 0.0375 
→ ESTABLISHMENT OF LOCALIZATION 55 / 142 3243 / 10541 0.0332 
→→ VESICLE-MEDIATED TRANSPORT 15 / 142 621 / 10541 0.0381 
ION HOMEOSTASIS 10 / 142 341 / 10541 0.0394 
→ CELL ION HOMEOSTASIS 9 / 142 284 / 10541 0.0368 
CELL DIFFERENTIATION 27 / 142 1382 / 10541 0.0437 
NEGATIVE REGULATION OF BIOLOGICAL 
PROCESS 29 / 142 1454 / 10541 0.0281 
→ NEGATIVE REGULATION OF CELLULAR 
PROCESS 27 / 142 1366 / 10541 0.0387 
→→ NEGATIVE REGULATION OF CELLULAR 
PHYSIOLOGICAL PROCESS 25 / 142 1259 / 10541 0.0458 
NEGATIVE REGULATION OF PHYSIOLOGICAL 
PROCESS 26 / 142 1297 / 10541 0.0373 
AROMATIC COMPOUND METABOLISM 7 / 142 181 / 10541 0.0345 
INTERACTION BETWEEN ORGANISMS 9 / 142 298 / 10541 0.0466 
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Table 6.13.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly upregulated in aged Pdyn KO mice compared to aged WT mice 
in Experiment A. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
CELL ORGANIZATION AND BIOGENESIS 48 / 147 2289 / 10541 0.0020 
→ CELLULAR MORPHOGENESIS 22 / 147 815 / 10541 0.0041 
CELL DEVELOPMENT 16 / 147 628 / 10541 0.0273 
→ CELLULAR MORPHOGENESIS DURING 
DIFFERENTIATION 14 / 147 407 / 10541 0.0042 
NERVOUS SYSTEM DEVELOPMENT 23 / 147 1078 / 10541 0.0408 
→ NEUROGENESIS 16 / 147 605 / 10541 0.0203 
→→ NEURON DIFFERENTIATION 15 / 147 562 / 10541 0.0238 
→→→ NEURON DEVELOPMENT 14 / 147 443 / 10541 0.0085 
→→→→ NEURON MORPHOGENESIS DURING 
DIFFERENTIATION 14 / 147 377 / 10541 0.0022 
→→→→→ NEURITE MORPHOGENESIS 14 / 147 377 / 10541 0.0022 
→→→→→→AXONOGENESIS 11 / 147 348 / 10541 0.0228 
→→→→→→DENDRITE MORPHOGENESIS 7 / 147 157 / 10541 0.0219 
BLOOD VESSEL MORPHOGENESIS 10 / 147 333 / 10541 0.0418 
G1/S TRANSITION OF MITOTIC CELL CYCLE 8 / 147 214 / 10541 0.0292 
REGULATION OF BIOLOGICAL PROCESS 67 / 147 3907 / 10541 0.0257 
REGULATION OF PHYSIOLOGICAL PROCESS 62 / 147 3524 / 10541 0.0207 
→ REGULATION OF CELLULAR PROCESS 63 / 147 3535 / 10541 0.0145 
→→ POSITIVE REGULATION OF CELLULAR 
PROCESS 29 / 147 1254 / 10541 0.0069 
→ REGULATION OF CELLULAR PHYSIOLOGICAL 
PROCESS 59 / 147 3309 / 10541 0.0195 
→→ POSITIVE REGULATION OF CELLULAR 
PHYSIOLOGICAL PROCESS 28 / 147 1111 / 10541 0.0025 
→ POSITIVE REGULATION OF BIOLOGICAL 
PROCESS 31 / 147 1400 / 10541 0.0091 
→ POSITIVE REGULATION OF PHYSIOLOGICAL 
PROCESS 28 / 147 1150 / 10541 0.0041 
→→ POSITIVE REGULATION OF METABOLISM 16 / 147 598 / 10541 0.0185 
→→→ POSITIVE REGULATION OF CELLULAR 
METABOLISM 16 / 147 575 / 10541 0.0134 
→→→→ POSITIVE REGULATION OF 
GLUCONEOGENESIS 2 / 147 3 / 10541 0.0410 
→→→→ POSITIVE REGULATION OF NUCLEOBASE, 
NUCLEOSIDE, NUCLEOTIDE & NUCLEIC 
ACID METABOLISM 13 / 147 469 / 10541 0.0295 
→→→→→ POSITIVE REGULATION OF 
TRANSCRIPTION 13 / 147 465 / 10541 0.0278 
NEGATIVE REGULATION OF ENZYME ACTIVITY 8 / 147 236 / 10541 0.0457 
 
 
Table 6.14.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly downregulated in aged Pdyn KO mice compared to aged WT 
mice in Experiment B. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
PROTEASOME ACTIVATOR COMPLEX 2 / 79 3 / 7111 0.0326 
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Table 6.15.  Complete list of Biological Process identifiers over-represented among probe 
sets significantly upregulated in aged Pdyn KO mice compared to aged WT mice 
in Experiment B. 
Biological process category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
CELL ORGANIZATION AND BIOGENESIS 38 / 115 1667 / 7176 0.0148 
→ MICROTUBULE CYTOSKELETON 
ORGANIZATION AND BIOGENESIS 6 / 115 123 / 7176 0.0457 
→ GOLGI ORGANIZATION AND BIOGENESIS 4 / 115 50 / 7176 0.0446 
LOCALIZATION 48 / 115 2265 / 7176 0.0178 
→ ORGANELLE LOCALIZATION 4 / 115 41 / 7176 0.0269 
→ ESTABLISHMENT OF LOCALIZATION 47 / 115 2250 / 7176 0.0253 
→→ ION TRANSPORT 16 / 115 563 / 7176 0.0323 
→→ ESTABLISHMENT OF ORGANELLE 
LOCALIZATION 4 / 115 40 / 7176 0.0252 
MUSCLE CONTRACTION 9 / 115 229 / 7176 0.0289 
 
Table 6.16.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly downregulated with aging in Experiment A. 
Terms used in the following tables reflect those used in the Gene Ontology Molecular 
Function database.  Arrows precede categories that are subsets of one or more categories 
listed above them, with increasing numbers of arrows denoting more specific 
categorizations.  List hits and population hits are presented along with the corresponding 
totals.  Note that not all entries within a given probe set list are reflected in the total, since 
some probe sets do not have a corresponding annotation in the ontological system. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
STRUCTURE-SPECIFIC DNA BINDING 14 / 247 240 / 11005 0.0029 
→ DOUBLE-STRANDED DNA BINDING 12 / 247 185 / 11005 0.0029 
ZINC-MEDIATED TRANSCRIPTIONAL ACTIVATOR 
ACTIVITY 8 / 247 137 / 11005 0.0340 
TRANSPORTER ACTIVITY 55 / 247 1853 / 11005 0.0212 
→ ION TRANSPORTER ACTIVITY 30 / 247 884 / 11005 0.0234 
CYTOSKELETAL PROTEIN BINDING 23 / 247 641 / 11005 0.0297 
METALLOEXOPEPTIDASE ACTIVITY 9 / 247 174 / 11005 0.0416 
SULFURIC ESTER HYDROLASE ACTIVITY 8 / 247 137 / 11005 0.0340 
NUTRIENT RESERVOIR ACTIVITY 8 / 247 146 / 11005 0.0455 
 
Table 6.17.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly upregulated with aging in Experiment A. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
PROTEIN BINDING 134 / 241 5244 / 11005 0.0089 
ANTIGEN BINDING 6 / 241 65 / 11005 0.0135 
ENZYME INHIBITOR ACTIVITY 14 / 241 287 / 11005 0.0102 
STRUCTURAL CONSTITUENT OF RIBOSOME 11 / 241 244 / 11005 0.0413 
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Table 6.18.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly downregulated in aged WT mice compared to young WT 
mice in Experiment A. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
PROTEIN TRANSPORTER ACTIVITY 10 / 212 162 / 11005 0.0040 
BINDING 182 / 212 8519 / 11005 0.0014 
→ PROTEIN BINDING 119 / 212 5244 / 11005 0.0092 
→→ PHOSPHOPROTEIN BINDING 6 / 212 56 / 11005 0.0043 
→→→ PROTEIN PHOSPHORYLATED AMINO ACID 
BINDING 4 / 212 40 / 11005 0.0408 
→→ CYTOSKELETAL PROTEIN BINDING 20 / 212 641 / 11005 0.0389 
→→ SNARE BINDING 4 / 212 43 / 11005 0.0490 
→ SEQUENCE-SPECIFIC DNA BINDING 18 / 212 544 / 11005 0.0324 
→ STRUCTURE-SPECIFIC DNA BINDING 10 / 212 240 / 11005 0.0417 
→ ZINC ION BINDING 40 / 212 1546 / 11005 0.0418 
LIGASE ACTIVITY 23 / 212 652 / 11005 0.0070 
→ LIGASE ACTIVITY, FORMING CARBON-
NITROGEN BONDS 15 / 212 403 / 11005 0.0232 
→→ CTP SYNTHASE ACTIVITY 2 / 212 2 / 11005 0.0380 
LYASE ACTIVITY 9 / 212 205 / 11005 0.0438 
KINASE REGULATOR ACTIVITY 8 / 212 149 / 11005 0.0246 
→ PROTEIN KINASE REGULATOR ACTIVITY 7 / 212 102 / 11005 0.0136 
→→ CAMP-DEPENDENT PROTEIN KINASE 
REGULATOR ACTIVITY 3 / 212 17 / 11005 0.0412 
 
Table 6.19.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly upregulated in aged WT mice compared to young WT 
mice in Experiment A. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
ION BINDING 63 / 177 2881 / 11005 0.0047 
→ METAL ION BINDING 63 / 177 2881 / 11005 0.0047 
→ CATION BINDING 59 / 177 2668 / 11005 0.0053 
→→ CALCIUM ION BINDING 35 / 177 988 / 11005 <0.0001 
ACTIN BINDING 11 / 177 314 / 11005 0.0294 
RECEPTOR SIGNALING COMPLEX SCAFFOLD 
ACTIVITY 5 / 177 65 / 11005 0.0201 
RHO GTPASE BINDING 4 / 177 28 / 11005 0.0098 
GUANYL-NUCLEOTIDE EXCHANGE FACTOR 
ACTIVITY 6 / 177 122 / 11005 0.0460 
 
Table 6.20.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly downregulated in aged Pdyn KO mice compared to young 
Pdyn KO mice in Experiment A. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
TRIPEPTIDYL-PEPTIDASE I ACTIVITY 2 / 74 2 / 11005 0.0132 
PROTEIN TRANSPORTER ACTIVITY 5 / 74 162 / 11005 0.0225 
ALKALI METAL ION BINDING 5 / 74 168 / 11005 0.0253 
→ POTASSIUM ION BINDING 5 / 74 106 / 11005 0.0053 
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Table 6.21.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly upregulated in aged Pdyn KO mice compared to young 
Pdyn KO mice in Experiment A. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
LIGASE ACTIVITY 9 / 48 652 / 11005 0.0059 
→ LIGASE ACTIVITY, FORMING CARBON-
NITROGEN BONDS 6 / 48 403 / 11005 0.0279 
MHC CLASS I RECEPTOR ACTIVITY 3 / 48 30 / 11005 0.0072 
BINDING 43 / 48 8519 / 11005 0.0297 
→ PROTEIN BINDING 31 / 48 5244 / 11005 0.0186 
→ RNA BINDING 9 / 48 772 / 11005 0.0155 
 
Table 6.22.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly downregulated with Pdyn deletion in Experiment A. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
STRUCTURAL CONSTITUENT OF RIBOSOME 12 / 123 244 / 11005 0.0001 
OXIDOREDUCTASE ACTIVITY, ACTING ON 
DIPHENOLS AND RELATED SUBSTANCES 
AS DONORS 3 / 123 12 / 11005 0.0075 
→ OXIDOREDUCTASE ACTIVITY, ACTING ON 
DIPHENOLS AND RELATED SUBSTANCES 
AS DONORS, CYTOCHROME AS ACCEPTOR 3 / 123 12 / 11005 0.0075 
MONOVALENT INORGANIC CATION 
TRANSPORTER ACTIVITY 8 / 123 280 / 11005 0.0361 
→ HYDROGEN ION TRANSPORTER ACTIVITY 8 / 123 274 / 11005 0.0327 
→→ UBIQUINOL-CYTOCHROME-C REDUCTASE 
ACTIVITY 3 / 123 12 / 11005 0.0075 
NUCLEIC ACID BINDING 42 / 123 2711 / 11005 0.0157 
→ RNA BINDING 22 / 123 772 / 11005 0.0001 
RAN GTPASE BINDING 3 / 123 20 / 11005 0.0203 
UNFOLDED PROTEIN BINDING 8 / 123 196 / 11005 0.0061 
 
Table 6.23.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly upregulated with Pdyn deletion in Experiment A. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
ANTIGEN BINDING 5 / 151 65 / 11005 0.0118 
HYDROLASE ACTIVITY, ACTING ON ESTER BONDS 19 / 151 766 / 11005 0.0163 
GUANYL NUCLEOTIDE BINDING 11 / 151 375 / 11005 0.0324 
TRANSFERASE ACTIVITY, TRANSFERRING 
PHOSPHORUS-CONTAINING GROUPS 24 / 151 1141 / 11005 0.0357 
CYSTEINE-TYPE ENDOPEPTIDASE ACTIVITY 9 / 151 289 / 11005 0.0441 
 
Table 6.24.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly downregulated in young Pdyn KO mice compared to 
young WT mice in Experiment A. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
CALCIUM- AND CALMODULIN-DEPENDENT 
PROTEIN KINASE ACTIVITY 3 / 91 19 / 11005 0.0103 
LIGASE ACTIVITY, FORMING CARBON-NITROGEN 
BONDS 8 / 91 403 / 11005 0.0467 
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Table 6.25.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly upregulated in young Pdyn KO mice compared to young 
WT mice in Experiment A. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
RHO GTPASE BINDING 3 / 92 28 / 11005 0.0222 
CALCIUM ION BINDING 16 / 92 988 / 11005 0.0150 
COPPER ION BINDING 4 / 92 93 / 11005 0.0417 
CARBOHYDRATE BINDING 10 / 92 468 / 11005 0.0151 
→ SUGAR BINDING 6 / 92 229 / 11005 0.0411 
ACTIN BINDING 8 / 92 314 / 11005 0.0151 
PROTEIN BINDING, BRIDGING 5 / 92 146 / 11005 0.0327 
PATTERN BINDING 7 / 92 301 / 11005 0.0383 
PROTEIN-TYROSINE KINASE ACTIVITY 8 / 92 392 / 11005 0.0434 
OXIDOREDUCTASE ACTIVITY 12 / 92 752 / 11005 0.0453 
EXONUCLEASE ACTIVITY 4 / 92 99 / 11005 0.0486 
 
Table 6.26.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly downregulated in aged Pdyn KO mice compared to aged 
WT mice in Experiment A. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
ION BINDING 52 / 147 2881 / 11005 0.0115 
→ METAL ION BINDING 52 / 147 2881 / 11005 0.0115 
→ CATION BINDING 48 / 147 2668 / 11005 0.0175 
→→ CALCIUM ION BINDING 29 / 147 988 / 11005 0.0001 
→→ POTASSIUM ION BINDING 6 / 147 106 / 11005 0.0133 
RECEPTOR SIGNALING COMPLEX SCAFFOLD 
ACTIVITY 5 / 147 65 / 11005 0.0108 
GUANYL-NUCLEOTIDE EXCHANGE FACTOR 
ACTIVITY 6 / 147 122 / 11005 0.0231 
TRANSPORTER ACTIVITY 34 / 147 1853 / 11005 0.0427 
TRIPEPTIDYL-PEPTIDASE I ACTIVITY 2 / 147 2 / 11005 0.0264 
 
Table 6.27.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly upregulated in aged Pdyn KO mice compared to aged WT 
mice in Experiment A. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
BINDING 133 / 149 8519 / 11005 0.0002 
→ PROTEIN BINDING 88 / 149 5244 / 11005 0.0040 
→→ CYTOSKELETAL PROTEIN BINDING 18 / 149 641 / 11005 0.0056 
→→ PROTEIN DIMERIZATION ACTIVITY 13 / 149 523 / 11005 0.0493 
→→ PHOSPHOPROTEIN BINDING 4 / 149 56 / 11005 0.0394 
→→ TRANSCRIPTION COACTIVATOR ACTIVITY 11 / 149 401 / 11005 0.0441 
→ PEPTIDE BINDING 9 / 149 214 / 11005 0.0083 
→ SEQUENCE-SPECIFIC DNA BINDING 16 / 149 544 / 11005 0.0064 
→ STRUCTURE-SPECIFIC DNA BINDING 9 / 149 240 / 11005 0.0157 
 
  
114 
 
Table 6.28.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly downregulated in aged Pdyn KO mice compared to aged 
WT mice in Experiment B. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
PROTEIN KINASE C BINDING 3 / 79 26 / 7363 0.0306 
PROTEASOME ACTIVATOR ACTIVITY 2 / 79 3 / 7363 0.0314 
NADH DEHYDROGENASE ACTIVITY 3 / 79 33 / 7363 0.0473 
→ NADH DEHYDROGENASE (QUINONE) ACTIVITY 3 / 79 33 / 7363 0.0473 
→→ NADH DEHYDROGENASE (UBIQUINONE) 
ACTIVITY 3 / 79 33 / 7363 0.0473 
SODIUM ION TRANSPORTER ACTIVITY 3 / 79 34 / 7363 0.0500 
 
Table 6.29.  Complete list of Molecular Function identifiers over-represented among 
probe sets significantly upregulated in aged Pdyn KO mice compared to aged WT 
mice in Experiment B. 
Molecular function category identifier 
List hits / 
List total 
Population hits / 
Population total 
EASE 
score 
TRANSPORTER ACTIVITY 29 / 117 1277 / 7363 0.0380 
→ ION TRANSPORTER ACTIVITY 16 / 117 575 / 7363 0.0357 
→ CHANNEL OR PORE CLASS TRANSPORTER 
ACTIVITY 14 / 117 377 / 7363 0.0062 
→→ ALPHA-TYPE CHANNEL ACTIVITY 14 / 117 364 / 7363 0.0046 
→→→ ION CHANNEL ACTIVITY 14 / 117 346 / 7363 0.0030 
→→→→ VOLTAGE-GATED ION CHANNEL 
ACTIVITY 8 / 117 176 / 7363 0.0208 
PROTEIN BINDING 70 / 117 3732 / 7363 0.0343 
→ PROTEIN DOMAIN SPECIFIC BINDING 8 / 117 190 / 7363 0.0301 
→ DYNEIN BINDING 4 / 117 41 / 7363 0.0263 
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CHAPTER 7:  Discussion and Conclusions 
Summary of effects of aging and Pdyn deletion  
Behavioral effects  
Aging produced a significant decrease in water maze performance, with mild decreases in 
movement speed in both the water maze and open-field experiments and increased 
stereotypical behavior in open-field analyses.  The effects of Pdyn deletion on learning 
and memory observed in this dissertation include relative sparing of age-related 
impairment in spatial navigational memory and a subtle enhancement of passive 
avoidance retention in young mice, with minimal effect on object recogntion.  No 
significant age-associated deficits in performance were noted in the object recognition 
and passive avoidance tasks of this study.   
It is noteworthy that both of the learning and memory assays in which Pdyn 
deletion confers a beneficial effect are tasks in which performance is driven in large part 
by a response to an aversive stimulus in contrast to the relative neutral stimuli required 
for object recognition.  A likely interpretation of these findings is that Pdyn-derived 
peptides alter the subject's reward or motivational response, possibly in addition to any 
direct inhibitory effects of dynorphins on hippocampal neurotransmission previously 
reported (Drake et al., 1994; Terman et al., 1994).  Consistent with known effects of 
dopamine and dynorphin in reward pathways (Carlezon et al., 1998; Hurd et al., 1999; 
Zhang et al., 2004b), our data on dopamine alterations in Pdyn KO mice support such a 
role of dynorphins.  In the object recognition experiments, Pdyn deletion produces a 
relative avoidance of novel objects, despite demonstrating slightly increased total 
exploratory behavior following introduction of a new object.  Spontaneous locomotor 
activity in the open-field assay was also mildly elevated in male Pdyn KO mice in 
relation to the average activity of other groups of mice tested, arguing in favor of 
differentially regulated arousal or motivational processes in these mice.  These behavioral 
changes are likely influenced by significant elevations in striatal dopamine content, such 
as those noted in aged Pdyn KO mice.  
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Molecular changes 
A major finding of this dissertation was the markedly enhanced striatal dopamine in aged 
Pdyn KO mice, while aging alone in WT mice produced no significant changes in 
dopamine.  With evidence of increased phosphorylation of TH at Ser40 in Pdyn KO 
mice, it is reasonable to conclude that dynorphin peptides, through mechanisms that have 
not yet been fully delineated, suppress dopamine synthesis via modulation of TH activity.  
Aging also was associated with altered dynorphin expression, with declines in Dyn B in 
striatum and frontal cortex, while Dyn A showed a tendency to increase with age in 
frontal cortex.  These findings may account for some of the age dependence noted in the 
behavioral functional comparisons between WT and Pdyn KO mice. 
Moreover, the patterns of hippocampal gene expression from the microarray 
experiments suggest that aged Pdyn KO mice are metabolically and transcriptionally 
more active than aged WT mice, with increased expression of genes involved in neuronal 
development and basic cellular processes.  Furthermore, calcium binding and transport 
appears to be an important downstream consequence of Pdyn deletion based on 
microarray gene expression results.  This observation leads to the conclusion that 
prolonged suppression of dynorphin may induce significant changes in calcium 
regulation and other neuronal processes, including dopamine synthesis, which may 
significantly enhance neurotransmission within the parts of the brain where dynorphin is 
prevalent, such as striatum and hippocampus. 
 
Role of dynorphins in MPTP neurotoxicity 
In the data reported in the preceding chapters, MPTP induced decreases in locomotor 
activity that was ameliorated by Pdyn deletion or heterozygosity, but in a separate 
experiment on dopamine quantitation, Pdyn deletion conferred no protection against 
MPTP-induced dopamine depletion despite the finding that dopamine was elevated in 
Pdyn KO mice in an age-dependent manner.  These results suggest that although certain 
Pdyn-derived peptides can demonstrate direct neurotoxicty in various experimental 
situations (Hauser et al., 1999; Goody et al., 2003; Singh et al., 2003), their absence does 
not protect against striatal neurotoxicity by MPTP.  Interestingly, in the acute phase of 
MPTP injury, striatal dynorphin peptides are increased but eventually return to below 
117 
 
pre-injection levels, likely as a consequence of subsequently decreased dopaminergic 
tone.  Our results showing improved post-MPTP open-field activity in Pdyn KO mice in 
the absence of elevated dopamine are consistent with presumed effects of residual 
dynorphins on dopaminergic activity beyond that of maintaining total striatal dopamine 
content.   
 
A working model for the role of dynorphins in aging 
Early observations on the ability of dynorphins to antagonize morphine-induced analgesia 
in opiate-dependent subjects while potentiating it in opiate-naïve subjects have led to the 
proposal that dynorphins act in a modulatory capacity (Smith and Lee, 1988).  The results 
of the preceding chapters support such a role of physiological quantities of dynorphins, 
and, in an attempt to establish a working model to explain our findings, we propose the 
following framework to explain the role of dynorphins.  In the proposed model, basal 
dynorphinergic input is needed to maintain striatal dopaminergic activity within normal 
functional levels (Steiner and Gerfen, 1998) and to prevent excessive synaptic excitability 
in hippocampus (Simonato and Romualdi, 1996; Loacker et al., 2007), physiological 
functions which are necessary for homeostasis and have ample evolutionary advantages.  
In the Pdyn KO mice characterized in this dissertation, the absence of these basal 
regulatory functions of dynorphins may be offset by appropriate counter-regulatory 
elements.  In young adult mice, these compensatory mechanisms may be sufficient to 
mask functional effects of Pdyn deletion.  However, with advanced age, these 
mechanisms may be inadequate, resulting, for instance, in elevations in dopamine as 
noted in the preceding chapters. 
The elevated dopamine may be sufficient to produce increased motivational drive, 
increased alertness, or increased learning and memory functioning as manifested in the 
relative amelioration of age-related water maze performance impairment in the aged 
Pdyn KO relative to aged WT mice.  The absence of similar Pdyn effects among aged 
mice in the other learning and memory paradigms could be explained by the relatively 
greater reward and motivational component present in the water maze task.  Dynorphin 
peptides are an important component in the biological mechanisms of reward, as 
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supported by studies in which upregulation of prodynorphin by overexpressing CREB 
substantially decreases the rewarding effects of cocaine (Carlezon et al., 1998).   
In addition to the tonic dynorphinergic effect, there is likely another role of 
dynorphins in which Pdyn expression is inducible following various types of neuronal 
injury (Iadarola et al., 1986; Thai et al., 1996; Simpson et al., 1997; Zhang et al., 2004a).   
The short-term increases in dynorphin expression following a neurotoxic injury by MPTP 
in our studies raise the possibility that immediate-early genes activated during various 
neurologic stressors (Naranjo et al., 1991; Noguchi et al., 1991; Bronstein et al., 1994; 
Hunter et al., 1995) could induce episodic expression of supraphysiological levels of 
dynorphins.  Our findings that aging increases the amount of Dyn A relative to Dyn B 
may indicate alterations in prodynorphin processing that favor the more neurotoxic Dyn 
A product (Hauser et al., 2005).  While the episodic dynorphin upregulation may provide 
protective effects under some circumstances (Przewlocka et al., 1983; Simonato and 
Romualdi, 1996; Liu et al., 2001; Loacker et al., 2007), such as anticonvulsant activity 
during seizures or traumatic injury, the increased likelihood of direct neurotoxic or pro-
excitotoxic effects, mostly mediated by non-opioid mechanisms (Hauser et al., 2005), 
may over time lead to repetitive injury that may manifest as worsening of cognitive 
impairment.    
 
Potential areas of further inquiry 
One topic that was not directly addressed by this series of experiments is the potential 
differences in activity and mechanisms of action among the prodynorphin-derived 
peptides.  The knockout model, while effectively suppressing expression of the 
preprodynorphin precursor, does not address the potential differences between Dyn A, 
Dyn B, Dyn-32, and multiple other peptide derivatives of prodynorphin.  Previous studies 
have demonstrated significant variations in the biological effects and relative 
concentrations of the different Pdyn-derived peptides in various physiological and 
pathological states [reviewed in (Hauser et al., 2005)].  Given the discordant expression 
profiles of Dyn A and B during aging seen in the WT mice of this study, further 
characterization of the mechanisms controlling post-translational processing of the Pdyn 
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gene product would be needed to supplement existing data on dynorphin peptide and 
mRNA quantitation. 
While the experiments described in this dissertation require no assumption 
regarding the type of receptor through which any of the observed findings are mediated, 
it would be interesting to assess whether similar observations may be made in opioid 
receptor knockout mice.  Such studies, in conjunction with the results presented here, 
may help elucidate the extent to which the observed Pdyn deletion effects are due to 
opioid-mediated mechanisms.   Additional mechanistic studies will also be needed to 
dissect the components of the cellular pathways in which dynorphins interact during 
aging or neurotoxic injury.   
 
Extrapolation to human disease 
The findings of this dissertation may also be evaluated in the context of existing evidence 
of dynorphins in specific human disorders.  Information of potential clinical relevance to 
human disease has been obtained by laboratory or pathological investigations in patients 
with specific neurological disorders such as Alzheimer's disease (AD) or Parkinson's 
disease (PD).   One of the earliest studies of dynorphins in AD reported a 40% decline in 
Dyn A(1-8) levels in cerebrospinal fluid (CSF) compared to age-matched controls 
(Sunderland et al., 1991).   However, increased levels of Dyn A were later reported in 
frontal cortex (Risser et al., 1996) and parietal cortex (Yakovleva et al., 2006a) in AD 
patients post-mortem, with no similar increase observed for Dyn B (Yakovleva et al., 
2006a).  Another study reported that Pdyn mRNA expression is decreased with aging, but 
no differences were noted between normally aged subjects and PD patients (Backman et 
al., 2007).  Dynorphin peptide levels in most studies were similarly unchanged in various 
brain regions and in CSF of Parkinson's disease patients compared to controls (Taquet et 
al., 1985; Baronti et al., 1991; Yakovleva et al., 2006a), although one study of PD 
patients reported a decline in dynorphin-like immunoreactivity in substantia nigra but not 
basal ganglia (Waters et al., 1988).  In addition, neither aging alone nor L-dopa therapy 
induced any change in Dyn A in CSF in one clinical study (Baronti et al., 1991).    
The complexity of the aging process and the heterogeneity of subject populations, 
in addition to published reports of inconsistencies between animal and human studies 
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(Baronti et al., 1991), make it challenging to identify consistent trends in dynorphin 
expression.  The studies presented in this dissertation involve exclusively the 129SvEv 
mouse strain.  As presented in the preceding chapters, Dyn A shows some evidence of 
upward trend with age in striatum and frontal cortex of WT mice, but Dyn B exhibits an 
age-dependent decline.  Strain- and species-specific differences may render it difficult to 
generalize these findings to other rodents or to primates.   
Nonetheless, many results from animal studies have been replicated in the few 
clinical trials involving direct administration of dynorphins or related agents. Although 
few studies directly address the effects of pharmacologically applied dynorphins in 
cognition or motor function in human subjects, dynorphins have been evaluated with a 
broad array of other endpoints.  Intravenous Dyn A(1-13) infusion in healthy human 
subjects produces mild, transient mood and euphoric effects (King et al., 1999) and has 
varying efficacy in opiate withdrawal (Greenwald et al., 1997; Specker et al., 1998).   A 
dynorphin A derivative has also been found to be effective in treatment of post-herpetic 
neuralgia (Wallace et al., 2006).  In addition, an earlier trial reported dose-limiting 
adverse behavioral effects when administering the  agonist spiradoline to Parkinson’s 
disease patients (Giuffra et al., 1993) without effects on motor symptoms.  Prodynorphin-
derived peptides have also been noted to exhibit endocrine effects in healthy humans.  
Dyn A(1-13) was found to increase prolactin (Kreek et al., 1999; Bart et al., 2003), and a 
dynorphin analogue was noted to inhibit vasopressin (Ohnishi et al., 1994), consistent 
with findings in rodent studies.  These studies support the contention that many of the 
major properties of dynorphin peptides discovered in animal studies will likely be 
generalizable to humans.  However, the existing clinical literature unfortunately offers 
little data on effects of dynorphinergic activity or suppression during normal aging in 
humans. 
While the results of this dissertation addressing memory and motor effects of 
Pdyn deletion are felt to be relevant to disorders such as Alzheimer’s and Parkinson’s 
disease, the potential applicability of further research on dynorphins is clearly not limited 
to aging-associated disorders.  The role of dynorphinergic input on dopamine levels and 
its potential effects on reward pathways have significant implications for the 
pathophysiology of addiction, which has been aptly described as a maladaptive 
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interaction of reward pathways and learning mechanisms (Hyman, 2005).  The 
prevalence of addictive behavior and its effect of health care costs confirm the potential 
significance of the reward-mediating actions of dynorphins in human disease.  While 
further research is needed to address the mechanisms involved and to further characterize 
the effects of dynorphins on human disease, the results of this dissertation support an 
important role of dynorphins in age-related memory impairment and in modulation of the 
nigrostriatal dopaminergic system.  Further research into the roles dynorphins play in the 
processes discussed in this dissertation would be helpful in assessing the applicability and 
appropriateness of potential clinical interventions. 
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